id	sid	tid	token	lemma	pos
cord-354664-mzzvmyea	1	1	key	key	JJ
cord-354664-mzzvmyea	1	2	:	:	:
cord-354664-mzzvmyea	1	3	cord-354664-mzzvmyea	cord-354664-mzzvmyea	JJ
cord-354664-mzzvmyea	1	4	authors	author	NNS
cord-354664-mzzvmyea	1	5	:	:	:
cord-354664-mzzvmyea	1	6	Shumilak	Shumilak	NNP
cord-354664-mzzvmyea	1	7	,	,	,
cord-354664-mzzvmyea	1	8	Geoffrey	Geoffrey	NNP
cord-354664-mzzvmyea	1	9	;	;	:
cord-354664-mzzvmyea	1	10	Sligl	Sligl	NNP
cord-354664-mzzvmyea	1	11	,	,	,
cord-354664-mzzvmyea	1	12	Wendy	Wendy	NNP
cord-354664-mzzvmyea	1	13	I.	I.	NNP
cord-354664-mzzvmyea	1	14	title	title	NN
cord-354664-mzzvmyea	1	15	:	:	:
cord-354664-mzzvmyea	2	1	Moving	move	VBG
cord-354664-mzzvmyea	2	2	Past	past	RB
cord-354664-mzzvmyea	2	3	the	the	DT
cord-354664-mzzvmyea	2	4	Routine	Routine	NNP
cord-354664-mzzvmyea	2	5	Use	Use	NNP
cord-354664-mzzvmyea	2	6	of	of	IN
cord-354664-mzzvmyea	2	7	Macrolides	macrolide	NNS
cord-354664-mzzvmyea	2	8	—	—	:
cord-354664-mzzvmyea	3	1	Reviewing	review	VBG
cord-354664-mzzvmyea	3	2	the	the	DT
cord-354664-mzzvmyea	3	3	Role	role	NN
cord-354664-mzzvmyea	3	4	of	of	IN
cord-354664-mzzvmyea	3	5	Combination	Combination	NNP
cord-354664-mzzvmyea	3	6	Therapy	Therapy	NNP
cord-354664-mzzvmyea	3	7	in	in	IN
cord-354664-mzzvmyea	3	8	Community	Community	NNP
cord-354664-mzzvmyea	3	9	-	-	HYPH
cord-354664-mzzvmyea	3	10	Acquired	Acquired	NNP
cord-354664-mzzvmyea	3	11	Pneumonia	Pneumonia	NNP
cord-354664-mzzvmyea	3	12	date	date	NN
cord-354664-mzzvmyea	3	13	:	:	:
cord-354664-mzzvmyea	3	14	2018	2018	CD
cord-354664-mzzvmyea	3	15	-	-	HYPH
cord-354664-mzzvmyea	3	16	09	09	CD
cord-354664-mzzvmyea	3	17	-	-	HYPH
cord-354664-mzzvmyea	3	18	06	06	CD
cord-354664-mzzvmyea	3	19	journal	journal	NN
cord-354664-mzzvmyea	3	20	:	:	:
cord-354664-mzzvmyea	4	1	Curr	Curr	NNP
cord-354664-mzzvmyea	4	2	Infect	infect	VBP
cord-354664-mzzvmyea	4	3	Dis	Dis	NNP
cord-354664-mzzvmyea	4	4	Rep	Rep	NNP
cord-354664-mzzvmyea	4	5	DOI	doi	NN
cord-354664-mzzvmyea	4	6	:	:	:
cord-354664-mzzvmyea	5	1	10.1007	10.1007	CD
cord-354664-mzzvmyea	5	2	/	/	SYM
cord-354664-mzzvmyea	5	3	s11908	s11908	NN
cord-354664-mzzvmyea	5	4	-	-	HYPH
cord-354664-mzzvmyea	5	5	018	018	CD
cord-354664-mzzvmyea	5	6	-	-	HYPH
cord-354664-mzzvmyea	5	7	0651	0651	CD
cord-354664-mzzvmyea	5	8	-	-	HYPH
cord-354664-mzzvmyea	5	9	8	8	CD
cord-354664-mzzvmyea	5	10	sha	sha	NN
cord-354664-mzzvmyea	5	11	:	:	:
cord-354664-mzzvmyea	5	12	332d3e0cd20303c1d98e109645eaef4bfd97a8ee	332d3e0cd20303c1d98e109645eaef4bfd97a8ee	CD
cord-354664-mzzvmyea	5	13	doc_id	doc_id	CD
cord-354664-mzzvmyea	5	14	:	:	:
cord-354664-mzzvmyea	5	15	354664	354664	CD
cord-354664-mzzvmyea	5	16	cord_uid	cord_uid	NNS
cord-354664-mzzvmyea	5	17	:	:	:
cord-354664-mzzvmyea	5	18	mzzvmyea	mzzvmyea	JJ
cord-354664-mzzvmyea	5	19	PURPOSE	purpose	NN
cord-354664-mzzvmyea	5	20	OF	of	IN
cord-354664-mzzvmyea	5	21	REVIEW	review	NN
cord-354664-mzzvmyea	5	22	:	:	:
cord-354664-mzzvmyea	6	1	Despite	despite	IN
cord-354664-mzzvmyea	6	2	advances	advance	NNS
cord-354664-mzzvmyea	6	3	in	in	IN
cord-354664-mzzvmyea	6	4	diagnostic	diagnostic	JJ
cord-354664-mzzvmyea	6	5	microbiology	microbiology	NN
cord-354664-mzzvmyea	6	6	and	and	CC
cord-354664-mzzvmyea	6	7	sepsis	sepsis	NN
cord-354664-mzzvmyea	6	8	management	management	NN
cord-354664-mzzvmyea	6	9	,	,	,
cord-354664-mzzvmyea	6	10	community	community	NN
cord-354664-mzzvmyea	6	11	-	-	HYPH
cord-354664-mzzvmyea	6	12	acquired	acquire	VBN
cord-354664-mzzvmyea	6	13	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	6	14	(	(	-LRB-
cord-354664-mzzvmyea	6	15	CAP	CAP	NNP
cord-354664-mzzvmyea	6	16	)	)	-RRB-
cord-354664-mzzvmyea	6	17	remains	remain	VBZ
cord-354664-mzzvmyea	6	18	a	a	DT
cord-354664-mzzvmyea	6	19	significant	significant	JJ
cord-354664-mzzvmyea	6	20	cause	cause	NN
cord-354664-mzzvmyea	6	21	of	of	IN
cord-354664-mzzvmyea	6	22	morbidity	morbidity	NN
cord-354664-mzzvmyea	6	23	and	and	CC
cord-354664-mzzvmyea	6	24	mortality	mortality	NN
cord-354664-mzzvmyea	6	25	.	.	.
cord-354664-mzzvmyea	7	1	Current	current	JJ
cord-354664-mzzvmyea	7	2	recommendations	recommendation	NNS
cord-354664-mzzvmyea	7	3	regarding	regard	VBG
cord-354664-mzzvmyea	7	4	the	the	DT
cord-354664-mzzvmyea	7	5	use	use	NN
cord-354664-mzzvmyea	7	6	of	of	IN
cord-354664-mzzvmyea	7	7	beta	beta	NN
cord-354664-mzzvmyea	7	8	-	-	HYPH
cord-354664-mzzvmyea	7	9	lactams	lactam	NNS
cord-354664-mzzvmyea	7	10	in	in	IN
cord-354664-mzzvmyea	7	11	combination	combination	NN
cord-354664-mzzvmyea	7	12	with	with	IN
cord-354664-mzzvmyea	7	13	macrolides	macrolide	NNS
cord-354664-mzzvmyea	7	14	published	publish	VBN
cord-354664-mzzvmyea	7	15	in	in	IN
cord-354664-mzzvmyea	7	16	clinical	clinical	JJ
cord-354664-mzzvmyea	7	17	practice	practice	NN
cord-354664-mzzvmyea	7	18	guidelines	guideline	NNS
cord-354664-mzzvmyea	7	19	are	be	VBP
cord-354664-mzzvmyea	7	20	variable	variable	JJ
cord-354664-mzzvmyea	7	21	and	and	CC
cord-354664-mzzvmyea	7	22	based	base	VBN
cord-354664-mzzvmyea	7	23	on	on	IN
cord-354664-mzzvmyea	7	24	low	low	JJ
cord-354664-mzzvmyea	7	25	-	-	HYPH
cord-354664-mzzvmyea	7	26	quality	quality	NN
cord-354664-mzzvmyea	7	27	evidence	evidence	NN
cord-354664-mzzvmyea	7	28	that	that	WDT
cord-354664-mzzvmyea	7	29	is	be	VBZ
cord-354664-mzzvmyea	7	30	frequently	frequently	RB
cord-354664-mzzvmyea	7	31	retrospective	retrospective	JJ
cord-354664-mzzvmyea	7	32	,	,	,
cord-354664-mzzvmyea	7	33	observational	observational	JJ
cord-354664-mzzvmyea	7	34	,	,	,
cord-354664-mzzvmyea	7	35	and	and	CC
cord-354664-mzzvmyea	7	36	heterogeneous	heterogeneous	JJ
cord-354664-mzzvmyea	7	37	in	in	IN
cord-354664-mzzvmyea	7	38	nature	nature	NN
cord-354664-mzzvmyea	7	39	.	.	.
cord-354664-mzzvmyea	8	1	While	while	IN
cord-354664-mzzvmyea	8	2	population	population	NN
cord-354664-mzzvmyea	8	3	-	-	HYPH
cord-354664-mzzvmyea	8	4	based	base	VBN
cord-354664-mzzvmyea	8	5	studies	study	NNS
cord-354664-mzzvmyea	8	6	have	have	VBP
cord-354664-mzzvmyea	8	7	historically	historically	RB
cord-354664-mzzvmyea	8	8	suggested	suggest	VBN
cord-354664-mzzvmyea	8	9	improved	improve	VBN
cord-354664-mzzvmyea	8	10	clinical	clinical	JJ
cord-354664-mzzvmyea	8	11	outcomes	outcome	NNS
cord-354664-mzzvmyea	8	12	with	with	IN
cord-354664-mzzvmyea	8	13	the	the	DT
cord-354664-mzzvmyea	8	14	routine	routine	JJ
cord-354664-mzzvmyea	8	15	use	use	NN
cord-354664-mzzvmyea	8	16	of	of	IN
cord-354664-mzzvmyea	8	17	macrolide	macrolide	JJ
cord-354664-mzzvmyea	8	18	combination	combination	NN
cord-354664-mzzvmyea	8	19	therapy	therapy	NN
cord-354664-mzzvmyea	8	20	in	in	IN
cord-354664-mzzvmyea	8	21	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	8	22	patients	patient	NNS
cord-354664-mzzvmyea	8	23	with	with	IN
cord-354664-mzzvmyea	8	24	CAP	CAP	NNP
cord-354664-mzzvmyea	8	25	,	,	,
cord-354664-mzzvmyea	8	26	emerging	emerge	VBG
cord-354664-mzzvmyea	8	27	evidence	evidence	NN
cord-354664-mzzvmyea	8	28	from	from	IN
cord-354664-mzzvmyea	8	29	recent	recent	JJ
cord-354664-mzzvmyea	8	30	randomized	randomized	JJ
cord-354664-mzzvmyea	8	31	controlled	control	VBN
cord-354664-mzzvmyea	8	32	trials	trial	NNS
cord-354664-mzzvmyea	8	33	has	have	VBZ
cord-354664-mzzvmyea	8	34	challenged	challenge	VBN
cord-354664-mzzvmyea	8	35	this	this	DT
cord-354664-mzzvmyea	8	36	practice	practice	NN
cord-354664-mzzvmyea	8	37	.	.	.
cord-354664-mzzvmyea	9	1	In	in	IN
cord-354664-mzzvmyea	9	2	this	this	DT
cord-354664-mzzvmyea	9	3	article	article	NN
cord-354664-mzzvmyea	9	4	,	,	,
cord-354664-mzzvmyea	9	5	we	-PRON-	PRP
cord-354664-mzzvmyea	9	6	discuss	discuss	VBP
cord-354664-mzzvmyea	9	7	the	the	DT
cord-354664-mzzvmyea	9	8	historical	historical	JJ
cord-354664-mzzvmyea	9	9	rationale	rationale	NN
cord-354664-mzzvmyea	9	10	and	and	CC
cord-354664-mzzvmyea	9	11	current	current	JJ
cord-354664-mzzvmyea	9	12	evidence	evidence	NN
cord-354664-mzzvmyea	9	13	for	for	IN
cord-354664-mzzvmyea	9	14	combination	combination	NN
cord-354664-mzzvmyea	9	15	macrolide	macrolide	NN
cord-354664-mzzvmyea	9	16	therapy	therapy	NN
cord-354664-mzzvmyea	9	17	in	in	IN
cord-354664-mzzvmyea	9	18	the	the	DT
cord-354664-mzzvmyea	9	19	management	management	NN
cord-354664-mzzvmyea	9	20	of	of	IN
cord-354664-mzzvmyea	9	21	CAP	CAP	NNP
cord-354664-mzzvmyea	9	22	.	.	.
cord-354664-mzzvmyea	10	1	RECENT	recent	JJ
cord-354664-mzzvmyea	10	2	FINDINGS	finding	NNS
cord-354664-mzzvmyea	10	3	:	:	:
cord-354664-mzzvmyea	11	1	Recent	recent	JJ
cord-354664-mzzvmyea	11	2	randomized	randomized	JJ
cord-354664-mzzvmyea	11	3	controlled	control	VBN
cord-354664-mzzvmyea	11	4	trials	trial	NNS
cord-354664-mzzvmyea	11	5	have	have	VBP
cord-354664-mzzvmyea	11	6	assessed	assess	VBN
cord-354664-mzzvmyea	11	7	the	the	DT
cord-354664-mzzvmyea	11	8	non	non	JJ
cord-354664-mzzvmyea	11	9	-	-	JJ
cord-354664-mzzvmyea	11	10	inferiority	inferiority	NN
cord-354664-mzzvmyea	11	11	of	of	IN
cord-354664-mzzvmyea	11	12	beta	beta	NN
cord-354664-mzzvmyea	11	13	-	-	HYPH
cord-354664-mzzvmyea	11	14	lactam	lactam	NN
cord-354664-mzzvmyea	11	15	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	11	16	compared	compare	VBN
cord-354664-mzzvmyea	11	17	to	to	IN
cord-354664-mzzvmyea	11	18	beta	beta	NN
cord-354664-mzzvmyea	11	19	-	-	HYPH
cord-354664-mzzvmyea	11	20	lactam	lactam	NNS
cord-354664-mzzvmyea	11	21	/	/	SYM
cord-354664-mzzvmyea	11	22	macrolide	macrolide	NN
cord-354664-mzzvmyea	11	23	combination	combination	NN
cord-354664-mzzvmyea	11	24	therapy	therapy	NN
cord-354664-mzzvmyea	11	25	in	in	IN
cord-354664-mzzvmyea	11	26	adult	adult	NN
cord-354664-mzzvmyea	11	27	patients	patient	NNS
cord-354664-mzzvmyea	11	28	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	11	29	with	with	IN
cord-354664-mzzvmyea	11	30	CAP	CAP	NNP
cord-354664-mzzvmyea	11	31	.	.	.
cord-354664-mzzvmyea	12	1	Beta	beta	NN
cord-354664-mzzvmyea	12	2	-	-	HYPH
cord-354664-mzzvmyea	12	3	lactam	lactam	NN
cord-354664-mzzvmyea	12	4	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	12	5	was	be	VBD
cord-354664-mzzvmyea	12	6	associated	associate	VBN
cord-354664-mzzvmyea	12	7	with	with	IN
cord-354664-mzzvmyea	12	8	equivalent	equivalent	JJ
cord-354664-mzzvmyea	12	9	clinical	clinical	JJ
cord-354664-mzzvmyea	12	10	outcomes	outcome	NNS
cord-354664-mzzvmyea	12	11	in	in	IN
cord-354664-mzzvmyea	12	12	patients	patient	NNS
cord-354664-mzzvmyea	12	13	with	with	IN
cord-354664-mzzvmyea	12	14	mild	mild	JJ
cord-354664-mzzvmyea	12	15	to	to	IN
cord-354664-mzzvmyea	12	16	moderate	moderate	JJ
cord-354664-mzzvmyea	12	17	CAP	cap	NN
cord-354664-mzzvmyea	12	18	.	.	.
cord-354664-mzzvmyea	13	1	Patients	patient	NNS
cord-354664-mzzvmyea	13	2	with	with	IN
cord-354664-mzzvmyea	13	3	severe	severe	JJ
cord-354664-mzzvmyea	13	4	CAP	cap	NN
cord-354664-mzzvmyea	13	5	managed	manage	VBN
cord-354664-mzzvmyea	13	6	with	with	IN
cord-354664-mzzvmyea	13	7	beta	beta	NN
cord-354664-mzzvmyea	13	8	-	-	HYPH
cord-354664-mzzvmyea	13	9	lactam	lactam	NN
cord-354664-mzzvmyea	13	10	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	13	11	have	have	VBP
cord-354664-mzzvmyea	13	12	demonstrated	demonstrate	VBN
cord-354664-mzzvmyea	13	13	worse	bad	JJR
cord-354664-mzzvmyea	13	14	clinical	clinical	JJ
cord-354664-mzzvmyea	13	15	outcomes	outcome	NNS
cord-354664-mzzvmyea	13	16	when	when	WRB
cord-354664-mzzvmyea	13	17	compared	compare	VBN
cord-354664-mzzvmyea	13	18	to	to	IN
cord-354664-mzzvmyea	13	19	patients	patient	NNS
cord-354664-mzzvmyea	13	20	treated	treat	VBN
cord-354664-mzzvmyea	13	21	with	with	IN
cord-354664-mzzvmyea	13	22	combination	combination	NN
cord-354664-mzzvmyea	13	23	therapy	therapy	NN
cord-354664-mzzvmyea	13	24	.	.	.
cord-354664-mzzvmyea	14	1	In	in	IN
cord-354664-mzzvmyea	14	2	addition	addition	NN
cord-354664-mzzvmyea	14	3	,	,	,
cord-354664-mzzvmyea	14	4	previous	previous	JJ
cord-354664-mzzvmyea	14	5	beta	beta	NN
cord-354664-mzzvmyea	14	6	-	-	HYPH
cord-354664-mzzvmyea	14	7	lactam	lactam	NN
cord-354664-mzzvmyea	14	8	exposure	exposure	NN
cord-354664-mzzvmyea	14	9	prior	prior	RB
cord-354664-mzzvmyea	14	10	to	to	IN
cord-354664-mzzvmyea	14	11	hospitalization	hospitalization	NN
cord-354664-mzzvmyea	14	12	has	have	VBZ
cord-354664-mzzvmyea	14	13	not	not	RB
cord-354664-mzzvmyea	14	14	been	be	VBN
cord-354664-mzzvmyea	14	15	shown	show	VBN
cord-354664-mzzvmyea	14	16	to	to	TO
cord-354664-mzzvmyea	14	17	negatively	negatively	RB
cord-354664-mzzvmyea	14	18	impact	impact	NN
cord-354664-mzzvmyea	14	19	outcomes	outcome	NNS
cord-354664-mzzvmyea	14	20	in	in	IN
cord-354664-mzzvmyea	14	21	patients	patient	NNS
cord-354664-mzzvmyea	14	22	managed	manage	VBN
cord-354664-mzzvmyea	14	23	with	with	IN
cord-354664-mzzvmyea	14	24	beta	beta	NN
cord-354664-mzzvmyea	14	25	-	-	HYPH
cord-354664-mzzvmyea	14	26	lactam	lactam	NN
cord-354664-mzzvmyea	14	27	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	14	28	in	in	IN
cord-354664-mzzvmyea	14	29	the	the	DT
cord-354664-mzzvmyea	14	30	hospital	hospital	NN
cord-354664-mzzvmyea	14	31	.	.	.
cord-354664-mzzvmyea	15	1	SUMMARY	summary	NN
cord-354664-mzzvmyea	15	2	:	:	:
cord-354664-mzzvmyea	16	1	Current	current	JJ
cord-354664-mzzvmyea	16	2	evidence	evidence	NN
cord-354664-mzzvmyea	16	3	supports	support	VBZ
cord-354664-mzzvmyea	16	4	the	the	DT
cord-354664-mzzvmyea	16	5	use	use	NN
cord-354664-mzzvmyea	16	6	of	of	IN
cord-354664-mzzvmyea	16	7	beta	beta	NN
cord-354664-mzzvmyea	16	8	-	-	HYPH
cord-354664-mzzvmyea	16	9	lactam	lactam	NN
cord-354664-mzzvmyea	16	10	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	16	11	in	in	IN
cord-354664-mzzvmyea	16	12	adult	adult	NN
cord-354664-mzzvmyea	16	13	patients	patient	NNS
cord-354664-mzzvmyea	16	14	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	16	15	with	with	IN
cord-354664-mzzvmyea	16	16	mild	mild	JJ
cord-354664-mzzvmyea	16	17	to	to	IN
cord-354664-mzzvmyea	16	18	moderate	moderate	JJ
cord-354664-mzzvmyea	16	19	CAP	cap	NN
cord-354664-mzzvmyea	16	20	.	.	.
cord-354664-mzzvmyea	17	1	While	while	IN
cord-354664-mzzvmyea	17	2	existing	exist	VBG
cord-354664-mzzvmyea	17	3	evidence	evidence	NN
cord-354664-mzzvmyea	17	4	supports	support	VBZ
cord-354664-mzzvmyea	17	5	the	the	DT
cord-354664-mzzvmyea	17	6	use	use	NN
cord-354664-mzzvmyea	17	7	of	of	IN
cord-354664-mzzvmyea	17	8	combination	combination	NN
cord-354664-mzzvmyea	17	9	therapy	therapy	NN
cord-354664-mzzvmyea	17	10	in	in	IN
cord-354664-mzzvmyea	17	11	patients	patient	NNS
cord-354664-mzzvmyea	17	12	with	with	IN
cord-354664-mzzvmyea	17	13	severe	severe	JJ
cord-354664-mzzvmyea	17	14	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	17	15	,	,	,
cord-354664-mzzvmyea	17	16	further	further	JJ
cord-354664-mzzvmyea	17	17	large	large	JJ
cord-354664-mzzvmyea	17	18	-	-	HYPH
cord-354664-mzzvmyea	17	19	scale	scale	NN
cord-354664-mzzvmyea	17	20	randomized	randomize	VBN
cord-354664-mzzvmyea	17	21	controlled	control	VBN
cord-354664-mzzvmyea	17	22	trials	trial	NNS
cord-354664-mzzvmyea	17	23	are	be	VBP
cord-354664-mzzvmyea	17	24	urgently	urgently	RB
cord-354664-mzzvmyea	17	25	needed	need	VBN
cord-354664-mzzvmyea	17	26	to	to	TO
cord-354664-mzzvmyea	17	27	clarify	clarify	VB
cord-354664-mzzvmyea	17	28	the	the	DT
cord-354664-mzzvmyea	17	29	role	role	NN
cord-354664-mzzvmyea	17	30	of	of	IN
cord-354664-mzzvmyea	17	31	combination	combination	NN
cord-354664-mzzvmyea	17	32	therapy	therapy	NN
cord-354664-mzzvmyea	17	33	in	in	IN
cord-354664-mzzvmyea	17	34	this	this	DT
cord-354664-mzzvmyea	17	35	population	population	NN
cord-354664-mzzvmyea	17	36	.	.	.
cord-354664-mzzvmyea	18	1	Community	community	NN
cord-354664-mzzvmyea	18	2	-	-	HYPH
cord-354664-mzzvmyea	18	3	acquired	acquire	VBN
cord-354664-mzzvmyea	18	4	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	18	5	(	(	-LRB-
cord-354664-mzzvmyea	18	6	CAP	CAP	NNP
cord-354664-mzzvmyea	18	7	)	)	-RRB-
cord-354664-mzzvmyea	18	8	remains	remain	VBZ
cord-354664-mzzvmyea	18	9	a	a	DT
cord-354664-mzzvmyea	18	10	significant	significant	JJ
cord-354664-mzzvmyea	18	11	cause	cause	NN
cord-354664-mzzvmyea	18	12	of	of	IN
cord-354664-mzzvmyea	18	13	morbidity	morbidity	NN
cord-354664-mzzvmyea	18	14	and	and	CC
cord-354664-mzzvmyea	18	15	mortality	mortality	NN
cord-354664-mzzvmyea	18	16	,	,	,
cord-354664-mzzvmyea	18	17	resulting	result	VBG
cord-354664-mzzvmyea	18	18	in	in	IN
cord-354664-mzzvmyea	18	19	an	an	DT
cord-354664-mzzvmyea	18	20	estimated	estimate	VBN
cord-354664-mzzvmyea	18	21	1.5	1.5	CD
cord-354664-mzzvmyea	18	22	million	million	CD
cord-354664-mzzvmyea	18	23	adult	adult	NN
cord-354664-mzzvmyea	18	24	hospitalizations	hospitalization	NNS
cord-354664-mzzvmyea	18	25	annually	annually	RB
cord-354664-mzzvmyea	18	26	in	in	IN
cord-354664-mzzvmyea	18	27	the	the	DT
cord-354664-mzzvmyea	18	28	United	United	NNP
cord-354664-mzzvmyea	18	29	States	States	NNP
cord-354664-mzzvmyea	18	30	[	[	-LRB-
cord-354664-mzzvmyea	18	31	1•	1•	CD
cord-354664-mzzvmyea	18	32	,	,	,
cord-354664-mzzvmyea	18	33	2	2	CD
cord-354664-mzzvmyea	18	34	]	]	-RRB-
cord-354664-mzzvmyea	18	35	.	.	.
cord-354664-mzzvmyea	19	1	Despite	despite	IN
cord-354664-mzzvmyea	19	2	advances	advance	NNS
cord-354664-mzzvmyea	19	3	in	in	IN
cord-354664-mzzvmyea	19	4	sepsis	sepsis	NN
cord-354664-mzzvmyea	19	5	recognition	recognition	NN
cord-354664-mzzvmyea	19	6	and	and	CC
cord-354664-mzzvmyea	19	7	management	management	NN
cord-354664-mzzvmyea	19	8	and	and	CC
cord-354664-mzzvmyea	19	9	being	be	VBG
cord-354664-mzzvmyea	19	10	a	a	DT
cord-354664-mzzvmyea	19	11	core	core	NN
cord-354664-mzzvmyea	19	12	measure	measure	NN
cord-354664-mzzvmyea	19	13	by	by	IN
cord-354664-mzzvmyea	19	14	the	the	DT
cord-354664-mzzvmyea	19	15	Centers	Centers	NNPS
cord-354664-mzzvmyea	19	16	for	for	IN
cord-354664-mzzvmyea	19	17	Medicare	Medicare	NNP
cord-354664-mzzvmyea	19	18	&	&	CC
cord-354664-mzzvmyea	19	19	Medicaid	Medicaid	NNP
cord-354664-mzzvmyea	19	20	Services	Services	NNP
cord-354664-mzzvmyea	19	21	,	,	,
cord-354664-mzzvmyea	19	22	the	the	DT
cord-354664-mzzvmyea	19	23	in	in	IN
cord-354664-mzzvmyea	19	24	-	-	HYPH
cord-354664-mzzvmyea	19	25	hospital	hospital	NN
cord-354664-mzzvmyea	19	26	mortality	mortality	NN
cord-354664-mzzvmyea	19	27	of	of	IN
cord-354664-mzzvmyea	19	28	patients	patient	NNS
cord-354664-mzzvmyea	19	29	admitted	admit	VBN
cord-354664-mzzvmyea	19	30	with	with	IN
cord-354664-mzzvmyea	19	31	CAP	CAP	NNP
cord-354664-mzzvmyea	19	32	remains	remain	VBZ
cord-354664-mzzvmyea	19	33	high	high	JJ
cord-354664-mzzvmyea	19	34	at	at	IN
cord-354664-mzzvmyea	19	35	6.5	6.5	CD
cord-354664-mzzvmyea	19	36	%	%	NN
cord-354664-mzzvmyea	19	37	with	with	IN
cord-354664-mzzvmyea	19	38	all	all	DT
cord-354664-mzzvmyea	19	39	-	-	HYPH
cord-354664-mzzvmyea	19	40	cause	cause	NN
cord-354664-mzzvmyea	19	41	mortality	mortality	NN
cord-354664-mzzvmyea	19	42	at	at	IN
cord-354664-mzzvmyea	19	43	30	30	CD
cord-354664-mzzvmyea	19	44	days	day	NNS
cord-354664-mzzvmyea	19	45	,	,	,
cord-354664-mzzvmyea	19	46	6	6	CD
cord-354664-mzzvmyea	19	47	months	month	NNS
cord-354664-mzzvmyea	19	48	,	,	,
cord-354664-mzzvmyea	19	49	and	and	CC
cord-354664-mzzvmyea	19	50	1	1	CD
cord-354664-mzzvmyea	19	51	year	year	NN
cord-354664-mzzvmyea	19	52	estimated	estimate	VBN
cord-354664-mzzvmyea	19	53	to	to	TO
cord-354664-mzzvmyea	19	54	be	be	VB
cord-354664-mzzvmyea	19	55	13	13	CD
cord-354664-mzzvmyea	19	56	%	%	NN
cord-354664-mzzvmyea	19	57	,	,	,
cord-354664-mzzvmyea	19	58	23	23	CD
cord-354664-mzzvmyea	19	59	%	%	NN
cord-354664-mzzvmyea	19	60	,	,	,
cord-354664-mzzvmyea	19	61	and	and	CC
cord-354664-mzzvmyea	19	62	31	31	CD
cord-354664-mzzvmyea	19	63	%	%	NN
cord-354664-mzzvmyea	19	64	,	,	,
cord-354664-mzzvmyea	19	65	respectively	respectively	RB
cord-354664-mzzvmyea	19	66	[	[	-LRB-
cord-354664-mzzvmyea	19	67	1•	1•	CD
cord-354664-mzzvmyea	19	68	,	,	,
cord-354664-mzzvmyea	19	69	3	3	CD
cord-354664-mzzvmyea	19	70	]	]	-RRB-
cord-354664-mzzvmyea	19	71	.	.	.
cord-354664-mzzvmyea	20	1	The	the	DT
cord-354664-mzzvmyea	20	2	broad	broad	JJ
cord-354664-mzzvmyea	20	3	spectrum	spectrum	NN
cord-354664-mzzvmyea	20	4	of	of	IN
cord-354664-mzzvmyea	20	5	pathogens	pathogen	NNS
cord-354664-mzzvmyea	20	6	causing	cause	VBG
cord-354664-mzzvmyea	20	7	CAP	CAP	NNP
cord-354664-mzzvmyea	20	8	remains	remain	VBZ
cord-354664-mzzvmyea	20	9	unchanged	unchanged	JJ
cord-354664-mzzvmyea	20	10	and	and	CC
cord-354664-mzzvmyea	20	11	includes	include	VBZ
cord-354664-mzzvmyea	20	12	typical	typical	JJ
cord-354664-mzzvmyea	20	13	bacteria	bacteria	NNS
cord-354664-mzzvmyea	20	14	(	(	-LRB-
cord-354664-mzzvmyea	20	15	Streptococcus	streptococcus	NN
cord-354664-mzzvmyea	20	16	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	20	17	,	,	,
cord-354664-mzzvmyea	20	18	Haemophilus	haemophilus	JJ
cord-354664-mzzvmyea	20	19	influenzae	influenzae	NN
cord-354664-mzzvmyea	20	20	,	,	,
cord-354664-mzzvmyea	20	21	Moraxella	Moraxella	NNP
cord-354664-mzzvmyea	20	22	catarrhalis	catarrhalis	NNP
cord-354664-mzzvmyea	20	23	)	)	-RRB-
cord-354664-mzzvmyea	20	24	,	,	,
cord-354664-mzzvmyea	20	25	atypical	atypical	JJ
cord-354664-mzzvmyea	20	26	bacteria	bacteria	NNS
cord-354664-mzzvmyea	20	27	(	(	-LRB-
cord-354664-mzzvmyea	20	28	Mycoplasma	mycoplasma	NN
cord-354664-mzzvmyea	20	29	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	20	30	,	,	,
cord-354664-mzzvmyea	20	31	Chlamydia	Chlamydia	NNP
cord-354664-mzzvmyea	20	32	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	20	33	,	,	,
cord-354664-mzzvmyea	20	34	Legionella	Legionella	NNP
cord-354664-mzzvmyea	20	35	spp	spp	NNP
cord-354664-mzzvmyea	20	36	.	.	.
cord-354664-mzzvmyea	20	37	)	)	-RRB-
cord-354664-mzzvmyea	20	38	,	,	,
cord-354664-mzzvmyea	20	39	viruses	virus	NNS
cord-354664-mzzvmyea	20	40	(	(	-LRB-
cord-354664-mzzvmyea	20	41	such	such	JJ
cord-354664-mzzvmyea	20	42	as	as	IN
cord-354664-mzzvmyea	20	43	rhinovirus	rhinovirus	NN
cord-354664-mzzvmyea	20	44	,	,	,
cord-354664-mzzvmyea	20	45	influenza	influenza	NN
cord-354664-mzzvmyea	20	46	,	,	,
cord-354664-mzzvmyea	20	47	parainfluenza	parainfluenza	NNP
cord-354664-mzzvmyea	20	48	,	,	,
cord-354664-mzzvmyea	20	49	respiratory	respiratory	JJ
cord-354664-mzzvmyea	20	50	syncytial	syncytial	JJ
cord-354664-mzzvmyea	20	51	virus	virus	NN
cord-354664-mzzvmyea	20	52	,	,	,
cord-354664-mzzvmyea	20	53	coronaviruses	coronaviruse	NNS
cord-354664-mzzvmyea	20	54	,	,	,
cord-354664-mzzvmyea	20	55	human	human	JJ
cord-354664-mzzvmyea	20	56	metapneumovirus	metapneumovirus	NNP
cord-354664-mzzvmyea	20	57	)	)	-RRB-
cord-354664-mzzvmyea	20	58	and	and	CC
cord-354664-mzzvmyea	20	59	less	less	RBR
cord-354664-mzzvmyea	20	60	frequently	frequently	RB
cord-354664-mzzvmyea	20	61	Staphylococcus	Staphylococcus	NNP
cord-354664-mzzvmyea	20	62	aureus	aureus	NN
cord-354664-mzzvmyea	20	63	,	,	,
cord-354664-mzzvmyea	20	64	gram	gram	NN
cord-354664-mzzvmyea	20	65	-	-	HYPH
cord-354664-mzzvmyea	20	66	negative	negative	JJ
cord-354664-mzzvmyea	20	67	bacilli	bacilli	NN
cord-354664-mzzvmyea	20	68	,	,	,
cord-354664-mzzvmyea	20	69	fungi	fungus	NNS
cord-354664-mzzvmyea	20	70	,	,	,
cord-354664-mzzvmyea	20	71	and	and	CC
cord-354664-mzzvmyea	20	72	mycobacteria	mycobacterium	NNS
cord-354664-mzzvmyea	20	73	[	[	-LRB-
cord-354664-mzzvmyea	20	74	4	4	CD
cord-354664-mzzvmyea	20	75	]	]	-RRB-
cord-354664-mzzvmyea	20	76	.	.	.
cord-354664-mzzvmyea	21	1	While	while	IN
cord-354664-mzzvmyea	21	2	diagnostic	diagnostic	JJ
cord-354664-mzzvmyea	21	3	techniques	technique	NNS
cord-354664-mzzvmyea	21	4	to	to	TO
cord-354664-mzzvmyea	21	5	facilitate	facilitate	VB
cord-354664-mzzvmyea	21	6	the	the	DT
cord-354664-mzzvmyea	21	7	accurate	accurate	JJ
cord-354664-mzzvmyea	21	8	identification	identification	NN
cord-354664-mzzvmyea	21	9	of	of	IN
cord-354664-mzzvmyea	21	10	causative	causative	JJ
cord-354664-mzzvmyea	21	11	agents	agent	NNS
cord-354664-mzzvmyea	21	12	have	have	VBP
cord-354664-mzzvmyea	21	13	improved	improve	VBN
cord-354664-mzzvmyea	21	14	,	,	,
cord-354664-mzzvmyea	21	15	including	include	VBG
cord-354664-mzzvmyea	21	16	the	the	DT
cord-354664-mzzvmyea	21	17	rapid	rapid	JJ
cord-354664-mzzvmyea	21	18	evolution	evolution	NN
cord-354664-mzzvmyea	21	19	of	of	IN
cord-354664-mzzvmyea	21	20	commercial	commercial	JJ
cord-354664-mzzvmyea	21	21	multiplex	multiplex	NN
cord-354664-mzzvmyea	21	22	PCR	pcr	NN
cord-354664-mzzvmyea	21	23	assays	assay	NNS
cord-354664-mzzvmyea	21	24	,	,	,
cord-354664-mzzvmyea	21	25	an	an	DT
cord-354664-mzzvmyea	21	26	etiologic	etiologic	JJ
cord-354664-mzzvmyea	21	27	agent	agent	NN
cord-354664-mzzvmyea	21	28	is	be	VBZ
cord-354664-mzzvmyea	21	29	identified	identify	VBN
cord-354664-mzzvmyea	21	30	in	in	IN
cord-354664-mzzvmyea	21	31	fewer	few	JJR
cord-354664-mzzvmyea	21	32	than	than	IN
cord-354664-mzzvmyea	21	33	half	half	NN
cord-354664-mzzvmyea	21	34	of	of	IN
cord-354664-mzzvmyea	21	35	CAP	cap	NN
cord-354664-mzzvmyea	21	36	cases	case	NNS
cord-354664-mzzvmyea	21	37	and	and	CC
cord-354664-mzzvmyea	21	38	frequently	frequently	RB
cord-354664-mzzvmyea	21	39	leaves	leave	VBZ
cord-354664-mzzvmyea	21	40	clinicians	clinician	NNS
cord-354664-mzzvmyea	21	41	to	to	TO
cord-354664-mzzvmyea	21	42	rely	rely	VB
cord-354664-mzzvmyea	21	43	on	on	IN
cord-354664-mzzvmyea	21	44	empiric	empiric	JJ
cord-354664-mzzvmyea	21	45	antimicrobials	antimicrobial	NNS
cord-354664-mzzvmyea	21	46	for	for	IN
cord-354664-mzzvmyea	21	47	management	management	NN
cord-354664-mzzvmyea	21	48	[	[	-LRB-
cord-354664-mzzvmyea	21	49	5	5	CD
cord-354664-mzzvmyea	21	50	,	,	,
cord-354664-mzzvmyea	21	51	6•	6•	CD
cord-354664-mzzvmyea	21	52	]	]	-RRB-
cord-354664-mzzvmyea	21	53	.	.	.
cord-354664-mzzvmyea	22	1	Macrolide	macrolide	JJ
cord-354664-mzzvmyea	22	2	antimicrobials	antimicrobial	NNS
cord-354664-mzzvmyea	22	3	are	be	VBP
cord-354664-mzzvmyea	22	4	commonly	commonly	RB
cord-354664-mzzvmyea	22	5	prescribed	prescribe	VBN
cord-354664-mzzvmyea	22	6	agents	agent	NNS
cord-354664-mzzvmyea	22	7	for	for	IN
cord-354664-mzzvmyea	22	8	the	the	DT
cord-354664-mzzvmyea	22	9	management	management	NN
cord-354664-mzzvmyea	22	10	of	of	IN
cord-354664-mzzvmyea	22	11	respiratory	respiratory	JJ
cord-354664-mzzvmyea	22	12	tract	tract	NN
cord-354664-mzzvmyea	22	13	infections	infection	NNS
cord-354664-mzzvmyea	22	14	[	[	-LRB-
cord-354664-mzzvmyea	22	15	7	7	CD
cord-354664-mzzvmyea	22	16	]	]	-RRB-
cord-354664-mzzvmyea	22	17	.	.	.
cord-354664-mzzvmyea	23	1	As	as	IN
cord-354664-mzzvmyea	23	2	a	a	DT
cord-354664-mzzvmyea	23	3	class	class	NN
cord-354664-mzzvmyea	23	4	,	,	,
cord-354664-mzzvmyea	23	5	macrolides	macrolide	NNS
cord-354664-mzzvmyea	23	6	are	be	VBP
cord-354664-mzzvmyea	23	7	bacteriostatic	bacteriostatic	JJ
cord-354664-mzzvmyea	23	8	and	and	CC
cord-354664-mzzvmyea	23	9	function	function	VB
cord-354664-mzzvmyea	23	10	by	by	IN
cord-354664-mzzvmyea	23	11	inhibiting	inhibit	VBG
cord-354664-mzzvmyea	23	12	bacterial	bacterial	JJ
cord-354664-mzzvmyea	23	13	protein	protein	NN
cord-354664-mzzvmyea	23	14	synthesis	synthesis	NN
cord-354664-mzzvmyea	23	15	through	through	IN
cord-354664-mzzvmyea	23	16	reversible	reversible	JJ
cord-354664-mzzvmyea	23	17	binding	binding	NN
cord-354664-mzzvmyea	23	18	to	to	IN
cord-354664-mzzvmyea	23	19	23S	23S	NNP
cord-354664-mzzvmyea	23	20	ribosomal	ribosomal	NNP
cord-354664-mzzvmyea	23	21	RNA	RNA	NNP
cord-354664-mzzvmyea	23	22	of	of	IN
cord-354664-mzzvmyea	23	23	the	the	DT
cord-354664-mzzvmyea	23	24	50S	50s	CD
cord-354664-mzzvmyea	23	25	ribosomal	ribosomal	JJ
cord-354664-mzzvmyea	23	26	subunit	subunit	NN
cord-354664-mzzvmyea	23	27	,	,	,
cord-354664-mzzvmyea	23	28	resulting	result	VBG
cord-354664-mzzvmyea	23	29	in	in	IN
cord-354664-mzzvmyea	23	30	inhibition	inhibition	NN
cord-354664-mzzvmyea	23	31	of	of	IN
cord-354664-mzzvmyea	23	32	RNA	RNA	NNP
cord-354664-mzzvmyea	23	33	-	-	HYPH
cord-354664-mzzvmyea	23	34	dependent	dependent	JJ
cord-354664-mzzvmyea	23	35	protein	protein	NN
cord-354664-mzzvmyea	23	36	synthesis	synthesis	NN
cord-354664-mzzvmyea	23	37	[	[	-LRB-
cord-354664-mzzvmyea	23	38	8	8	CD
cord-354664-mzzvmyea	23	39	]	]	-RRB-
cord-354664-mzzvmyea	23	40	.	.	.
cord-354664-mzzvmyea	24	1	However	however	RB
cord-354664-mzzvmyea	24	2	,	,	,
cord-354664-mzzvmyea	24	3	widespread	widespread	JJ
cord-354664-mzzvmyea	24	4	resistance	resistance	NN
cord-354664-mzzvmyea	24	5	to	to	IN
cord-354664-mzzvmyea	24	6	macrolides	macrolide	NNS
cord-354664-mzzvmyea	24	7	due	due	JJ
cord-354664-mzzvmyea	24	8	to	to	IN
cord-354664-mzzvmyea	24	9	point	point	NN
cord-354664-mzzvmyea	24	10	mutations	mutation	NNS
cord-354664-mzzvmyea	24	11	in	in	IN
cord-354664-mzzvmyea	24	12	the	the	DT
cord-354664-mzzvmyea	24	13	23S	23S	NNP
cord-354664-mzzvmyea	24	14	rRNA	rRNA	NNP
cord-354664-mzzvmyea	24	15	binding	bind	VBG
cord-354664-mzzvmyea	24	16	site	site	NN
cord-354664-mzzvmyea	24	17	has	have	VBZ
cord-354664-mzzvmyea	24	18	significantly	significantly	RB
cord-354664-mzzvmyea	24	19	limited	limit	VBN
cord-354664-mzzvmyea	24	20	their	-PRON-	PRP$
cord-354664-mzzvmyea	24	21	utility	utility	NN
cord-354664-mzzvmyea	24	22	[	[	-LRB-
cord-354664-mzzvmyea	24	23	9	9	CD
cord-354664-mzzvmyea	24	24	,	,	,
cord-354664-mzzvmyea	24	25	10	10	CD
cord-354664-mzzvmyea	24	26	]	]	-RRB-
cord-354664-mzzvmyea	24	27	.	.	.
cord-354664-mzzvmyea	25	1	S.	S.	NNP
cord-354664-mzzvmyea	25	2	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	25	3	resistance	resistance	NN
cord-354664-mzzvmyea	25	4	to	to	IN
cord-354664-mzzvmyea	25	5	macrolides	macrolide	NNS
cord-354664-mzzvmyea	25	6	has	have	VBZ
cord-354664-mzzvmyea	25	7	demonstrated	demonstrate	VBN
cord-354664-mzzvmyea	25	8	regional	regional	JJ
cord-354664-mzzvmyea	25	9	variability	variability	NN
cord-354664-mzzvmyea	25	10	with	with	IN
cord-354664-mzzvmyea	25	11	rates	rate	NNS
cord-354664-mzzvmyea	25	12	ranging	range	VBG
cord-354664-mzzvmyea	25	13	from	from	IN
cord-354664-mzzvmyea	25	14	30	30	CD
cord-354664-mzzvmyea	25	15	%	%	NN
cord-354664-mzzvmyea	25	16	in	in	IN
cord-354664-mzzvmyea	25	17	North	North	NNP
cord-354664-mzzvmyea	25	18	America	America	NNP
cord-354664-mzzvmyea	25	19	to	to	IN
cord-354664-mzzvmyea	25	20	over	over	IN
cord-354664-mzzvmyea	25	21	90	90	CD
cord-354664-mzzvmyea	25	22	%	%	NN
cord-354664-mzzvmyea	25	23	in	in	IN
cord-354664-mzzvmyea	25	24	Vietnam	Vietnam	NNP
cord-354664-mzzvmyea	25	25	while	while	IN
cord-354664-mzzvmyea	25	26	M.	M.	NNP
cord-354664-mzzvmyea	25	27	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	25	28	demonstrates	demonstrate	VBZ
cord-354664-mzzvmyea	25	29	similar	similar	JJ
cord-354664-mzzvmyea	25	30	resistance	resistance	NN
cord-354664-mzzvmyea	25	31	ranging	range	VBG
cord-354664-mzzvmyea	25	32	from	from	IN
cord-354664-mzzvmyea	25	33	10	10	CD
cord-354664-mzzvmyea	25	34	%	%	NN
cord-354664-mzzvmyea	25	35	in	in	IN
cord-354664-mzzvmyea	25	36	the	the	DT
cord-354664-mzzvmyea	25	37	United	United	NNP
cord-354664-mzzvmyea	25	38	States	States	NNP
cord-354664-mzzvmyea	25	39	to	to	IN
cord-354664-mzzvmyea	25	40	over	over	IN
cord-354664-mzzvmyea	25	41	90	90	CD
cord-354664-mzzvmyea	25	42	%	%	NN
cord-354664-mzzvmyea	25	43	in	in	IN
cord-354664-mzzvmyea	25	44	regions	region	NNS
cord-354664-mzzvmyea	25	45	of	of	IN
cord-354664-mzzvmyea	25	46	Japan	Japan	NNP
cord-354664-mzzvmyea	25	47	[	[	-LRB-
cord-354664-mzzvmyea	25	48	11	11	CD
cord-354664-mzzvmyea	25	49	]	]	-RRB-
cord-354664-mzzvmyea	25	50	[	[	-LRB-
cord-354664-mzzvmyea	25	51	12	12	CD
cord-354664-mzzvmyea	25	52	]	]	-RRB-
cord-354664-mzzvmyea	25	53	[	[	-LRB-
cord-354664-mzzvmyea	25	54	13	13	CD
cord-354664-mzzvmyea	25	55	]	]	-RRB-
cord-354664-mzzvmyea	25	56	[	[	-LRB-
cord-354664-mzzvmyea	25	57	14	14	CD
cord-354664-mzzvmyea	25	58	]	]	-RRB-
cord-354664-mzzvmyea	25	59	.	.	.
cord-354664-mzzvmyea	26	1	Aside	aside	RB
cord-354664-mzzvmyea	26	2	from	from	IN
cord-354664-mzzvmyea	26	3	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	26	4	properties	property	NNS
cord-354664-mzzvmyea	26	5	,	,	,
cord-354664-mzzvmyea	26	6	macrolides	macrolide	NNS
cord-354664-mzzvmyea	26	7	are	be	VBP
cord-354664-mzzvmyea	26	8	also	also	RB
cord-354664-mzzvmyea	26	9	prescribed	prescribe	VBN
cord-354664-mzzvmyea	26	10	for	for	IN
cord-354664-mzzvmyea	26	11	their	-PRON-	PRP$
cord-354664-mzzvmyea	26	12	immune	immune	JJ
cord-354664-mzzvmyea	26	13	modulating	modulate	VBG
cord-354664-mzzvmyea	26	14	effects	effect	NNS
cord-354664-mzzvmyea	26	15	,	,	,
cord-354664-mzzvmyea	26	16	particularly	particularly	RB
cord-354664-mzzvmyea	26	17	in	in	IN
cord-354664-mzzvmyea	26	18	the	the	DT
cord-354664-mzzvmyea	26	19	setting	setting	NN
cord-354664-mzzvmyea	26	20	of	of	IN
cord-354664-mzzvmyea	26	21	chronic	chronic	JJ
cord-354664-mzzvmyea	26	22	inflammatory	inflammatory	JJ
cord-354664-mzzvmyea	26	23	lung	lung	NN
cord-354664-mzzvmyea	26	24	diseases	disease	NNS
cord-354664-mzzvmyea	26	25	.	.	.
cord-354664-mzzvmyea	27	1	M	M	NNP
cord-354664-mzzvmyea	27	2	a	a	DT
cord-354664-mzzvmyea	27	3	c	c	NN
cord-354664-mzzvmyea	27	4	r	r	NN
cord-354664-mzzvmyea	28	1	o	o	UH
cord-354664-mzzvmyea	28	2	l	l	NN
cord-354664-mzzvmyea	29	1	i	i	PRP
cord-354664-mzzvmyea	30	1	d	d	NNP
cord-354664-mzzvmyea	30	2	e	e	NN
cord-354664-mzzvmyea	30	3	s	s	NN
cord-354664-mzzvmyea	31	1	h	h	NNP
cord-354664-mzzvmyea	31	2	a	a	NN
cord-354664-mzzvmyea	31	3	v	v	NN
cord-354664-mzzvmyea	31	4	e	e	NN
cord-354664-mzzvmyea	31	5	b	b	NN
cord-354664-mzzvmyea	31	6	e	e	NN
cord-354664-mzzvmyea	31	7	e	e	NN
cord-354664-mzzvmyea	31	8	n	n	NN
cord-354664-mzzvmyea	31	9	s	s	NN
cord-354664-mzzvmyea	31	10	h	h	NN
cord-354664-mzzvmyea	31	11	o	o	NN
cord-354664-mzzvmyea	32	1	w	w	NN
cord-354664-mzzvmyea	32	2	n	n	CC
cord-354664-mzzvmyea	32	3	t	t	NN
cord-354664-mzzvmyea	32	4	o	o	NN
cord-354664-mzzvmyea	32	5	s	s	NN
cord-354664-mzzvmyea	33	1	u	u	NN
cord-354664-mzzvmyea	33	2	p	p	NN
cord-354664-mzzvmyea	33	3	p	p	NN
cord-354664-mzzvmyea	33	4	r	r	NN
cord-354664-mzzvmyea	33	5	e	e	NN
cord-354664-mzzvmyea	33	6	s	s	NN
cord-354664-mzzvmyea	33	7	s	s	NN
cord-354664-mzzvmyea	33	8	p	p	NN
cord-354664-mzzvmyea	33	9	r	r	NNP
cord-354664-mzzvmyea	33	10	oinflammatory	oinflammatory	NNP
cord-354664-mzzvmyea	33	11	cytokines	cytokine	NNS
cord-354664-mzzvmyea	33	12	[	[	-LRB-
cord-354664-mzzvmyea	33	13	15	15	CD
cord-354664-mzzvmyea	33	14	]	]	-RRB-
cord-354664-mzzvmyea	33	15	,	,	,
cord-354664-mzzvmyea	33	16	decrease	decrease	VB
cord-354664-mzzvmyea	33	17	polymorphonuclear	polymorphonuclear	JJ
cord-354664-mzzvmyea	33	18	cell	cell	NN
cord-354664-mzzvmyea	33	19	recruitment	recruitment	NN
cord-354664-mzzvmyea	33	20	[	[	-LRB-
cord-354664-mzzvmyea	33	21	16	16	CD
cord-354664-mzzvmyea	33	22	]	]	-RRB-
cord-354664-mzzvmyea	33	23	,	,	,
cord-354664-mzzvmyea	33	24	attenuate	attenuate	VB
cord-354664-mzzvmyea	33	25	reactive	reactive	JJ
cord-354664-mzzvmyea	33	26	oxygen	oxygen	NN
cord-354664-mzzvmyea	33	27	species	specie	NNS
cord-354664-mzzvmyea	33	28	[	[	-LRB-
cord-354664-mzzvmyea	33	29	17	17	CD
cord-354664-mzzvmyea	33	30	]	]	-RRB-
cord-354664-mzzvmyea	33	31	,	,	,
cord-354664-mzzvmyea	33	32	and	and	CC
cord-354664-mzzvmyea	33	33	alter	alter	VB
cord-354664-mzzvmyea	33	34	key	key	JJ
cord-354664-mzzvmyea	33	35	transcription	transcription	NN
cord-354664-mzzvmyea	33	36	factors	factor	NNS
cord-354664-mzzvmyea	33	37	[	[	-LRB-
cord-354664-mzzvmyea	33	38	18	18	CD
cord-354664-mzzvmyea	33	39	]	]	-RRB-
cord-354664-mzzvmyea	33	40	.	.	.
cord-354664-mzzvmyea	34	1	While	while	IN
cord-354664-mzzvmyea	34	2	several	several	JJ
cord-354664-mzzvmyea	34	3	small	small	JJ
cord-354664-mzzvmyea	34	4	studies	study	NNS
cord-354664-mzzvmyea	34	5	have	have	VBP
cord-354664-mzzvmyea	34	6	shown	show	VBN
cord-354664-mzzvmyea	34	7	that	that	IN
cord-354664-mzzvmyea	34	8	immune	immune	JJ
cord-354664-mzzvmyea	34	9	modulation	modulation	NN
cord-354664-mzzvmyea	34	10	from	from	IN
cord-354664-mzzvmyea	34	11	macrolides	macrolide	NNS
cord-354664-mzzvmyea	34	12	may	may	MD
cord-354664-mzzvmyea	34	13	also	also	RB
cord-354664-mzzvmyea	34	14	be	be	VB
cord-354664-mzzvmyea	34	15	beneficial	beneficial	JJ
cord-354664-mzzvmyea	34	16	in	in	IN
cord-354664-mzzvmyea	34	17	acute	acute	JJ
cord-354664-mzzvmyea	34	18	CAP	cap	NN
cord-354664-mzzvmyea	34	19	by	by	IN
cord-354664-mzzvmyea	34	20	reducing	reduce	VBG
cord-354664-mzzvmyea	34	21	inflammatory	inflammatory	JJ
cord-354664-mzzvmyea	34	22	mediators	mediator	NNS
cord-354664-mzzvmyea	34	23	,	,	,
cord-354664-mzzvmyea	34	24	supportive	supportive	JJ
cord-354664-mzzvmyea	34	25	research	research	NN
cord-354664-mzzvmyea	34	26	linked	link	VBN
cord-354664-mzzvmyea	34	27	to	to	IN
cord-354664-mzzvmyea	34	28	clinical	clinical	JJ
cord-354664-mzzvmyea	34	29	outcomes	outcome	NNS
cord-354664-mzzvmyea	34	30	remains	remain	VBZ
cord-354664-mzzvmyea	34	31	limited	limited	JJ
cord-354664-mzzvmyea	34	32	and	and	CC
cord-354664-mzzvmyea	34	33	a	a	DT
cord-354664-mzzvmyea	34	34	clear	clear	JJ
cord-354664-mzzvmyea	34	35	benefit	benefit	NN
cord-354664-mzzvmyea	34	36	has	have	VBZ
cord-354664-mzzvmyea	34	37	not	not	RB
cord-354664-mzzvmyea	34	38	been	be	VBN
cord-354664-mzzvmyea	34	39	established	establish	VBN
cord-354664-mzzvmyea	34	40	[	[	-LRB-
cord-354664-mzzvmyea	34	41	19	19	CD
cord-354664-mzzvmyea	34	42	,	,	,
cord-354664-mzzvmyea	34	43	20	20	CD
cord-354664-mzzvmyea	34	44	]	]	-RRB-
cord-354664-mzzvmyea	34	45	.	.	.
cord-354664-mzzvmyea	35	1	A	a	DT
cord-354664-mzzvmyea	35	2	recent	recent	JJ
cord-354664-mzzvmyea	35	3	effort	effort	NN
cord-354664-mzzvmyea	35	4	to	to	TO
cord-354664-mzzvmyea	35	5	characterize	characterize	VB
cord-354664-mzzvmyea	35	6	causative	causative	JJ
cord-354664-mzzvmyea	35	7	CAP	cap	NN
cord-354664-mzzvmyea	35	8	pathogens	pathogen	NNS
cord-354664-mzzvmyea	35	9	through	through	IN
cord-354664-mzzvmyea	35	10	the	the	DT
cord-354664-mzzvmyea	35	11	use	use	NN
cord-354664-mzzvmyea	35	12	of	of	IN
cord-354664-mzzvmyea	35	13	modern	modern	JJ
cord-354664-mzzvmyea	35	14	diagnostic	diagnostic	JJ
cord-354664-mzzvmyea	35	15	tests	test	NNS
cord-354664-mzzvmyea	35	16	has	have	VBZ
cord-354664-mzzvmyea	35	17	been	be	VBN
cord-354664-mzzvmyea	35	18	published	publish	VBN
cord-354664-mzzvmyea	35	19	in	in	IN
cord-354664-mzzvmyea	35	20	the	the	DT
cord-354664-mzzvmyea	35	21	Center	Center	NNP
cord-354664-mzzvmyea	35	22	for	for	IN
cord-354664-mzzvmyea	36	1	Disease	Disease	NNP
cord-354664-mzzvmyea	36	2	Control	Control	NNP
cord-354664-mzzvmyea	36	3	and	and	CC
cord-354664-mzzvmyea	36	4	Prevention	Prevention	NNP
cord-354664-mzzvmyea	36	5	(	(	-LRB-
cord-354664-mzzvmyea	36	6	CDC	CDC	NNP
cord-354664-mzzvmyea	36	7	)	)	-RRB-
cord-354664-mzzvmyea	36	8	Etiology	etiology	NN
cord-354664-mzzvmyea	36	9	of	of	IN
cord-354664-mzzvmyea	36	10	Pneumonia	Pneumonia	NNP
cord-354664-mzzvmyea	36	11	in	in	IN
cord-354664-mzzvmyea	36	12	the	the	DT
cord-354664-mzzvmyea	36	13	Community	Community	NNP
cord-354664-mzzvmyea	36	14	(	(	-LRB-
cord-354664-mzzvmyea	36	15	EPIC	EPIC	NNP
cord-354664-mzzvmyea	36	16	)	)	-RRB-
cord-354664-mzzvmyea	36	17	study	study	VB
cord-354664-mzzvmyea	36	18	[	[	-LRB-
cord-354664-mzzvmyea	36	19	6•	6•	CD
cord-354664-mzzvmyea	36	20	]	]	-RRB-
cord-354664-mzzvmyea	36	21	.	.	.
cord-354664-mzzvmyea	37	1	The	the	DT
cord-354664-mzzvmyea	37	2	CDC	CDC	NNP
cord-354664-mzzvmyea	37	3	EPIC	EPIC	NNP
cord-354664-mzzvmyea	37	4	study	study	NN
cord-354664-mzzvmyea	37	5	was	be	VBD
cord-354664-mzzvmyea	37	6	a	a	DT
cord-354664-mzzvmyea	37	7	prospective	prospective	JJ
cord-354664-mzzvmyea	37	8	,	,	,
cord-354664-mzzvmyea	37	9	multicenter	multicenter	JJ
cord-354664-mzzvmyea	37	10	,	,	,
cord-354664-mzzvmyea	37	11	population	population	NN
cord-354664-mzzvmyea	37	12	-	-	HYPH
cord-354664-mzzvmyea	37	13	based	base	VBN
cord-354664-mzzvmyea	37	14	active	active	JJ
cord-354664-mzzvmyea	37	15	surveillance	surveillance	NN
cord-354664-mzzvmyea	37	16	study	study	NN
cord-354664-mzzvmyea	37	17	of	of	IN
cord-354664-mzzvmyea	37	18	2320	2320	CD
cord-354664-mzzvmyea	37	19	patients	patient	NNS
cord-354664-mzzvmyea	37	20	with	with	IN
cord-354664-mzzvmyea	37	21	radiographically	radiographically	RB
cord-354664-mzzvmyea	37	22	confirmed	confirm	VBN
cord-354664-mzzvmyea	37	23	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	37	24	at	at	IN
cord-354664-mzzvmyea	37	25	five	five	CD
cord-354664-mzzvmyea	37	26	US	US	NNP
cord-354664-mzzvmyea	37	27	hospitals	hospital	NNS
cord-354664-mzzvmyea	37	28	between	between	IN
cord-354664-mzzvmyea	37	29	2010	2010	CD
cord-354664-mzzvmyea	37	30	and	and	CC
cord-354664-mzzvmyea	37	31	2012	2012	CD
cord-354664-mzzvmyea	37	32	.	.	.
cord-354664-mzzvmyea	38	1	In	in	IN
cord-354664-mzzvmyea	38	2	addition	addition	NN
cord-354664-mzzvmyea	38	3	to	to	IN
cord-354664-mzzvmyea	38	4	conventional	conventional	JJ
cord-354664-mzzvmyea	38	5	diagnostic	diagnostic	JJ
cord-354664-mzzvmyea	38	6	tests	test	NNS
cord-354664-mzzvmyea	38	7	,	,	,
cord-354664-mzzvmyea	38	8	extensive	extensive	JJ
cord-354664-mzzvmyea	38	9	molecular	molecular	JJ
cord-354664-mzzvmyea	38	10	and	and	CC
cord-354664-mzzvmyea	38	11	serologic	serologic	NN
cord-354664-mzzvmyea	38	12	testing	testing	NN
cord-354664-mzzvmyea	38	13	was	be	VBD
cord-354664-mzzvmyea	38	14	employed	employ	VBN
cord-354664-mzzvmyea	38	15	to	to	TO
cord-354664-mzzvmyea	38	16	characterize	characterize	VB
cord-354664-mzzvmyea	38	17	causative	causative	JJ
cord-354664-mzzvmyea	38	18	pathogens	pathogen	NNS
cord-354664-mzzvmyea	38	19	.	.	.
cord-354664-mzzvmyea	39	1	In	in	IN
cord-354664-mzzvmyea	39	2	this	this	DT
cord-354664-mzzvmyea	39	3	cohort	cohort	NN
cord-354664-mzzvmyea	39	4	,	,	,
cord-354664-mzzvmyea	39	5	human	human	JJ
cord-354664-mzzvmyea	39	6	rhinovirus	rhinovirus	NN
cord-354664-mzzvmyea	39	7	,	,	,
cord-354664-mzzvmyea	39	8	influenza	influenza	NN
cord-354664-mzzvmyea	39	9	,	,	,
cord-354664-mzzvmyea	39	10	and	and	CC
cord-354664-mzzvmyea	39	11	S.	S.	NNP
cord-354664-mzzvmyea	39	12	pneumoniae	pneumoniae	NNS
cord-354664-mzzvmyea	39	13	were	be	VBD
cord-354664-mzzvmyea	39	14	the	the	DT
cord-354664-mzzvmyea	39	15	most	most	RBS
cord-354664-mzzvmyea	39	16	common	common	JJ
cord-354664-mzzvmyea	39	17	etiologic	etiologic	JJ
cord-354664-mzzvmyea	39	18	agents	agent	NNS
cord-354664-mzzvmyea	39	19	.	.	.
cord-354664-mzzvmyea	40	1	Atypical	atypical	JJ
cord-354664-mzzvmyea	40	2	pathogens	pathogen	NNS
cord-354664-mzzvmyea	40	3	were	be	VBD
cord-354664-mzzvmyea	40	4	infrequently	infrequently	RB
cord-354664-mzzvmyea	40	5	identifiedwith	identifiedwith	VB
cord-354664-mzzvmyea	40	6	the	the	DT
cord-354664-mzzvmyea	40	7	incidence	incidence	NN
cord-354664-mzzvmyea	40	8	of	of	IN
cord-354664-mzzvmyea	40	9	M.	M.	NNP
cord-354664-mzzvmyea	40	10	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	40	11	,	,	,
cord-354664-mzzvmyea	40	12	C.	C.	NNP
cord-354664-mzzvmyea	40	13	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	40	14	,	,	,
cord-354664-mzzvmyea	40	15	and	and	CC
cord-354664-mzzvmyea	40	16	L.	L.	NNP
cord-354664-mzzvmyea	40	17	pneumophila	pneumophila	NN
cord-354664-mzzvmyea	40	18	each	each	DT
cord-354664-mzzvmyea	40	19	representing	represent	VBG
cord-354664-mzzvmyea	40	20	less	less	JJR
cord-354664-mzzvmyea	40	21	than	than	IN
cord-354664-mzzvmyea	40	22	0.5	0.5	CD
cord-354664-mzzvmyea	40	23	cases	case	NNS
cord-354664-mzzvmyea	40	24	per	per	IN
cord-354664-mzzvmyea	40	25	10,000	10,000	CD
cord-354664-mzzvmyea	40	26	adults	adult	NNS
cord-354664-mzzvmyea	40	27	in	in	IN
cord-354664-mzzvmyea	40	28	the	the	DT
cord-354664-mzzvmyea	40	29	community	community	NN
cord-354664-mzzvmyea	40	30	.	.	.
cord-354664-mzzvmyea	41	1	This	this	DT
cord-354664-mzzvmyea	41	2	study	study	NN
cord-354664-mzzvmyea	41	3	provides	provide	VBZ
cord-354664-mzzvmyea	41	4	contemporary	contemporary	JJ
cord-354664-mzzvmyea	41	5	,	,	,
cord-354664-mzzvmyea	41	6	comprehensive	comprehensive	JJ
cord-354664-mzzvmyea	41	7	microbiologic	microbiologic	JJ
cord-354664-mzzvmyea	41	8	CAP	CAP	NNP
cord-354664-mzzvmyea	41	9	data	datum	NNS
cord-354664-mzzvmyea	41	10	that	that	WDT
cord-354664-mzzvmyea	41	11	is	be	VBZ
cord-354664-mzzvmyea	41	12	essential	essential	JJ
cord-354664-mzzvmyea	41	13	in	in	IN
cord-354664-mzzvmyea	41	14	informing	inform	VBG
cord-354664-mzzvmyea	41	15	guidelines	guideline	NNS
cord-354664-mzzvmyea	41	16	and	and	CC
cord-354664-mzzvmyea	41	17	choosing	choose	VBG
cord-354664-mzzvmyea	41	18	empiric	empiric	JJ
cord-354664-mzzvmyea	41	19	therapies	therapy	NNS
cord-354664-mzzvmyea	41	20	wisely	wisely	RB
cord-354664-mzzvmyea	41	21	.	.	.
cord-354664-mzzvmyea	42	1	The	the	DT
cord-354664-mzzvmyea	42	2	low	low	JJ
cord-354664-mzzvmyea	42	3	incidence	incidence	NN
cord-354664-mzzvmyea	42	4	of	of	IN
cord-354664-mzzvmyea	42	5	atypical	atypical	JJ
cord-354664-mzzvmyea	42	6	pathogens	pathogen	NNS
cord-354664-mzzvmyea	42	7	is	be	VBZ
cord-354664-mzzvmyea	42	8	of	of	IN
cord-354664-mzzvmyea	42	9	particular	particular	JJ
cord-354664-mzzvmyea	42	10	interest	interest	NN
cord-354664-mzzvmyea	42	11	.	.	.
cord-354664-mzzvmyea	43	1	Published	publish	VBN
cord-354664-mzzvmyea	43	2	recommendations	recommendation	NNS
cord-354664-mzzvmyea	43	3	regarding	regard	VBG
cord-354664-mzzvmyea	43	4	the	the	DT
cord-354664-mzzvmyea	43	5	use	use	NN
cord-354664-mzzvmyea	43	6	of	of	IN
cord-354664-mzzvmyea	43	7	beta	beta	NN
cord-354664-mzzvmyea	43	8	-	-	HYPH
cord-354664-mzzvmyea	43	9	lactams	lactam	NNS
cord-354664-mzzvmyea	43	10	in	in	IN
cord-354664-mzzvmyea	43	11	combination	combination	NN
cord-354664-mzzvmyea	43	12	with	with	IN
cord-354664-mzzvmyea	43	13	macrolides	macrolide	NNS
cord-354664-mzzvmyea	43	14	in	in	IN
cord-354664-mzzvmyea	43	15	current	current	JJ
cord-354664-mzzvmyea	43	16	clinical	clinical	JJ
cord-354664-mzzvmyea	43	17	practice	practice	NN
cord-354664-mzzvmyea	43	18	guidelines	guideline	NNS
cord-354664-mzzvmyea	43	19	are	be	VBP
cord-354664-mzzvmyea	43	20	variable	variable	JJ
cord-354664-mzzvmyea	43	21	and	and	CC
cord-354664-mzzvmyea	43	22	based	base	VBN
cord-354664-mzzvmyea	43	23	on	on	IN
cord-354664-mzzvmyea	43	24	relatively	relatively	RB
cord-354664-mzzvmyea	43	25	low	low	JJ
cord-354664-mzzvmyea	43	26	quality	quality	NN
cord-354664-mzzvmyea	43	27	evidence	evidence	NN
cord-354664-mzzvmyea	43	28	that	that	WDT
cord-354664-mzzvmyea	43	29	is	be	VBZ
cord-354664-mzzvmyea	43	30	frequently	frequently	RB
cord-354664-mzzvmyea	43	31	retrospective	retrospective	JJ
cord-354664-mzzvmyea	43	32	,	,	,
cord-354664-mzzvmyea	43	33	observational	observational	JJ
cord-354664-mzzvmyea	43	34	,	,	,
cord-354664-mzzvmyea	43	35	and	and	CC
cord-354664-mzzvmyea	43	36	heterogeneous	heterogeneous	JJ
cord-354664-mzzvmyea	43	37	in	in	IN
cord-354664-mzzvmyea	43	38	nature	nature	NN
cord-354664-mzzvmyea	43	39	.	.	.
cord-354664-mzzvmyea	44	1	Last	last	JJ
cord-354664-mzzvmyea	44	2	updated	update	VBN
cord-354664-mzzvmyea	44	3	in	in	IN
cord-354664-mzzvmyea	44	4	2007	2007	CD
cord-354664-mzzvmyea	44	5	,	,	,
cord-354664-mzzvmyea	44	6	the	the	DT
cord-354664-mzzvmyea	44	7	joint	joint	JJ
cord-354664-mzzvmyea	44	8	Infectious	Infectious	NNP
cord-354664-mzzvmyea	44	9	Disease	Disease	NNP
cord-354664-mzzvmyea	44	10	Society	Society	NNP
cord-354664-mzzvmyea	44	11	of	of	IN
cord-354664-mzzvmyea	44	12	America	America	NNP
cord-354664-mzzvmyea	44	13	(	(	-LRB-
cord-354664-mzzvmyea	44	14	IDSA)/American	IDSA)/American	NNP
cord-354664-mzzvmyea	44	15	Thoracic	Thoracic	NNP
cord-354664-mzzvmyea	44	16	Society	Society	NNP
cord-354664-mzzvmyea	44	17	(	(	-LRB-
cord-354664-mzzvmyea	44	18	ATS	ATS	NNP
cord-354664-mzzvmyea	44	19	)	)	-RRB-
cord-354664-mzzvmyea	44	20	guidelines	guideline	NNS
cord-354664-mzzvmyea	44	21	for	for	IN
cord-354664-mzzvmyea	44	22	CAP	cap	NN
cord-354664-mzzvmyea	44	23	recommend	recommend	VBP
cord-354664-mzzvmyea	44	24	empiric	empiric	JJ
cord-354664-mzzvmyea	44	25	combination	combination	NN
cord-354664-mzzvmyea	44	26	therapy	therapy	NN
cord-354664-mzzvmyea	44	27	with	with	IN
cord-354664-mzzvmyea	44	28	a	a	DT
cord-354664-mzzvmyea	44	29	beta	beta	NN
cord-354664-mzzvmyea	44	30	-	-	HYPH
cord-354664-mzzvmyea	44	31	lactam	lactam	NNS
cord-354664-mzzvmyea	44	32	plus	plus	CC
cord-354664-mzzvmyea	44	33	macrolide	macrolide	NN
cord-354664-mzzvmyea	44	34	or	or	CC
cord-354664-mzzvmyea	44	35	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	44	36	with	with	IN
cord-354664-mzzvmyea	44	37	a	a	DT
cord-354664-mzzvmyea	44	38	respiratory	respiratory	JJ
cord-354664-mzzvmyea	44	39	fluoroquinolone	fluoroquinolone	NN
cord-354664-mzzvmyea	44	40	(	(	-LRB-
cord-354664-mzzvmyea	44	41	e.g.	e.g.	RB
cord-354664-mzzvmyea	44	42	,	,	,
cord-354664-mzzvmyea	44	43	moxifloxacin	moxifloxacin	NNS
cord-354664-mzzvmyea	44	44	)	)	-RRB-
cord-354664-mzzvmyea	44	45	for	for	IN
cord-354664-mzzvmyea	44	46	adult	adult	NN
cord-354664-mzzvmyea	44	47	patients	patient	NNS
cord-354664-mzzvmyea	44	48	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	44	49	with	with	IN
cord-354664-mzzvmyea	44	50	CAP	CAP	NNP
cord-354664-mzzvmyea	44	51	in	in	IN
cord-354664-mzzvmyea	44	52	a	a	DT
cord-354664-mzzvmyea	44	53	non	non	JJ
cord-354664-mzzvmyea	44	54	-	-	JJ
cord-354664-mzzvmyea	44	55	ICU	icu	JJ
cord-354664-mzzvmyea	44	56	setting	set	VBG
cord-354664-mzzvmyea	44	57	[	[	-LRB-
cord-354664-mzzvmyea	44	58	21	21	CD
cord-354664-mzzvmyea	44	59	]	]	-RRB-
cord-354664-mzzvmyea	44	60	.	.	.
cord-354664-mzzvmyea	45	1	Combination	combination	NN
cord-354664-mzzvmyea	45	2	therapy	therapy	NN
cord-354664-mzzvmyea	45	3	is	be	VBZ
cord-354664-mzzvmyea	45	4	recommended	recommend	VBN
cord-354664-mzzvmyea	45	5	for	for	IN
cord-354664-mzzvmyea	45	6	all	all	DT
cord-354664-mzzvmyea	45	7	patients	patient	NNS
cord-354664-mzzvmyea	45	8	with	with	IN
cord-354664-mzzvmyea	45	9	severe	severe	JJ
cord-354664-mzzvmyea	45	10	CAP	cap	NN
cord-354664-mzzvmyea	45	11	(	(	-LRB-
cord-354664-mzzvmyea	45	12	inpatient	inpatient	JJ
cord-354664-mzzvmyea	45	13	ICU	ICU	NNP
cord-354664-mzzvmyea	45	14	)	)	-RRB-
cord-354664-mzzvmyea	45	15	.	.	.
cord-354664-mzzvmyea	46	1	In	in	IN
cord-354664-mzzvmyea	46	2	contrast	contrast	NN
cord-354664-mzzvmyea	46	3	,	,	,
cord-354664-mzzvmyea	46	4	guidelines	guideline	NNS
cord-354664-mzzvmyea	46	5	published	publish	VBN
cord-354664-mzzvmyea	46	6	by	by	IN
cord-354664-mzzvmyea	46	7	the	the	DT
cord-354664-mzzvmyea	46	8	British	British	NNP
cord-354664-mzzvmyea	46	9	Thoracic	Thoracic	NNP
cord-354664-mzzvmyea	46	10	Society	Society	NNP
cord-354664-mzzvmyea	46	11	(	(	-LRB-
cord-354664-mzzvmyea	46	12	BTS	BTS	NNP
cord-354664-mzzvmyea	46	13	,	,	,
cord-354664-mzzvmyea	46	14	2009	2009	CD
cord-354664-mzzvmyea	46	15	)	)	-RRB-
cord-354664-mzzvmyea	46	16	and	and	CC
cord-354664-mzzvmyea	46	17	National	National	NNP
cord-354664-mzzvmyea	46	18	Institute	Institute	NNP
cord-354664-mzzvmyea	46	19	for	for	IN
cord-354664-mzzvmyea	46	20	Health	Health	NNP
cord-354664-mzzvmyea	46	21	and	and	CC
cord-354664-mzzvmyea	46	22	Care	Care	NNP
cord-354664-mzzvmyea	46	23	Excellence	Excellence	NNP
cord-354664-mzzvmyea	46	24	(	(	-LRB-
cord-354664-mzzvmyea	46	25	NICE	nice	JJ
cord-354664-mzzvmyea	46	26	,	,	,
cord-354664-mzzvmyea	46	27	2014	2014	CD
cord-354664-mzzvmyea	46	28	)	)	-RRB-
cord-354664-mzzvmyea	46	29	recommend	recommend	VB
cord-354664-mzzvmyea	46	30	beta	beta	NN
cord-354664-mzzvmyea	46	31	-	-	HYPH
cord-354664-mzzvmyea	46	32	lactam	lactam	NN
cord-354664-mzzvmyea	46	33	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	46	34	for	for	IN
cord-354664-mzzvmyea	46	35	lowseverity	lowseverity	NNP
cord-354664-mzzvmyea	46	36	CAP	CAP	NNP
cord-354664-mzzvmyea	46	37	with	with	IN
cord-354664-mzzvmyea	46	38	consideration	consideration	NN
cord-354664-mzzvmyea	46	39	of	of	IN
cord-354664-mzzvmyea	46	40	combination	combination	NN
cord-354664-mzzvmyea	46	41	therapy	therapy	NN
cord-354664-mzzvmyea	46	42	only	only	RB
cord-354664-mzzvmyea	46	43	in	in	IN
cord-354664-mzzvmyea	46	44	moderate	moderate	JJ
cord-354664-mzzvmyea	46	45	to	to	IN
cord-354664-mzzvmyea	46	46	severe	severe	JJ
cord-354664-mzzvmyea	46	47	CAP	cap	NN
cord-354664-mzzvmyea	46	48	[	[	-LRB-
cord-354664-mzzvmyea	46	49	22	22	CD
cord-354664-mzzvmyea	46	50	,	,	,
cord-354664-mzzvmyea	46	51	23	23	CD
cord-354664-mzzvmyea	46	52	]	]	-RRB-
cord-354664-mzzvmyea	46	53	.	.	.
cord-354664-mzzvmyea	47	1	The	the	DT
cord-354664-mzzvmyea	47	2	body	body	NN
cord-354664-mzzvmyea	47	3	of	of	IN
cord-354664-mzzvmyea	47	4	evidence	evidence	NN
cord-354664-mzzvmyea	47	5	used	use	VBN
cord-354664-mzzvmyea	47	6	to	to	TO
cord-354664-mzzvmyea	47	7	support	support	VB
cord-354664-mzzvmyea	47	8	current	current	JJ
cord-354664-mzzvmyea	47	9	IDSA	IDSA	NNP
cord-354664-mzzvmyea	47	10	/	/	SYM
cord-354664-mzzvmyea	47	11	ATS	ATS	NNP
cord-354664-mzzvmyea	47	12	guideline	guideline	NN
cord-354664-mzzvmyea	47	13	recommendations	recommendation	NNS
cord-354664-mzzvmyea	47	14	that	that	WDT
cord-354664-mzzvmyea	47	15	advocate	advocate	VBP
cord-354664-mzzvmyea	47	16	for	for	IN
cord-354664-mzzvmyea	47	17	combination	combination	NN
cord-354664-mzzvmyea	47	18	therapy	therapy	NN
cord-354664-mzzvmyea	47	19	with	with	IN
cord-354664-mzzvmyea	47	20	a	a	DT
cord-354664-mzzvmyea	47	21	beta	beta	NN
cord-354664-mzzvmyea	47	22	-	-	HYPH
cord-354664-mzzvmyea	47	23	lactam	lactam	NNS
cord-354664-mzzvmyea	47	24	plus	plus	CC
cord-354664-mzzvmyea	47	25	macrolide	macrolide	NN
cord-354664-mzzvmyea	47	26	in	in	IN
cord-354664-mzzvmyea	47	27	the	the	DT
cord-354664-mzzvmyea	47	28	management	management	NN
cord-354664-mzzvmyea	47	29	of	of	IN
cord-354664-mzzvmyea	47	30	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	47	31	adult	adult	NN
cord-354664-mzzvmyea	47	32	patients	patient	NNS
cord-354664-mzzvmyea	47	33	with	with	IN
cord-354664-mzzvmyea	47	34	CAP	cap	NN
cord-354664-mzzvmyea	47	35	originates	originate	VBZ
cord-354664-mzzvmyea	47	36	from	from	IN
cord-354664-mzzvmyea	47	37	a	a	DT
cord-354664-mzzvmyea	47	38	series	series	NN
cord-354664-mzzvmyea	47	39	of	of	IN
cord-354664-mzzvmyea	47	40	large	large	JJ
cord-354664-mzzvmyea	47	41	,	,	,
cord-354664-mzzvmyea	47	42	retrospective	retrospective	JJ
cord-354664-mzzvmyea	47	43	cohort	cohort	NN
cord-354664-mzzvmyea	47	44	studies	study	NNS
cord-354664-mzzvmyea	47	45	that	that	WDT
cord-354664-mzzvmyea	47	46	showed	show	VBD
cord-354664-mzzvmyea	47	47	improved	improved	JJ
cord-354664-mzzvmyea	47	48	clinical	clinical	JJ
cord-354664-mzzvmyea	47	49	outcomes	outcome	NNS
cord-354664-mzzvmyea	47	50	in	in	IN
cord-354664-mzzvmyea	47	51	patients	patient	NNS
cord-354664-mzzvmyea	47	52	treated	treat	VBN
cord-354664-mzzvmyea	47	53	with	with	IN
cord-354664-mzzvmyea	47	54	combination	combination	NN
cord-354664-mzzvmyea	47	55	therapy	therapy	NN
cord-354664-mzzvmyea	47	56	.	.	.
cord-354664-mzzvmyea	48	1	Gleason	Gleason	NNP
cord-354664-mzzvmyea	48	2	et	et	NNP
cord-354664-mzzvmyea	48	3	al	al	NNP
cord-354664-mzzvmyea	48	4	.	.	NNP
cord-354664-mzzvmyea	48	5	evaluated	evaluate	VBD
cord-354664-mzzvmyea	48	6	the	the	DT
cord-354664-mzzvmyea	48	7	relationship	relationship	NN
cord-354664-mzzvmyea	48	8	between	between	IN
cord-354664-mzzvmyea	48	9	initial	initial	JJ
cord-354664-mzzvmyea	48	10	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	48	11	therapy	therapy	NN
cord-354664-mzzvmyea	48	12	and	and	CC
cord-354664-mzzvmyea	48	13	clinical	clinical	JJ
cord-354664-mzzvmyea	48	14	outcomes	outcome	NNS
cord-354664-mzzvmyea	48	15	in	in	IN
cord-354664-mzzvmyea	48	16	a	a	DT
cord-354664-mzzvmyea	48	17	retrospective	retrospective	JJ
cord-354664-mzzvmyea	48	18	cohort	cohort	NN
cord-354664-mzzvmyea	48	19	of	of	IN
cord-354664-mzzvmyea	48	20	12,945	12,945	CD
cord-354664-mzzvmyea	48	21	Medicare	Medicare	NNP
cord-354664-mzzvmyea	48	22	patients	patient	NNS
cord-354664-mzzvmyea	48	23	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	48	24	with	with	IN
cord-354664-mzzvmyea	48	25	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	48	26	[	[	-LRB-
cord-354664-mzzvmyea	48	27	24	24	CD
cord-354664-mzzvmyea	48	28	]	]	-RRB-
cord-354664-mzzvmyea	48	29	.	.	.
cord-354664-mzzvmyea	49	1	Thirty	thirty	CD
cord-354664-mzzvmyea	49	2	-	-	HYPH
cord-354664-mzzvmyea	49	3	day	day	NN
cord-354664-mzzvmyea	49	4	mortality	mortality	NN
cord-354664-mzzvmyea	49	5	was	be	VBD
cord-354664-mzzvmyea	49	6	lower	low	JJR
cord-354664-mzzvmyea	49	7	when	when	WRB
cord-354664-mzzvmyea	49	8	a	a	DT
cord-354664-mzzvmyea	49	9	macrolide	macrolide	NN
cord-354664-mzzvmyea	49	10	was	be	VBD
cord-354664-mzzvmyea	49	11	combined	combine	VBN
cord-354664-mzzvmyea	49	12	with	with	IN
cord-354664-mzzvmyea	49	13	a	a	DT
cord-354664-mzzvmyea	49	14	second	second	JJ
cord-354664-mzzvmyea	49	15	-	-	HYPH
cord-354664-mzzvmyea	49	16	generation	generation	NN
cord-354664-mzzvmyea	49	17	cephalosporin	cephalosporin	NN
cord-354664-mzzvmyea	49	18	(	(	-LRB-
cord-354664-mzzvmyea	49	19	HR	HR	NNP
cord-354664-mzzvmyea	49	20	,	,	,
cord-354664-mzzvmyea	49	21	0.71	0.71	CD
cord-354664-mzzvmyea	49	22	;	;	:
cord-354664-mzzvmyea	49	23	95	95	CD
cord-354664-mzzvmyea	49	24	%	%	NN
cord-354664-mzzvmyea	49	25	CI	CI	NNP
cord-354664-mzzvmyea	49	26	,	,	,
cord-354664-mzzvmyea	49	27	0.52	0.52	CD
cord-354664-mzzvmyea	49	28	-	-	SYM
cord-354664-mzzvmyea	49	29	0.96	0.96	CD
cord-354664-mzzvmyea	49	30	)	)	-RRB-
cord-354664-mzzvmyea	49	31	or	or	CC
cord-354664-mzzvmyea	49	32	third	third	JJ
cord-354664-mzzvmyea	49	33	-	-	HYPH
cord-354664-mzzvmyea	49	34	generation	generation	NN
cord-354664-mzzvmyea	49	35	cephalosporin	cephalosporin	NN
cord-354664-mzzvmyea	49	36	(	(	-LRB-
cord-354664-mzzvmyea	49	37	HR	hr	NN
cord-354664-mzzvmyea	49	38	,	,	,
cord-354664-mzzvmyea	49	39	0.74	0.74	CD
cord-354664-mzzvmyea	49	40	;	;	:
cord-354664-mzzvmyea	49	41	95	95	CD
cord-354664-mzzvmyea	49	42	%	%	NN
cord-354664-mzzvmyea	49	43	CI	CI	NNP
cord-354664-mzzvmyea	49	44	,	,	,
cord-354664-mzzvmyea	49	45	0.60	0.60	CD
cord-354664-mzzvmyea	49	46	-	-	HYPH
cord-354664-mzzvmyea	49	47	0.92	0.92	CD
cord-354664-mzzvmyea	49	48	)	)	-RRB-
cord-354664-mzzvmyea	49	49	compared	compare	VBN
cord-354664-mzzvmyea	49	50	to	to	IN
cord-354664-mzzvmyea	49	51	conventional	conventional	JJ
cord-354664-mzzvmyea	49	52	beta	beta	NN
cord-354664-mzzvmyea	49	53	-	-	HYPH
cord-354664-mzzvmyea	49	54	lactam	lactam	NN
cord-354664-mzzvmyea	49	55	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	49	56	.	.	.
cord-354664-mzzvmyea	50	1	Houck	Houck	NNP
cord-354664-mzzvmyea	50	2	et	et	NNP
cord-354664-mzzvmyea	50	3	al	al	NNP
cord-354664-mzzvmyea	50	4	.	.	.
cord-354664-mzzvmyea	51	1	similarly	similarly	RB
cord-354664-mzzvmyea	51	2	evaluated	evaluate	VBD
cord-354664-mzzvmyea	51	3	a	a	DT
cord-354664-mzzvmyea	51	4	retrospective	retrospective	JJ
cord-354664-mzzvmyea	51	5	cohort	cohort	NN
cord-354664-mzzvmyea	51	6	of	of	IN
cord-354664-mzzvmyea	51	7	Medicare	Medicare	NNP
cord-354664-mzzvmyea	51	8	patients	patient	NNS
cord-354664-mzzvmyea	51	9	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	51	10	with	with	IN
cord-354664-mzzvmyea	51	11	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	51	12	in	in	IN
cord-354664-mzzvmyea	51	13	10	10	CD
cord-354664-mzzvmyea	51	14	western	western	JJ
cord-354664-mzzvmyea	51	15	states	state	NNS
cord-354664-mzzvmyea	51	16	during	during	IN
cord-354664-mzzvmyea	51	17	the	the	DT
cord-354664-mzzvmyea	51	18	years	year	NNS
cord-354664-mzzvmyea	51	19	1993	1993	CD
cord-354664-mzzvmyea	51	20	,	,	,
cord-354664-mzzvmyea	51	21	1995	1995	CD
cord-354664-mzzvmyea	51	22	,	,	,
cord-354664-mzzvmyea	51	23	and	and	CC
cord-354664-mzzvmyea	51	24	1997	1997	CD
cord-354664-mzzvmyea	51	25	[	[	-LRB-
cord-354664-mzzvmyea	51	26	25	25	CD
cord-354664-mzzvmyea	51	27	]	]	-RRB-
cord-354664-mzzvmyea	51	28	.	.	.
cord-354664-mzzvmyea	52	1	Therapy	therapy	NN
cord-354664-mzzvmyea	52	2	with	with	IN
cord-354664-mzzvmyea	52	3	a	a	DT
cord-354664-mzzvmyea	52	4	macrolide	macrolide	NN
cord-354664-mzzvmyea	52	5	in	in	IN
cord-354664-mzzvmyea	52	6	combination	combination	NN
cord-354664-mzzvmyea	52	7	with	with	IN
cord-354664-mzzvmyea	52	8	a	a	DT
cord-354664-mzzvmyea	52	9	beta	beta	NN
cord-354664-mzzvmyea	52	10	-	-	HYPH
cord-354664-mzzvmyea	52	11	lactam	lactam	NN
cord-354664-mzzvmyea	52	12	was	be	VBD
cord-354664-mzzvmyea	52	13	associated	associate	VBN
cord-354664-mzzvmyea	52	14	with	with	IN
cord-354664-mzzvmyea	52	15	a	a	DT
cord-354664-mzzvmyea	52	16	significant	significant	JJ
cord-354664-mzzvmyea	52	17	reduction	reduction	NN
cord-354664-mzzvmyea	52	18	in	in	IN
cord-354664-mzzvmyea	52	19	mortality	mortality	NN
cord-354664-mzzvmyea	52	20	(	(	-LRB-
cord-354664-mzzvmyea	52	21	aOR	aor	NN
cord-354664-mzzvmyea	52	22	,	,	,
cord-354664-mzzvmyea	52	23	0.42	0.42	CD
cord-354664-mzzvmyea	52	24	;	;	:
cord-354664-mzzvmyea	52	25	95	95	CD
cord-354664-mzzvmyea	52	26	%	%	NN
cord-354664-mzzvmyea	52	27	CI	ci	NN
cord-354664-mzzvmyea	52	28	,	,	,
cord-354664-mzzvmyea	52	29	0.25	0.25	CD
cord-354664-mzzvmyea	52	30	-	-	SYM
cord-354664-mzzvmyea	52	31	0.69	0.69	CD
cord-354664-mzzvmyea	52	32	)	)	-RRB-
cord-354664-mzzvmyea	52	33	in	in	IN
cord-354664-mzzvmyea	52	34	1993	1993	CD
cord-354664-mzzvmyea	52	35	but	but	CC
cord-354664-mzzvmyea	52	36	this	this	DT
cord-354664-mzzvmyea	52	37	effect	effect	NN
cord-354664-mzzvmyea	52	38	was	be	VBD
cord-354664-mzzvmyea	52	39	not	not	RB
cord-354664-mzzvmyea	52	40	observed	observe	VBN
cord-354664-mzzvmyea	52	41	during	during	IN
cord-354664-mzzvmyea	52	42	the	the	DT
cord-354664-mzzvmyea	52	43	other	other	JJ
cord-354664-mzzvmyea	52	44	years	year	NNS
cord-354664-mzzvmyea	52	45	of	of	IN
cord-354664-mzzvmyea	52	46	study	study	NN
cord-354664-mzzvmyea	52	47	.	.	.
cord-354664-mzzvmyea	53	1	Dudas	Dudas	NNP
cord-354664-mzzvmyea	53	2	et	et	NNP
cord-354664-mzzvmyea	53	3	al	al	NNP
cord-354664-mzzvmyea	53	4	.	.	.
cord-354664-mzzvmyea	54	1	subsequently	subsequently	RB
cord-354664-mzzvmyea	54	2	performed	perform	VBD
cord-354664-mzzvmyea	54	3	a	a	DT
cord-354664-mzzvmyea	54	4	prospective	prospective	JJ
cord-354664-mzzvmyea	54	5	,	,	,
cord-354664-mzzvmyea	54	6	observational	observational	JJ
cord-354664-mzzvmyea	54	7	cohort	cohort	NN
cord-354664-mzzvmyea	54	8	study	study	NN
cord-354664-mzzvmyea	54	9	at	at	IN
cord-354664-mzzvmyea	54	10	72	72	CD
cord-354664-mzzvmyea	54	11	community	community	NN
cord-354664-mzzvmyea	54	12	hospitals	hospital	NNS
cord-354664-mzzvmyea	54	13	to	to	TO
cord-354664-mzzvmyea	54	14	evaluate	evaluate	VB
cord-354664-mzzvmyea	54	15	compliance	compliance	NN
cord-354664-mzzvmyea	54	16	with	with	IN
cord-354664-mzzvmyea	54	17	ATS	ATS	NNP
cord-354664-mzzvmyea	54	18	guidelines	guideline	NNS
cord-354664-mzzvmyea	54	19	in	in	IN
cord-354664-mzzvmyea	54	20	patients	patient	NNS
cord-354664-mzzvmyea	54	21	with	with	IN
cord-354664-mzzvmyea	54	22	non	non	JJ
cord-354664-mzzvmyea	54	23	-	-	JJ
cord-354664-mzzvmyea	54	24	severe	severe	JJ
cord-354664-mzzvmyea	54	25	community	community	NN
cord-354664-mzzvmyea	54	26	-	-	HYPH
cord-354664-mzzvmyea	54	27	acquired	acquire	VBN
cord-354664-mzzvmyea	54	28	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	54	29	and	and	CC
cord-354664-mzzvmyea	54	30	compared	compare	VBN
cord-354664-mzzvmyea	54	31	outcomes	outcome	NNS
cord-354664-mzzvmyea	54	32	between	between	IN
cord-354664-mzzvmyea	54	33	patients	patient	NNS
cord-354664-mzzvmyea	54	34	administered	administer	VBD
cord-354664-mzzvmyea	54	35	varying	vary	VBG
cord-354664-mzzvmyea	54	36	combinations	combination	NNS
cord-354664-mzzvmyea	54	37	of	of	IN
cord-354664-mzzvmyea	54	38	antimicrobials	antimicrobial	NNS
cord-354664-mzzvmyea	54	39	[	[	-LRB-
cord-354664-mzzvmyea	54	40	26	26	CD
cord-354664-mzzvmyea	54	41	]	]	-RRB-
cord-354664-mzzvmyea	54	42	.	.	.
cord-354664-mzzvmyea	55	1	Compliance	compliance	NN
cord-354664-mzzvmyea	55	2	with	with	IN
cord-354664-mzzvmyea	55	3	ATS	ATS	NNP
cord-354664-mzzvmyea	55	4	guidelines	guideline	NNS
cord-354664-mzzvmyea	55	5	was	be	VBD
cord-354664-mzzvmyea	55	6	found	find	VBN
cord-354664-mzzvmyea	55	7	to	to	TO
cord-354664-mzzvmyea	55	8	be	be	VB
cord-354664-mzzvmyea	55	9	81	81	CD
cord-354664-mzzvmyea	55	10	%	%	NN
cord-354664-mzzvmyea	55	11	and	and	CC
cord-354664-mzzvmyea	55	12	the	the	DT
cord-354664-mzzvmyea	55	13	addition	addition	NN
cord-354664-mzzvmyea	55	14	of	of	IN
cord-354664-mzzvmyea	55	15	a	a	DT
cord-354664-mzzvmyea	55	16	macrolide	macrolide	NN
cord-354664-mzzvmyea	55	17	to	to	IN
cord-354664-mzzvmyea	55	18	a	a	DT
cord-354664-mzzvmyea	55	19	beta	beta	NN
cord-354664-mzzvmyea	55	20	-	-	HYPH
cord-354664-mzzvmyea	55	21	lactam	lactam	NN
cord-354664-mzzvmyea	55	22	was	be	VBD
cord-354664-mzzvmyea	55	23	associated	associate	VBN
cord-354664-mzzvmyea	55	24	with	with	IN
cord-354664-mzzvmyea	55	25	decreased	decrease	VBN
cord-354664-mzzvmyea	55	26	mortality	mortality	NN
cord-354664-mzzvmyea	55	27	and	and	CC
cord-354664-mzzvmyea	55	28	reduced	reduce	VBN
cord-354664-mzzvmyea	55	29	length	length	NN
cord-354664-mzzvmyea	55	30	of	of	IN
cord-354664-mzzvmyea	55	31	hospital	hospital	NN
cord-354664-mzzvmyea	55	32	stay	stay	NN
cord-354664-mzzvmyea	55	33	.	.	.
cord-354664-mzzvmyea	56	1	Brown	Brown	NNP
cord-354664-mzzvmyea	56	2	et	et	NNP
cord-354664-mzzvmyea	56	3	al	al	NNP
cord-354664-mzzvmyea	56	4	.	.	.
cord-354664-mzzvmyea	57	1	further	further	RB
cord-354664-mzzvmyea	57	2	reinforced	reinforce	VBD
cord-354664-mzzvmyea	57	3	these	these	DT
cord-354664-mzzvmyea	57	4	findings	finding	NNS
cord-354664-mzzvmyea	57	5	by	by	IN
cord-354664-mzzvmyea	57	6	evaluating	evaluate	VBG
cord-354664-mzzvmyea	57	7	a	a	DT
cord-354664-mzzvmyea	57	8	retrospective	retrospective	JJ
cord-354664-mzzvmyea	57	9	cohort	cohort	NN
cord-354664-mzzvmyea	57	10	of	of	IN
cord-354664-mzzvmyea	57	11	44,814	44,814	CD
cord-354664-mzzvmyea	57	12	patients	patient	NNS
cord-354664-mzzvmyea	57	13	in	in	IN
cord-354664-mzzvmyea	57	14	a	a	DT
cord-354664-mzzvmyea	57	15	hospital	hospital	NN
cord-354664-mzzvmyea	57	16	claims	claim	NNS
cord-354664-mzzvmyea	57	17	database	database	NN
cord-354664-mzzvmyea	57	18	[	[	-LRB-
cord-354664-mzzvmyea	57	19	27	27	CD
cord-354664-mzzvmyea	57	20	]	]	-RRB-
cord-354664-mzzvmyea	57	21	.	.	.
cord-354664-mzzvmyea	58	1	In	in	IN
cord-354664-mzzvmyea	58	2	this	this	DT
cord-354664-mzzvmyea	58	3	cohort	cohort	NN
cord-354664-mzzvmyea	58	4	,	,	,
cord-354664-mzzvmyea	58	5	macrolide	macrolide	NN
cord-354664-mzzvmyea	58	6	combination	combination	NN
cord-354664-mzzvmyea	58	7	therapy	therapy	NN
cord-354664-mzzvmyea	58	8	was	be	VBD
cord-354664-mzzvmyea	58	9	associated	associate	VBN
cord-354664-mzzvmyea	58	10	with	with	IN
cord-354664-mzzvmyea	58	11	decreased	decrease	VBN
cord-354664-mzzvmyea	58	12	mortality	mortality	NN
cord-354664-mzzvmyea	58	13	,	,	,
cord-354664-mzzvmyea	58	14	length	length	NN
cord-354664-mzzvmyea	58	15	of	of	IN
cord-354664-mzzvmyea	58	16	hospital	hospital	NN
cord-354664-mzzvmyea	58	17	stay	stay	NN
cord-354664-mzzvmyea	58	18	,	,	,
cord-354664-mzzvmyea	58	19	and	and	CC
cord-354664-mzzvmyea	58	20	healthcare	healthcare	NN
cord-354664-mzzvmyea	58	21	-	-	HYPH
cord-354664-mzzvmyea	58	22	associated	associate	VBN
cord-354664-mzzvmyea	58	23	costs	cost	NNS
cord-354664-mzzvmyea	58	24	overall	overall	RB
cord-354664-mzzvmyea	58	25	.	.	.
cord-354664-mzzvmyea	59	1	Based	base	VBN
cord-354664-mzzvmyea	59	2	on	on	IN
cord-354664-mzzvmyea	59	3	the	the	DT
cord-354664-mzzvmyea	59	4	findings	finding	NNS
cord-354664-mzzvmyea	59	5	of	of	IN
cord-354664-mzzvmyea	59	6	these	these	DT
cord-354664-mzzvmyea	59	7	large	large	JJ
cord-354664-mzzvmyea	59	8	observational	observational	JJ
cord-354664-mzzvmyea	59	9	studies	study	NNS
cord-354664-mzzvmyea	59	10	,	,	,
cord-354664-mzzvmyea	59	11	many	many	JJ
cord-354664-mzzvmyea	59	12	clinical	clinical	JJ
cord-354664-mzzvmyea	59	13	practice	practice	NN
cord-354664-mzzvmyea	59	14	guidelines	guideline	NNS
cord-354664-mzzvmyea	59	15	recommend	recommend	VBP
cord-354664-mzzvmyea	59	16	combination	combination	NN
cord-354664-mzzvmyea	59	17	therapy	therapy	NN
cord-354664-mzzvmyea	59	18	with	with	IN
cord-354664-mzzvmyea	59	19	a	a	DT
cord-354664-mzzvmyea	59	20	beta	beta	NN
cord-354664-mzzvmyea	59	21	-	-	HYPH
cord-354664-mzzvmyea	59	22	lactam	lactam	NNS
cord-354664-mzzvmyea	59	23	plus	plus	CC
cord-354664-mzzvmyea	59	24	macrolide	macrolide	NN
cord-354664-mzzvmyea	59	25	or	or	CC
cord-354664-mzzvmyea	59	26	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	59	27	with	with	IN
cord-354664-mzzvmyea	59	28	a	a	DT
cord-354664-mzzvmyea	59	29	respiratory	respiratory	JJ
cord-354664-mzzvmyea	59	30	fluoroquinolone	fluoroquinolone	NN
cord-354664-mzzvmyea	59	31	as	as	IN
cord-354664-mzzvmyea	59	32	first	first	JJ
cord-354664-mzzvmyea	59	33	-	-	HYPH
cord-354664-mzzvmyea	59	34	line	line	NN
cord-354664-mzzvmyea	59	35	therapy	therapy	NN
cord-354664-mzzvmyea	59	36	for	for	IN
cord-354664-mzzvmyea	59	37	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	59	38	adult	adult	NN
cord-354664-mzzvmyea	59	39	patients	patient	NNS
cord-354664-mzzvmyea	59	40	with	with	IN
cord-354664-mzzvmyea	59	41	CAP	CAP	NNP
cord-354664-mzzvmyea	59	42	.	.	.
cord-354664-mzzvmyea	60	1	However	however	RB
cord-354664-mzzvmyea	60	2	,	,	,
cord-354664-mzzvmyea	60	3	this	this	DT
cord-354664-mzzvmyea	60	4	recommendation	recommendation	NN
cord-354664-mzzvmyea	60	5	for	for	IN
cord-354664-mzzvmyea	60	6	routine	routine	JJ
cord-354664-mzzvmyea	60	7	combination	combination	NN
cord-354664-mzzvmyea	60	8	therapy	therapy	NN
cord-354664-mzzvmyea	60	9	for	for	IN
cord-354664-mzzvmyea	60	10	the	the	DT
cord-354664-mzzvmyea	60	11	management	management	NN
cord-354664-mzzvmyea	60	12	of	of	IN
cord-354664-mzzvmyea	60	13	CAP	CAP	NNP
cord-354664-mzzvmyea	60	14	has	have	VBZ
cord-354664-mzzvmyea	60	15	remained	remain	VBN
cord-354664-mzzvmyea	60	16	a	a	DT
cord-354664-mzzvmyea	60	17	contentious	contentious	JJ
cord-354664-mzzvmyea	60	18	issue	issue	NN
cord-354664-mzzvmyea	60	19	.	.	.
cord-354664-mzzvmyea	61	1	Despite	despite	IN
cord-354664-mzzvmyea	61	2	the	the	DT
cord-354664-mzzvmyea	61	3	body	body	NN
cord-354664-mzzvmyea	61	4	of	of	IN
cord-354664-mzzvmyea	61	5	(	(	-LRB-
cord-354664-mzzvmyea	61	6	predominantly	predominantly	RB
cord-354664-mzzvmyea	61	7	retrospective	retrospective	JJ
cord-354664-mzzvmyea	61	8	,	,	,
cord-354664-mzzvmyea	61	9	observational	observational	JJ
cord-354664-mzzvmyea	61	10	)	)	-RRB-
cord-354664-mzzvmyea	61	11	evidence	evidence	NN
cord-354664-mzzvmyea	61	12	that	that	WDT
cord-354664-mzzvmyea	61	13	demonstrates	demonstrate	VBZ
cord-354664-mzzvmyea	61	14	improved	improve	VBN
cord-354664-mzzvmyea	61	15	clinical	clinical	JJ
cord-354664-mzzvmyea	61	16	outcomes	outcome	NNS
cord-354664-mzzvmyea	61	17	,	,	,
cord-354664-mzzvmyea	61	18	many	many	JJ
cord-354664-mzzvmyea	61	19	clinicians	clinician	NNS
cord-354664-mzzvmyea	61	20	regard	regard	VBP
cord-354664-mzzvmyea	61	21	this	this	DT
cord-354664-mzzvmyea	61	22	evidence	evidence	NN
cord-354664-mzzvmyea	61	23	(	(	-LRB-
cord-354664-mzzvmyea	61	24	which	which	WDT
cord-354664-mzzvmyea	61	25	grounds	ground	VBZ
cord-354664-mzzvmyea	61	26	guideline	guideline	NN
cord-354664-mzzvmyea	61	27	recommendations	recommendation	NNS
cord-354664-mzzvmyea	61	28	)	)	-RRB-
cord-354664-mzzvmyea	61	29	to	to	TO
cord-354664-mzzvmyea	61	30	be	be	VB
cord-354664-mzzvmyea	61	31	low	low	JJ
cord-354664-mzzvmyea	61	32	quality	quality	NN
cord-354664-mzzvmyea	61	33	and	and	CC
cord-354664-mzzvmyea	61	34	have	have	VBP
cord-354664-mzzvmyea	61	35	called	call	VBN
cord-354664-mzzvmyea	61	36	for	for	IN
cord-354664-mzzvmyea	61	37	further	further	JJ
cord-354664-mzzvmyea	61	38	prospective	prospective	JJ
cord-354664-mzzvmyea	61	39	,	,	,
cord-354664-mzzvmyea	61	40	randomized	randomized	JJ
cord-354664-mzzvmyea	61	41	-	-	HYPH
cord-354664-mzzvmyea	61	42	controlled	control	VBN
cord-354664-mzzvmyea	61	43	trials	trial	NNS
cord-354664-mzzvmyea	61	44	to	to	TO
cord-354664-mzzvmyea	61	45	address	address	VB
cord-354664-mzzvmyea	61	46	this	this	DT
cord-354664-mzzvmyea	61	47	question	question	NN
cord-354664-mzzvmyea	61	48	.	.	.
cord-354664-mzzvmyea	62	1	The	the	DT
cord-354664-mzzvmyea	62	2	routine	routine	JJ
cord-354664-mzzvmyea	62	3	use	use	NN
cord-354664-mzzvmyea	62	4	of	of	IN
cord-354664-mzzvmyea	62	5	macrolides	macrolide	NNS
cord-354664-mzzvmyea	62	6	in	in	IN
cord-354664-mzzvmyea	62	7	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	62	8	adults	adult	NNS
cord-354664-mzzvmyea	62	9	to	to	TO
cord-354664-mzzvmyea	62	10	augment	augment	VB
cord-354664-mzzvmyea	62	11	the	the	DT
cord-354664-mzzvmyea	62	12	spectrum	spectrum	NN
cord-354664-mzzvmyea	62	13	of	of	IN
cord-354664-mzzvmyea	62	14	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	62	15	coverage	coverage	NN
cord-354664-mzzvmyea	62	16	in	in	IN
cord-354664-mzzvmyea	62	17	mild	mild	JJ
cord-354664-mzzvmyea	62	18	to	to	IN
cord-354664-mzzvmyea	62	19	moderate	moderate	JJ
cord-354664-mzzvmyea	62	20	CAP	cap	NN
cord-354664-mzzvmyea	62	21	patients	patient	NNS
cord-354664-mzzvmyea	62	22	to	to	TO
cord-354664-mzzvmyea	62	23	include	include	VB
cord-354664-mzzvmyea	62	24	atypical	atypical	JJ
cord-354664-mzzvmyea	62	25	pathogens	pathogen	NNS
cord-354664-mzzvmyea	62	26	has	have	VBZ
cord-354664-mzzvmyea	62	27	been	be	VBN
cord-354664-mzzvmyea	62	28	questioned	question	VBN
cord-354664-mzzvmyea	62	29	owing	owe	VBG
cord-354664-mzzvmyea	62	30	to	to	IN
cord-354664-mzzvmyea	62	31	the	the	DT
cord-354664-mzzvmyea	62	32	infrequent	infrequent	JJ
cord-354664-mzzvmyea	62	33	identification	identification	NN
cord-354664-mzzvmyea	62	34	of	of	IN
cord-354664-mzzvmyea	62	35	these	these	DT
cord-354664-mzzvmyea	62	36	pathogens	pathogen	NNS
cord-354664-mzzvmyea	62	37	.	.	.
cord-354664-mzzvmyea	63	1	M.	M.	NNP
cord-354664-mzzvmyea	63	2	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	63	3	and	and	CC
cord-354664-mzzvmyea	63	4	C.	C.	NNP
cord-354664-mzzvmyea	63	5	pneumoniae	pneumoniae	NNS
cord-354664-mzzvmyea	63	6	are	be	VBP
cord-354664-mzzvmyea	63	7	also	also	RB
cord-354664-mzzvmyea	63	8	specifically	specifically	RB
cord-354664-mzzvmyea	63	9	known	know	VBN
cord-354664-mzzvmyea	63	10	for	for	IN
cord-354664-mzzvmyea	63	11	producing	produce	VBG
cord-354664-mzzvmyea	63	12	relatively	relatively	RB
cord-354664-mzzvmyea	63	13	mild	mild	JJ
cord-354664-mzzvmyea	63	14	illness	illness	NN
cord-354664-mzzvmyea	63	15	with	with	IN
cord-354664-mzzvmyea	63	16	minimal	minimal	JJ
cord-354664-mzzvmyea	63	17	existing	exist	VBG
cord-354664-mzzvmyea	63	18	literature	literature	NN
cord-354664-mzzvmyea	63	19	that	that	WDT
cord-354664-mzzvmyea	63	20	targeted	target	VBD
cord-354664-mzzvmyea	63	21	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	63	22	therapy	therapy	NN
cord-354664-mzzvmyea	63	23	impacts	impact	NNS
cord-354664-mzzvmyea	63	24	patient	patient	JJ
cord-354664-mzzvmyea	63	25	mortality	mortality	NN
cord-354664-mzzvmyea	63	26	[	[	-LRB-
cord-354664-mzzvmyea	63	27	28	28	CD
cord-354664-mzzvmyea	63	28	]	]	-RRB-
cord-354664-mzzvmyea	63	29	.	.	.
cord-354664-mzzvmyea	64	1	Additionally	additionally	RB
cord-354664-mzzvmyea	64	2	,	,	,
cord-354664-mzzvmyea	64	3	any	any	DT
cord-354664-mzzvmyea	64	4	adjunctive	adjunctive	JJ
cord-354664-mzzvmyea	64	5	benefit	benefit	NN
cord-354664-mzzvmyea	64	6	from	from	IN
cord-354664-mzzvmyea	64	7	the	the	DT
cord-354664-mzzvmyea	64	8	postulated	postulate	VBN
cord-354664-mzzvmyea	64	9	anti	anti	JJ
cord-354664-mzzvmyea	64	10	-	-	JJ
cord-354664-mzzvmyea	64	11	inflammatory	inflammatory	JJ
cord-354664-mzzvmyea	64	12	effect	effect	NN
cord-354664-mzzvmyea	64	13	of	of	IN
cord-354664-mzzvmyea	64	14	macrolides	macrolide	NNS
cord-354664-mzzvmyea	64	15	in	in	IN
cord-354664-mzzvmyea	64	16	the	the	DT
cord-354664-mzzvmyea	64	17	treatment	treatment	NN
cord-354664-mzzvmyea	64	18	of	of	IN
cord-354664-mzzvmyea	64	19	CAP	CAP	NNP
cord-354664-mzzvmyea	64	20	remains	remain	VBZ
cord-354664-mzzvmyea	64	21	unproven	unproven	JJ
cord-354664-mzzvmyea	64	22	.	.	.
cord-354664-mzzvmyea	65	1	Given	give	VBN
cord-354664-mzzvmyea	65	2	the	the	DT
cord-354664-mzzvmyea	65	3	increasing	increase	VBG
cord-354664-mzzvmyea	65	4	resistance	resistance	NN
cord-354664-mzzvmyea	65	5	of	of	IN
cord-354664-mzzvmyea	65	6	S.	S.	NNP
cord-354664-mzzvmyea	65	7	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	65	8	and	and	CC
cord-354664-mzzvmyea	65	9	M.	M.	NNP
cord-354664-mzzvmyea	65	10	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	65	11	isolates	isolate	VBZ
cord-354664-mzzvmyea	65	12	to	to	IN
cord-354664-mzzvmyea	65	13	macrolide	macrolide	NN
cord-354664-mzzvmyea	65	14	antibiotics	antibiotic	NNS
cord-354664-mzzvmyea	65	15	,	,	,
cord-354664-mzzvmyea	65	16	unnecessary	unnecessary	JJ
cord-354664-mzzvmyea	65	17	exposure	exposure	NN
cord-354664-mzzvmyea	65	18	to	to	IN
cord-354664-mzzvmyea	65	19	potential	potential	JJ
cord-354664-mzzvmyea	65	20	harms	harm	NNS
cord-354664-mzzvmyea	65	21	associated	associate	VBN
cord-354664-mzzvmyea	65	22	with	with	IN
cord-354664-mzzvmyea	65	23	macrolide	macrolide	JJ
cord-354664-mzzvmyea	65	24	use	use	NN
cord-354664-mzzvmyea	65	25	(	(	-LRB-
cord-354664-mzzvmyea	65	26	potential	potential	JJ
cord-354664-mzzvmyea	65	27	cardiotoxicity	cardiotoxicity	NN
cord-354664-mzzvmyea	65	28	,	,	,
cord-354664-mzzvmyea	65	29	Clostridium	clostridium	NN
cord-354664-mzzvmyea	65	30	difficile	difficile	NN
cord-354664-mzzvmyea	65	31	infection	infection	NN
cord-354664-mzzvmyea	65	32	,	,	,
cord-354664-mzzvmyea	65	33	etc	etc	FW
cord-354664-mzzvmyea	65	34	.	.	.
cord-354664-mzzvmyea	65	35	)	)	-RRB-
cord-354664-mzzvmyea	65	36	,	,	,
cord-354664-mzzvmyea	65	37	and	and	CC
cord-354664-mzzvmyea	65	38	the	the	DT
cord-354664-mzzvmyea	65	39	economic	economic	JJ
cord-354664-mzzvmyea	65	40	costs	cost	NNS
cord-354664-mzzvmyea	65	41	of	of	IN
cord-354664-mzzvmyea	65	42	unnecessary	unnecessary	JJ
cord-354664-mzzvmyea	65	43	combination	combination	NN
cord-354664-mzzvmyea	65	44	therapy	therapy	NN
cord-354664-mzzvmyea	65	45	,	,	,
cord-354664-mzzvmyea	65	46	many	many	JJ
cord-354664-mzzvmyea	65	47	have	have	VBP
cord-354664-mzzvmyea	65	48	called	call	VBN
cord-354664-mzzvmyea	65	49	the	the	DT
cord-354664-mzzvmyea	65	50	routine	routine	JJ
cord-354664-mzzvmyea	65	51	use	use	NN
cord-354664-mzzvmyea	65	52	of	of	IN
cord-354664-mzzvmyea	65	53	combination	combination	NN
cord-354664-mzzvmyea	65	54	beta	beta	NN
cord-354664-mzzvmyea	65	55	-	-	HYPH
cord-354664-mzzvmyea	65	56	lactams	lactam	NNS
cord-354664-mzzvmyea	65	57	plus	plus	CC
cord-354664-mzzvmyea	65	58	macrolides	macrolide	NNS
cord-354664-mzzvmyea	65	59	into	into	IN
cord-354664-mzzvmyea	65	60	question	question	NN
cord-354664-mzzvmyea	65	61	[	[	-LRB-
cord-354664-mzzvmyea	65	62	29	29	CD
cord-354664-mzzvmyea	65	63	]	]	-RRB-
cord-354664-mzzvmyea	65	64	[	[	-LRB-
cord-354664-mzzvmyea	65	65	30	30	CD
cord-354664-mzzvmyea	65	66	]	]	-RRB-
cord-354664-mzzvmyea	65	67	[	[	-LRB-
cord-354664-mzzvmyea	65	68	31	31	CD
cord-354664-mzzvmyea	65	69	]	]	-RRB-
cord-354664-mzzvmyea	65	70	[	[	-LRB-
cord-354664-mzzvmyea	65	71	32	32	CD
cord-354664-mzzvmyea	65	72	]	]	-RRB-
cord-354664-mzzvmyea	65	73	[	[	-LRB-
cord-354664-mzzvmyea	65	74	33	33	CD
cord-354664-mzzvmyea	65	75	]	]	-RRB-
cord-354664-mzzvmyea	65	76	.	.	.
cord-354664-mzzvmyea	66	1	Additional	additional	JJ
cord-354664-mzzvmyea	66	2	studies	study	NNS
cord-354664-mzzvmyea	66	3	have	have	VBP
cord-354664-mzzvmyea	66	4	attempted	attempt	VBN
cord-354664-mzzvmyea	66	5	to	to	TO
cord-354664-mzzvmyea	66	6	bring	bring	VB
cord-354664-mzzvmyea	66	7	clarity	clarity	NN
cord-354664-mzzvmyea	66	8	to	to	IN
cord-354664-mzzvmyea	66	9	this	this	DT
cord-354664-mzzvmyea	66	10	controversy	controversy	NN
cord-354664-mzzvmyea	66	11	.	.	.
cord-354664-mzzvmyea	67	1	A	a	DT
cord-354664-mzzvmyea	67	2	systematic	systematic	JJ
cord-354664-mzzvmyea	67	3	review	review	NN
cord-354664-mzzvmyea	67	4	and	and	CC
cord-354664-mzzvmyea	67	5	meta	meta	NNP
cord-354664-mzzvmyea	67	6	-	-	HYPH
cord-354664-mzzvmyea	67	7	analysis	analysis	NN
cord-354664-mzzvmyea	67	8	performed	perform	VBN
cord-354664-mzzvmyea	67	9	by	by	IN
cord-354664-mzzvmyea	67	10	the	the	DT
cord-354664-mzzvmyea	67	11	Cochrane	Cochrane	NNP
cord-354664-mzzvmyea	67	12	Acute	Acute	NNP
cord-354664-mzzvmyea	67	13	Respiratory	Respiratory	NNP
cord-354664-mzzvmyea	67	14	Infections	Infections	NNPS
cord-354664-mzzvmyea	67	15	Group	Group	NNP
cord-354664-mzzvmyea	67	16	explored	explore	VBD
cord-354664-mzzvmyea	67	17	if	if	IN
cord-354664-mzzvmyea	67	18	the	the	DT
cord-354664-mzzvmyea	67	19	addition	addition	NN
cord-354664-mzzvmyea	67	20	of	of	IN
cord-354664-mzzvmyea	67	21	atypical	atypical	JJ
cord-354664-mzzvmyea	67	22	coverage	coverage	NN
cord-354664-mzzvmyea	67	23	to	to	IN
cord-354664-mzzvmyea	67	24	an	an	DT
cord-354664-mzzvmyea	67	25	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	67	26	regimen	regimen	NN
cord-354664-mzzvmyea	67	27	would	would	MD
cord-354664-mzzvmyea	67	28	improve	improve	VB
cord-354664-mzzvmyea	67	29	patient	patient	JJ
cord-354664-mzzvmyea	67	30	outcomes	outcome	NNS
cord-354664-mzzvmyea	67	31	[	[	-LRB-
cord-354664-mzzvmyea	67	32	34	34	CD
cord-354664-mzzvmyea	67	33	]	]	-RRB-
cord-354664-mzzvmyea	67	34	.	.	.
cord-354664-mzzvmyea	68	1	In	in	IN
cord-354664-mzzvmyea	68	2	28	28	CD
cord-354664-mzzvmyea	68	3	trials	trial	NNS
cord-354664-mzzvmyea	68	4	,	,	,
cord-354664-mzzvmyea	68	5	including	include	VBG
cord-354664-mzzvmyea	68	6	5939	5939	CD
cord-354664-mzzvmyea	68	7	patients	patient	NNS
cord-354664-mzzvmyea	68	8	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	68	9	with	with	IN
cord-354664-mzzvmyea	68	10	CAP	CAP	NNP
cord-354664-mzzvmyea	68	11	,	,	,
cord-354664-mzzvmyea	68	12	there	there	EX
cord-354664-mzzvmyea	68	13	was	be	VBD
cord-354664-mzzvmyea	68	14	no	no	DT
cord-354664-mzzvmyea	68	15	overall	overall	JJ
cord-354664-mzzvmyea	68	16	difference	difference	NN
cord-354664-mzzvmyea	68	17	in	in	IN
cord-354664-mzzvmyea	68	18	mortality	mortality	NN
cord-354664-mzzvmyea	68	19	(	(	-LRB-
cord-354664-mzzvmyea	68	20	RR	RR	NNP
cord-354664-mzzvmyea	68	21	1.14	1.14	CD
cord-354664-mzzvmyea	68	22	,	,	,
cord-354664-mzzvmyea	68	23	95	95	CD
cord-354664-mzzvmyea	68	24	%	%	NN
cord-354664-mzzvmyea	68	25	CI	ci	NN
cord-354664-mzzvmyea	68	26	:	:	:
cord-354664-mzzvmyea	68	27	0.84	0.84	CD
cord-354664-mzzvmyea	68	28	-	-	HYPH
cord-354664-mzzvmyea	68	29	1.55	1.55	CD
cord-354664-mzzvmyea	68	30	)	)	-RRB-
cord-354664-mzzvmyea	68	31	between	between	IN
cord-354664-mzzvmyea	68	32	the	the	DT
cord-354664-mzzvmyea	68	33	atypical	atypical	JJ
cord-354664-mzzvmyea	68	34	and	and	CC
cord-354664-mzzvmyea	68	35	the	the	DT
cord-354664-mzzvmyea	68	36	typical	typical	JJ
cord-354664-mzzvmyea	68	37	coverage	coverage	NN
cord-354664-mzzvmyea	68	38	arms	arm	NNS
cord-354664-mzzvmyea	68	39	.	.	.
cord-354664-mzzvmyea	69	1	A	a	DT
cord-354664-mzzvmyea	69	2	trend	trend	NN
cord-354664-mzzvmyea	69	3	towards	towards	IN
cord-354664-mzzvmyea	69	4	fewer	few	JJR
cord-354664-mzzvmyea	69	5	clinical	clinical	JJ
cord-354664-mzzvmyea	69	6	failures	failure	NNS
cord-354664-mzzvmyea	69	7	was	be	VBD
cord-354664-mzzvmyea	69	8	observed	observe	VBN
cord-354664-mzzvmyea	69	9	in	in	IN
cord-354664-mzzvmyea	69	10	the	the	DT
cord-354664-mzzvmyea	69	11	atypical	atypical	JJ
cord-354664-mzzvmyea	69	12	therapy	therapy	NN
cord-354664-mzzvmyea	69	13	arm	arm	NN
cord-354664-mzzvmyea	69	14	,	,	,
cord-354664-mzzvmyea	69	15	but	but	CC
cord-354664-mzzvmyea	69	16	this	this	DT
cord-354664-mzzvmyea	69	17	did	do	VBD
cord-354664-mzzvmyea	69	18	not	not	RB
cord-354664-mzzvmyea	69	19	achieve	achieve	VB
cord-354664-mzzvmyea	69	20	statistical	statistical	JJ
cord-354664-mzzvmyea	69	21	significance	significance	NN
cord-354664-mzzvmyea	69	22	(	(	-LRB-
cord-354664-mzzvmyea	69	23	RR	rr	NN
cord-354664-mzzvmyea	69	24	0.93	0.93	CD
cord-354664-mzzvmyea	69	25	;	;	:
cord-354664-mzzvmyea	69	26	95	95	CD
cord-354664-mzzvmyea	69	27	%	%	NN
cord-354664-mzzvmyea	69	28	CI	ci	NN
cord-354664-mzzvmyea	69	29	:	:	:
cord-354664-mzzvmyea	69	30	0.84	0.84	CD
cord-354664-mzzvmyea	69	31	-	-	HYPH
cord-354664-mzzvmyea	69	32	1.04	1.04	CD
cord-354664-mzzvmyea	69	33	)	)	-RRB-
cord-354664-mzzvmyea	69	34	.	.	.
cord-354664-mzzvmyea	70	1	Of	of	IN
cord-354664-mzzvmyea	70	2	note	note	NN
cord-354664-mzzvmyea	70	3	,	,	,
cord-354664-mzzvmyea	70	4	the	the	DT
cord-354664-mzzvmyea	70	5	Cochrane	Cochrane	NNP
cord-354664-mzzvmyea	70	6	Review	Review	NNP
cord-354664-mzzvmyea	70	7	only	only	RB
cord-354664-mzzvmyea	70	8	included	include	VBD
cord-354664-mzzvmyea	70	9	one	one	CD
cord-354664-mzzvmyea	70	10	study	study	NN
cord-354664-mzzvmyea	70	11	that	that	WDT
cord-354664-mzzvmyea	70	12	specifically	specifically	RB
cord-354664-mzzvmyea	70	13	focused	focus	VBD
cord-354664-mzzvmyea	70	14	on	on	IN
cord-354664-mzzvmyea	70	15	the	the	DT
cord-354664-mzzvmyea	70	16	comparison	comparison	NN
cord-354664-mzzvmyea	70	17	of	of	IN
cord-354664-mzzvmyea	70	18	beta	beta	NN
cord-354664-mzzvmyea	70	19	-	-	HYPH
cord-354664-mzzvmyea	70	20	lactam	lactam	NN
cord-354664-mzzvmyea	70	21	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	70	22	to	to	IN
cord-354664-mzzvmyea	70	23	beta	beta	NN
cord-354664-mzzvmyea	70	24	-	-	HYPH
cord-354664-mzzvmyea	70	25	lactam	lactam	NNS
cord-354664-mzzvmyea	70	26	/	/	SYM
cord-354664-mzzvmyea	70	27	macrolide	macrolide	NN
cord-354664-mzzvmyea	70	28	combination	combination	NN
cord-354664-mzzvmyea	70	29	therapy	therapy	NN
cord-354664-mzzvmyea	70	30	.	.	.
cord-354664-mzzvmyea	71	1	Asadi	Asadi	NNP
cord-354664-mzzvmyea	71	2	et	et	NNP
cord-354664-mzzvmyea	71	3	al	al	NNP
cord-354664-mzzvmyea	71	4	.	.	.
cord-354664-mzzvmyea	72	1	also	also	RB
cord-354664-mzzvmyea	72	2	compared	compare	VBN
cord-354664-mzzvmyea	72	3	macrolides	macrolide	NNS
cord-354664-mzzvmyea	72	4	to	to	IN
cord-354664-mzzvmyea	72	5	other	other	JJ
cord-354664-mzzvmyea	72	6	treatment	treatment	NN
cord-354664-mzzvmyea	72	7	regimens	regimen	NNS
cord-354664-mzzvmyea	72	8	in	in	IN
cord-354664-mzzvmyea	72	9	adults	adult	NNS
cord-354664-mzzvmyea	72	10	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	72	11	with	with	IN
cord-354664-mzzvmyea	72	12	CAP	CAP	NNP
cord-354664-mzzvmyea	72	13	in	in	IN
cord-354664-mzzvmyea	72	14	a	a	DT
cord-354664-mzzvmyea	72	15	systematic	systematic	JJ
cord-354664-mzzvmyea	72	16	review	review	NN
cord-354664-mzzvmyea	72	17	and	and	CC
cord-354664-mzzvmyea	72	18	metaanalysis	metaanalysis	NN
cord-354664-mzzvmyea	72	19	including	include	VBG
cord-354664-mzzvmyea	72	20	23	23	CD
cord-354664-mzzvmyea	72	21	studies	study	NNS
cord-354664-mzzvmyea	72	22	and	and	CC
cord-354664-mzzvmyea	72	23	137,574	137,574	CD
cord-354664-mzzvmyea	72	24	patients	patient	NNS
cord-354664-mzzvmyea	72	25	[	[	-LRB-
cord-354664-mzzvmyea	72	26	35	35	CD
cord-354664-mzzvmyea	72	27	]	]	-RRB-
cord-354664-mzzvmyea	72	28	.	.	.
cord-354664-mzzvmyea	73	1	While	while	IN
cord-354664-mzzvmyea	73	2	overall	overall	JJ
cord-354664-mzzvmyea	73	3	macrolide	macrolide	NN
cord-354664-mzzvmyea	73	4	use	use	NN
cord-354664-mzzvmyea	73	5	was	be	VBD
cord-354664-mzzvmyea	73	6	associated	associate	VBN
cord-354664-mzzvmyea	73	7	with	with	IN
cord-354664-mzzvmyea	73	8	a	a	DT
cord-354664-mzzvmyea	73	9	statistically	statistically	RB
cord-354664-mzzvmyea	73	10	significant	significant	JJ
cord-354664-mzzvmyea	73	11	reduction	reduction	NN
cord-354664-mzzvmyea	73	12	in	in	IN
cord-354664-mzzvmyea	73	13	mortality	mortality	NN
cord-354664-mzzvmyea	73	14	when	when	WRB
cord-354664-mzzvmyea	73	15	compared	compare	VBN
cord-354664-mzzvmyea	73	16	to	to	IN
cord-354664-mzzvmyea	73	17	nonmacrolide	nonmacrolide	NNP
cord-354664-mzzvmyea	73	18	use	use	NN
cord-354664-mzzvmyea	73	19	,	,	,
cord-354664-mzzvmyea	73	20	the	the	DT
cord-354664-mzzvmyea	73	21	survival	survival	NN
cord-354664-mzzvmyea	73	22	advantage	advantage	NN
cord-354664-mzzvmyea	73	23	disappeared	disappear	VBD
cord-354664-mzzvmyea	73	24	(	(	-LRB-
cord-354664-mzzvmyea	73	25	4.6	4.6	CD
cord-354664-mzzvmyea	73	26	vs	vs	IN
cord-354664-mzzvmyea	73	27	4.1	4.1	CD
cord-354664-mzzvmyea	73	28	%	%	NN
cord-354664-mzzvmyea	73	29	;	;	:
cord-354664-mzzvmyea	73	30	RR	RR	NNP
cord-354664-mzzvmyea	73	31	1.13	1.13	CD
cord-354664-mzzvmyea	73	32	;	;	:
cord-354664-mzzvmyea	73	33	95	95	CD
cord-354664-mzzvmyea	73	34	%	%	NN
cord-354664-mzzvmyea	73	35	CI	ci	NN
cord-354664-mzzvmyea	73	36	:	:	:
cord-354664-mzzvmyea	73	37	0.65	0.65	CD
cord-354664-mzzvmyea	73	38	-	-	SYM
cord-354664-mzzvmyea	73	39	1.98	1.98	CD
cord-354664-mzzvmyea	73	40	)	)	-RRB-
cord-354664-mzzvmyea	73	41	when	when	WRB
cord-354664-mzzvmyea	73	42	analyses	analysis	NNS
cord-354664-mzzvmyea	73	43	were	be	VBD
cord-354664-mzzvmyea	73	44	restricted	restrict	VBN
cord-354664-mzzvmyea	73	45	to	to	IN
cord-354664-mzzvmyea	73	46	RCTs	rct	NNS
cord-354664-mzzvmyea	73	47	.	.	.
cord-354664-mzzvmyea	74	1	In	in	IN
cord-354664-mzzvmyea	74	2	recent	recent	JJ
cord-354664-mzzvmyea	74	3	years	year	NNS
cord-354664-mzzvmyea	74	4	,	,	,
cord-354664-mzzvmyea	74	5	researchers	researcher	NNS
cord-354664-mzzvmyea	74	6	have	have	VBP
cord-354664-mzzvmyea	74	7	attempted	attempt	VBN
cord-354664-mzzvmyea	74	8	to	to	TO
cord-354664-mzzvmyea	74	9	address	address	VB
cord-354664-mzzvmyea	74	10	the	the	DT
cord-354664-mzzvmyea	74	11	paucity	paucity	NN
cord-354664-mzzvmyea	74	12	of	of	IN
cord-354664-mzzvmyea	74	13	high	high	JJ
cord-354664-mzzvmyea	74	14	-	-	HYPH
cord-354664-mzzvmyea	74	15	quality	quality	NN
cord-354664-mzzvmyea	74	16	evidence	evidence	NN
cord-354664-mzzvmyea	74	17	with	with	IN
cord-354664-mzzvmyea	74	18	several	several	JJ
cord-354664-mzzvmyea	74	19	prospective	prospective	JJ
cord-354664-mzzvmyea	74	20	,	,	,
cord-354664-mzzvmyea	74	21	randomized	randomize	VBN
cord-354664-mzzvmyea	74	22	-	-	HYPH
cord-354664-mzzvmyea	74	23	controlled	control	VBN
cord-354664-mzzvmyea	74	24	trials	trial	NNS
cord-354664-mzzvmyea	74	25	aimed	aim	VBN
cord-354664-mzzvmyea	74	26	at	at	IN
cord-354664-mzzvmyea	74	27	evaluating	evaluate	VBG
cord-354664-mzzvmyea	74	28	the	the	DT
cord-354664-mzzvmyea	74	29	utility	utility	NN
cord-354664-mzzvmyea	74	30	of	of	IN
cord-354664-mzzvmyea	74	31	combination	combination	NN
cord-354664-mzzvmyea	74	32	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	74	33	therapy	therapy	NN
cord-354664-mzzvmyea	74	34	in	in	IN
cord-354664-mzzvmyea	74	35	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	74	36	adults	adult	NNS
cord-354664-mzzvmyea	74	37	with	with	IN
cord-354664-mzzvmyea	74	38	CAP	CAP	NNP
cord-354664-mzzvmyea	74	39	.	.	.
cord-354664-mzzvmyea	75	1	Garin	Garin	NNP
cord-354664-mzzvmyea	75	2	et	et	NNP
cord-354664-mzzvmyea	75	3	al	al	NNP
cord-354664-mzzvmyea	75	4	.	.	.
cord-354664-mzzvmyea	76	1	tested	test	VBD
cord-354664-mzzvmyea	76	2	the	the	DT
cord-354664-mzzvmyea	76	3	non	non	JJ
cord-354664-mzzvmyea	76	4	-	-	JJ
cord-354664-mzzvmyea	76	5	inferiority	inferiority	NN
cord-354664-mzzvmyea	76	6	of	of	IN
cord-354664-mzzvmyea	76	7	beta	beta	NN
cord-354664-mzzvmyea	76	8	-	-	HYPH
cord-354664-mzzvmyea	76	9	lactam	lactam	NN
cord-354664-mzzvmyea	76	10	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	76	11	compared	compare	VBN
cord-354664-mzzvmyea	76	12	with	with	IN
cord-354664-mzzvmyea	76	13	beta	beta	NN
cord-354664-mzzvmyea	76	14	-	-	HYPH
cord-354664-mzzvmyea	76	15	lactam	lactam	NNS
cord-354664-mzzvmyea	76	16	/	/	SYM
cord-354664-mzzvmyea	76	17	macrolide	macrolide	NN
cord-354664-mzzvmyea	76	18	combination	combination	NN
cord-354664-mzzvmyea	76	19	therapy	therapy	NN
cord-354664-mzzvmyea	76	20	in	in	IN
cord-354664-mzzvmyea	76	21	moderately	moderately	RB
cord-354664-mzzvmyea	76	22	severe	severe	JJ
cord-354664-mzzvmyea	76	23	patients	patient	NNS
cord-354664-mzzvmyea	76	24	with	with	IN
cord-354664-mzzvmyea	76	25	CAP	CAP	NNP
cord-354664-mzzvmyea	76	26	in	in	IN
cord-354664-mzzvmyea	76	27	an	an	DT
cord-354664-mzzvmyea	76	28	openlabel	openlabel	NN
cord-354664-mzzvmyea	76	29	,	,	,
cord-354664-mzzvmyea	76	30	multicenter	multicenter	JJ
cord-354664-mzzvmyea	76	31	,	,	,
cord-354664-mzzvmyea	76	32	non	non	JJ
cord-354664-mzzvmyea	76	33	-	-	JJ
cord-354664-mzzvmyea	76	34	inferiority	inferiority	JJ
cord-354664-mzzvmyea	76	35	randomized	randomized	JJ
cord-354664-mzzvmyea	76	36	control	control	NN
cord-354664-mzzvmyea	76	37	trial	trial	NN
cord-354664-mzzvmyea	76	38	[	[	-LRB-
cord-354664-mzzvmyea	76	39	36••	36••	CD
cord-354664-mzzvmyea	76	40	]	]	-RRB-
cord-354664-mzzvmyea	76	41	.	.	.
cord-354664-mzzvmyea	77	1	The	the	DT
cord-354664-mzzvmyea	77	2	study	study	NN
cord-354664-mzzvmyea	77	3	was	be	VBD
cord-354664-mzzvmyea	77	4	conducted	conduct	VBN
cord-354664-mzzvmyea	77	5	in	in	IN
cord-354664-mzzvmyea	77	6	six	six	CD
cord-354664-mzzvmyea	77	7	acute	acute	JJ
cord-354664-mzzvmyea	77	8	care	care	NN
cord-354664-mzzvmyea	77	9	hospitals	hospital	NNS
cord-354664-mzzvmyea	77	10	in	in	IN
cord-354664-mzzvmyea	77	11	Switzerland	Switzerland	NNP
cord-354664-mzzvmyea	77	12	from	from	IN
cord-354664-mzzvmyea	77	13	2009	2009	CD
cord-354664-mzzvmyea	77	14	to	to	IN
cord-354664-mzzvmyea	77	15	2013	2013	CD
cord-354664-mzzvmyea	77	16	.	.	.
cord-354664-mzzvmyea	78	1	The	the	DT
cord-354664-mzzvmyea	78	2	primary	primary	JJ
cord-354664-mzzvmyea	78	3	endpoint	endpoint	NN
cord-354664-mzzvmyea	78	4	in	in	IN
cord-354664-mzzvmyea	78	5	this	this	DT
cord-354664-mzzvmyea	78	6	trial	trial	NN
cord-354664-mzzvmyea	78	7	was	be	VBD
cord-354664-mzzvmyea	78	8	the	the	DT
cord-354664-mzzvmyea	78	9	proportion	proportion	NN
cord-354664-mzzvmyea	78	10	of	of	IN
cord-354664-mzzvmyea	78	11	patients	patient	NNS
cord-354664-mzzvmyea	78	12	not	not	RB
cord-354664-mzzvmyea	78	13	achieving	achieve	VBG
cord-354664-mzzvmyea	78	14	clinical	clinical	JJ
cord-354664-mzzvmyea	78	15	stability	stability	NN
cord-354664-mzzvmyea	78	16	at	at	IN
cord-354664-mzzvmyea	78	17	day	day	NN
cord-354664-mzzvmyea	78	18	7	7	CD
cord-354664-mzzvmyea	78	19	.	.	.
cord-354664-mzzvmyea	79	1	After	after	IN
cord-354664-mzzvmyea	79	2	7	7	CD
cord-354664-mzzvmyea	79	3	days	day	NNS
cord-354664-mzzvmyea	79	4	of	of	IN
cord-354664-mzzvmyea	79	5	therapy	therapy	NN
cord-354664-mzzvmyea	79	6	,	,	,
cord-354664-mzzvmyea	79	7	41	41	CD
cord-354664-mzzvmyea	79	8	%	%	NN
cord-354664-mzzvmyea	79	9	in	in	IN
cord-354664-mzzvmyea	79	10	the	the	DT
cord-354664-mzzvmyea	79	11	monotherapy	monotherapy	NNP
cord-354664-mzzvmyea	79	12	arm	arm	NN
cord-354664-mzzvmyea	79	13	and	and	CC
cord-354664-mzzvmyea	79	14	33	33	CD
cord-354664-mzzvmyea	79	15	%	%	NN
cord-354664-mzzvmyea	79	16	in	in	IN
cord-354664-mzzvmyea	79	17	the	the	DT
cord-354664-mzzvmyea	79	18	combination	combination	NN
cord-354664-mzzvmyea	79	19	arm	arm	NN
cord-354664-mzzvmyea	79	20	had	have	VBD
cord-354664-mzzvmyea	79	21	not	not	RB
cord-354664-mzzvmyea	79	22	reached	reach	VBN
cord-354664-mzzvmyea	79	23	clinical	clinical	JJ
cord-354664-mzzvmyea	79	24	stability	stability	NN
cord-354664-mzzvmyea	79	25	(	(	-LRB-
cord-354664-mzzvmyea	79	26	7	7	CD
cord-354664-mzzvmyea	79	27	%	%	NN
cord-354664-mzzvmyea	79	28	difference	difference	NN
cord-354664-mzzvmyea	79	29	,	,	,
cord-354664-mzzvmyea	79	30	p	p	NN
cord-354664-mzzvmyea	79	31	=	=	SYM
cord-354664-mzzvmyea	79	32	0.07	0.07	CD
cord-354664-mzzvmyea	79	33	)	)	-RRB-
cord-354664-mzzvmyea	79	34	,	,	,
cord-354664-mzzvmyea	79	35	exceeding	exceed	VBG
cord-354664-mzzvmyea	79	36	the	the	DT
cord-354664-mzzvmyea	79	37	predefined	predefined	JJ
cord-354664-mzzvmyea	79	38	non	non	JJ
cord-354664-mzzvmyea	79	39	-	-	JJ
cord-354664-mzzvmyea	79	40	inferiority	inferiority	JJ
cord-354664-mzzvmyea	79	41	boundary	boundary	NN
cord-354664-mzzvmyea	79	42	.	.	.
cord-354664-mzzvmyea	80	1	Patients	patient	NNS
cord-354664-mzzvmyea	80	2	identified	identify	VBN
cord-354664-mzzvmyea	80	3	to	to	TO
cord-354664-mzzvmyea	80	4	have	have	VB
cord-354664-mzzvmyea	80	5	atypical	atypical	JJ
cord-354664-mzzvmyea	80	6	pathogens	pathogen	NNS
cord-354664-mzzvmyea	80	7	or	or	CC
cord-354664-mzzvmyea	80	8	severe	severe	JJ
cord-354664-mzzvmyea	80	9	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	81	1	(	(	-LRB-
cord-354664-mzzvmyea	81	2	PSI	PSI	NNP
cord-354664-mzzvmyea	81	3	≥	≥	CD
cord-354664-mzzvmyea	81	4	4	4	CD
cord-354664-mzzvmyea	81	5	)	)	-RRB-
cord-354664-mzzvmyea	81	6	were	be	VBD
cord-354664-mzzvmyea	81	7	less	less	RBR
cord-354664-mzzvmyea	81	8	likely	likely	JJ
cord-354664-mzzvmyea	81	9	to	to	TO
cord-354664-mzzvmyea	81	10	reach	reach	VB
cord-354664-mzzvmyea	81	11	clinical	clinical	JJ
cord-354664-mzzvmyea	81	12	stability	stability	NN
cord-354664-mzzvmyea	81	13	with	with	IN
cord-354664-mzzvmyea	81	14	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	81	15	while	while	IN
cord-354664-mzzvmyea	81	16	patients	patient	NNS
cord-354664-mzzvmyea	81	17	infected	infect	VBN
cord-354664-mzzvmyea	81	18	with	with	IN
cord-354664-mzzvmyea	81	19	typical	typical	JJ
cord-354664-mzzvmyea	81	20	pathogens	pathogen	NNS
cord-354664-mzzvmyea	81	21	or	or	CC
cord-354664-mzzvmyea	81	22	mild	mild	JJ
cord-354664-mzzvmyea	81	23	to	to	IN
cord-354664-mzzvmyea	81	24	moderate	moderate	JJ
cord-354664-mzzvmyea	81	25	CAP	cap	NN
cord-354664-mzzvmyea	81	26	severity	severity	NN
cord-354664-mzzvmyea	81	27	(	(	-LRB-
cord-354664-mzzvmyea	81	28	PSI	psi	NN
cord-354664-mzzvmyea	81	29	1	1	CD
cord-354664-mzzvmyea	81	30	to	to	IN
cord-354664-mzzvmyea	81	31	3	3	CD
cord-354664-mzzvmyea	81	32	)	)	-RRB-
cord-354664-mzzvmyea	81	33	had	have	VBD
cord-354664-mzzvmyea	81	34	equivalent	equivalent	JJ
cord-354664-mzzvmyea	81	35	outcomes	outcome	NNS
cord-354664-mzzvmyea	81	36	.	.	.
cord-354664-mzzvmyea	82	1	Secondary	secondary	JJ
cord-354664-mzzvmyea	82	2	endpoints	endpoint	NNS
cord-354664-mzzvmyea	82	3	that	that	WDT
cord-354664-mzzvmyea	82	4	included	include	VBD
cord-354664-mzzvmyea	82	5	overall	overall	JJ
cord-354664-mzzvmyea	82	6	mortality	mortality	NN
cord-354664-mzzvmyea	82	7	,	,	,
cord-354664-mzzvmyea	82	8	need	need	VBP
cord-354664-mzzvmyea	82	9	for	for	IN
cord-354664-mzzvmyea	82	10	ICU	ICU	NNP
cord-354664-mzzvmyea	82	11	admission	admission	NN
cord-354664-mzzvmyea	82	12	,	,	,
cord-354664-mzzvmyea	82	13	complications	complication	NNS
cord-354664-mzzvmyea	82	14	,	,	,
cord-354664-mzzvmyea	82	15	length	length	NN
cord-354664-mzzvmyea	82	16	of	of	IN
cord-354664-mzzvmyea	82	17	stay	stay	NN
cord-354664-mzzvmyea	82	18	,	,	,
cord-354664-mzzvmyea	82	19	and	and	CC
cord-354664-mzzvmyea	82	20	recurrence	recurrence	NN
cord-354664-mzzvmyea	82	21	of	of	IN
cord-354664-mzzvmyea	82	22	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	82	23	within	within	IN
cord-354664-mzzvmyea	82	24	90	90	CD
cord-354664-mzzvmyea	82	25	days	day	NNS
cord-354664-mzzvmyea	82	26	did	do	VBD
cord-354664-mzzvmyea	82	27	not	not	RB
cord-354664-mzzvmyea	82	28	differ	differ	VB
cord-354664-mzzvmyea	82	29	significantly	significantly	RB
cord-354664-mzzvmyea	82	30	between	between	IN
cord-354664-mzzvmyea	82	31	the	the	DT
cord-354664-mzzvmyea	82	32	two	two	CD
cord-354664-mzzvmyea	82	33	groups	group	NNS
cord-354664-mzzvmyea	82	34	.	.	.
cord-354664-mzzvmyea	83	1	Postma	Postma	NNP
cord-354664-mzzvmyea	83	2	et	et	FW
cord-354664-mzzvmyea	83	3	al	al	NNP
cord-354664-mzzvmyea	83	4	.	.	.
cord-354664-mzzvmyea	84	1	designed	design	VBN
cord-354664-mzzvmyea	84	2	the	the	DT
cord-354664-mzzvmyea	84	3	CAP	CAP	NNP
cord-354664-mzzvmyea	84	4	-	-	HYPH
cord-354664-mzzvmyea	84	5	START	START	NNP
cord-354664-mzzvmyea	84	6	Trial	Trial	NNP
cord-354664-mzzvmyea	84	7	,	,	,
cord-354664-mzzvmyea	84	8	a	a	DT
cord-354664-mzzvmyea	84	9	multicenter	multicenter	JJ
cord-354664-mzzvmyea	84	10	cluster	cluster	NN
cord-354664-mzzvmyea	84	11	-	-	HYPH
cord-354664-mzzvmyea	84	12	randomized	randomized	JJ
cord-354664-mzzvmyea	84	13	,	,	,
cord-354664-mzzvmyea	84	14	crossover	crossover	NN
cord-354664-mzzvmyea	84	15	,	,	,
cord-354664-mzzvmyea	84	16	non	non	JJ
cord-354664-mzzvmyea	84	17	-	-	JJ
cord-354664-mzzvmyea	84	18	inferiority	inferiority	JJ
cord-354664-mzzvmyea	84	19	trial	trial	NN
cord-354664-mzzvmyea	84	20	conducted	conduct	VBN
cord-354664-mzzvmyea	84	21	at	at	IN
cord-354664-mzzvmyea	84	22	7	7	CD
cord-354664-mzzvmyea	84	23	hospitals	hospital	NNS
cord-354664-mzzvmyea	84	24	in	in	IN
cord-354664-mzzvmyea	84	25	the	the	DT
cord-354664-mzzvmyea	84	26	Netherlands	Netherlands	NNP
cord-354664-mzzvmyea	84	27	to	to	TO
cord-354664-mzzvmyea	84	28	determine	determine	VB
cord-354664-mzzvmyea	84	29	if	if	IN
cord-354664-mzzvmyea	84	30	empiric	empiric	JJ
cord-354664-mzzvmyea	84	31	therapy	therapy	NN
cord-354664-mzzvmyea	84	32	for	for	IN
cord-354664-mzzvmyea	84	33	CAP	cap	NN
cord-354664-mzzvmyea	84	34	with	with	IN
cord-354664-mzzvmyea	84	35	beta	beta	NN
cord-354664-mzzvmyea	84	36	-	-	HYPH
cord-354664-mzzvmyea	84	37	lactam	lactam	NN
cord-354664-mzzvmyea	84	38	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	84	39	was	be	VBD
cord-354664-mzzvmyea	84	40	noninferior	noninferior	JJ
cord-354664-mzzvmyea	84	41	to	to	TO
cord-354664-mzzvmyea	84	42	combination	combination	NN
cord-354664-mzzvmyea	84	43	beta	beta	NN
cord-354664-mzzvmyea	84	44	-	-	HYPH
cord-354664-mzzvmyea	84	45	lactam	lactam	NN
cord-354664-mzzvmyea	84	46	/	/	SYM
cord-354664-mzzvmyea	84	47	macrolide	macrolide	NN
cord-354664-mzzvmyea	84	48	therapy	therapy	NN
cord-354664-mzzvmyea	84	49	or	or	CC
cord-354664-mzzvmyea	84	50	a	a	DT
cord-354664-mzzvmyea	84	51	respiratory	respiratory	JJ
cord-354664-mzzvmyea	84	52	fluoroquinolone	fluoroquinolone	NN
cord-354664-mzzvmyea	84	53	[	[	-LRB-
cord-354664-mzzvmyea	84	54	37••	37••	CD
cord-354664-mzzvmyea	84	55	]	]	-RRB-
cord-354664-mzzvmyea	84	56	.	.	.
cord-354664-mzzvmyea	85	1	Adult	adult	NN
cord-354664-mzzvmyea	85	2	patients	patient	NNS
cord-354664-mzzvmyea	85	3	were	be	VBD
cord-354664-mzzvmyea	85	4	included	include	VBN
cord-354664-mzzvmyea	85	5	if	if	IN
cord-354664-mzzvmyea	85	6	they	-PRON-	PRP
cord-354664-mzzvmyea	85	7	demonstrated	demonstrate	VBD
cord-354664-mzzvmyea	85	8	radiographic	radiographic	JJ
cord-354664-mzzvmyea	85	9	evidence	evidence	NN
cord-354664-mzzvmyea	85	10	of	of	IN
cord-354664-mzzvmyea	85	11	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	85	12	and	and	CC
cord-354664-mzzvmyea	85	13	compatible	compatible	JJ
cord-354664-mzzvmyea	85	14	clinical	clinical	JJ
cord-354664-mzzvmyea	85	15	findings	finding	NNS
cord-354664-mzzvmyea	85	16	.	.	.
cord-354664-mzzvmyea	86	1	Patients	patient	NNS
cord-354664-mzzvmyea	86	2	were	be	VBD
cord-354664-mzzvmyea	86	3	excluded	exclude	VBN
cord-354664-mzzvmyea	86	4	if	if	IN
cord-354664-mzzvmyea	86	5	they	-PRON-	PRP
cord-354664-mzzvmyea	86	6	had	have	VBD
cord-354664-mzzvmyea	86	7	cystic	cystic	JJ
cord-354664-mzzvmyea	86	8	fibrosis	fibrosis	NN
cord-354664-mzzvmyea	86	9	,	,	,
cord-354664-mzzvmyea	86	10	positive	positive	JJ
cord-354664-mzzvmyea	86	11	Legionella	Legionella	NNP
cord-354664-mzzvmyea	86	12	antigen	antigen	NN
cord-354664-mzzvmyea	86	13	,	,	,
cord-354664-mzzvmyea	86	14	recent	recent	JJ
cord-354664-mzzvmyea	86	15	hospitalization	hospitalization	NN
cord-354664-mzzvmyea	86	16	,	,	,
cord-354664-mzzvmyea	86	17	or	or	CC
cord-354664-mzzvmyea	86	18	were	be	VBD
cord-354664-mzzvmyea	86	19	from	from	IN
cord-354664-mzzvmyea	86	20	a	a	DT
cord-354664-mzzvmyea	86	21	long	long	JJ
cord-354664-mzzvmyea	86	22	-	-	HYPH
cord-354664-mzzvmyea	86	23	term	term	NN
cord-354664-mzzvmyea	86	24	care	care	NN
cord-354664-mzzvmyea	86	25	facility	facility	NN
cord-354664-mzzvmyea	86	26	.	.	.
cord-354664-mzzvmyea	87	1	The	the	DT
cord-354664-mzzvmyea	87	2	unadjusted	unadjusted	JJ
cord-354664-mzzvmyea	87	3	90-day	90-day	CD
cord-354664-mzzvmyea	87	4	all	all	DT
cord-354664-mzzvmyea	87	5	-	-	HYPH
cord-354664-mzzvmyea	87	6	cause	cause	NN
cord-354664-mzzvmyea	87	7	mortality	mortality	NN
cord-354664-mzzvmyea	87	8	was	be	VBD
cord-354664-mzzvmyea	87	9	9.0	9.0	CD
cord-354664-mzzvmyea	87	10	%	%	NN
cord-354664-mzzvmyea	87	11	(	(	-LRB-
cord-354664-mzzvmyea	87	12	betalactam	betalactam	NNP
cord-354664-mzzvmyea	87	13	monotherapy	monotherapy	NNP
cord-354664-mzzvmyea	87	14	)	)	-RRB-
cord-354664-mzzvmyea	87	15	,	,	,
cord-354664-mzzvmyea	87	16	8.8	8.8	CD
cord-354664-mzzvmyea	87	17	%	%	NN
cord-354664-mzzvmyea	87	18	(	(	-LRB-
cord-354664-mzzvmyea	87	19	FQ	FQ	NNP
cord-354664-mzzvmyea	87	20	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	87	21	)	)	-RRB-
cord-354664-mzzvmyea	87	22	,	,	,
cord-354664-mzzvmyea	87	23	and	and	CC
cord-354664-mzzvmyea	87	24	11.1	11.1	CD
cord-354664-mzzvmyea	87	25	%	%	NN
cord-354664-mzzvmyea	87	26	(	(	-LRB-
cord-354664-mzzvmyea	87	27	beta	beta	NN
cord-354664-mzzvmyea	87	28	-	-	HYPH
cord-354664-mzzvmyea	87	29	lactam	lactam	NNS
cord-354664-mzzvmyea	87	30	/	/	SYM
cord-354664-mzzvmyea	87	31	macrolide	macrolide	NN
cord-354664-mzzvmyea	87	32	combination	combination	NN
cord-354664-mzzvmyea	87	33	)	)	-RRB-
cord-354664-mzzvmyea	87	34	.	.	.
cord-354664-mzzvmyea	88	1	Adjusted	adjusted	JJ
cord-354664-mzzvmyea	88	2	comparisons	comparison	NNS
cord-354664-mzzvmyea	88	3	for	for	IN
cord-354664-mzzvmyea	88	4	90-day	90-day	CD
cord-354664-mzzvmyea	88	5	all	all	DT
cord-354664-mzzvmyea	88	6	-	-	HYPH
cord-354664-mzzvmyea	88	7	cause	cause	NN
cord-354664-mzzvmyea	88	8	mortality	mortality	NN
cord-354664-mzzvmyea	88	9	favored	favor	VBN
cord-354664-mzzvmyea	88	10	beta	beta	NN
cord-354664-mzzvmyea	88	11	-	-	HYPH
cord-354664-mzzvmyea	88	12	lactam	lactam	NN
cord-354664-mzzvmyea	88	13	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	88	14	with	with	IN
cord-354664-mzzvmyea	88	15	a	a	DT
cord-354664-mzzvmyea	88	16	1.9	1.9	CD
cord-354664-mzzvmyea	88	17	%	%	NN
cord-354664-mzzvmyea	88	18	lower	low	JJR
cord-354664-mzzvmyea	88	19	risk	risk	NN
cord-354664-mzzvmyea	88	20	of	of	IN
cord-354664-mzzvmyea	88	21	death	death	NN
cord-354664-mzzvmyea	88	22	when	when	WRB
cord-354664-mzzvmyea	88	23	compared	compare	VBN
cord-354664-mzzvmyea	88	24	to	to	IN
cord-354664-mzzvmyea	88	25	macrolide	macrolide	JJ
cord-354664-mzzvmyea	88	26	combination	combination	NN
cord-354664-mzzvmyea	88	27	therapy	therapy	NN
cord-354664-mzzvmyea	88	28	(	(	-LRB-
cord-354664-mzzvmyea	88	29	90	90	CD
cord-354664-mzzvmyea	88	30	%	%	NN
cord-354664-mzzvmyea	88	31	CI	ci	NN
cord-354664-mzzvmyea	88	32	:	:	:
cord-354664-mzzvmyea	88	33	−0.6	−0.6	NN
cord-354664-mzzvmyea	88	34	to	to	IN
cord-354664-mzzvmyea	88	35	4.4	4.4	CD
cord-354664-mzzvmyea	88	36	)	)	-RRB-
cord-354664-mzzvmyea	88	37	.	.	.
cord-354664-mzzvmyea	89	1	Time	time	NN
cord-354664-mzzvmyea	89	2	to	to	IN
cord-354664-mzzvmyea	89	3	oral	oral	JJ
cord-354664-mzzvmyea	89	4	antibiotic	antibiotic	NN
cord-354664-mzzvmyea	89	5	de	de	NN
cord-354664-mzzvmyea	89	6	-	-	NN
cord-354664-mzzvmyea	89	7	escalation	escalation	NN
cord-354664-mzzvmyea	89	8	,	,	,
cord-354664-mzzvmyea	89	9	length	length	NN
cord-354664-mzzvmyea	89	10	of	of	IN
cord-354664-mzzvmyea	89	11	hospital	hospital	NN
cord-354664-mzzvmyea	89	12	stay	stay	NN
cord-354664-mzzvmyea	89	13	,	,	,
cord-354664-mzzvmyea	89	14	and	and	CC
cord-354664-mzzvmyea	89	15	occurrence	occurrence	NN
cord-354664-mzzvmyea	89	16	of	of	IN
cord-354664-mzzvmyea	89	17	complications	complication	NNS
cord-354664-mzzvmyea	89	18	during	during	IN
cord-354664-mzzvmyea	89	19	hospital	hospital	NN
cord-354664-mzzvmyea	89	20	stay	stay	NN
cord-354664-mzzvmyea	89	21	were	be	VBD
cord-354664-mzzvmyea	89	22	not	not	RB
cord-354664-mzzvmyea	89	23	significantly	significantly	RB
cord-354664-mzzvmyea	89	24	different	different	JJ
cord-354664-mzzvmyea	89	25	between	between	IN
cord-354664-mzzvmyea	89	26	the	the	DT
cord-354664-mzzvmyea	89	27	groups	group	NNS
cord-354664-mzzvmyea	89	28	.	.	.
cord-354664-mzzvmyea	90	1	While	while	IN
cord-354664-mzzvmyea	90	2	criticisms	criticism	NNS
cord-354664-mzzvmyea	90	3	of	of	IN
cord-354664-mzzvmyea	90	4	this	this	DT
cord-354664-mzzvmyea	90	5	study	study	NN
cord-354664-mzzvmyea	90	6	included	include	VBD
cord-354664-mzzvmyea	90	7	a	a	DT
cord-354664-mzzvmyea	90	8	high	high	JJ
cord-354664-mzzvmyea	90	9	rate	rate	NN
cord-354664-mzzvmyea	90	10	of	of	IN
cord-354664-mzzvmyea	90	11	protocol	protocol	NN
cord-354664-mzzvmyea	90	12	deviation	deviation	NN
cord-354664-mzzvmyea	90	13	in	in	IN
cord-354664-mzzvmyea	90	14	the	the	DT
cord-354664-mzzvmyea	90	15	beta	beta	NN
cord-354664-mzzvmyea	90	16	-	-	HYPH
cord-354664-mzzvmyea	90	17	lactam	lactam	NN
cord-354664-mzzvmyea	90	18	monotherapy	monotherapy	IN
cord-354664-mzzvmyea	90	19	group	group	NN
cord-354664-mzzvmyea	90	20	to	to	TO
cord-354664-mzzvmyea	90	21	include	include	VB
cord-354664-mzzvmyea	90	22	atypical	atypical	JJ
cord-354664-mzzvmyea	90	23	coverage	coverage	NN
cord-354664-mzzvmyea	90	24	,	,	,
cord-354664-mzzvmyea	90	25	subgroup	subgroup	NN
cord-354664-mzzvmyea	90	26	analyses	analysis	NNS
cord-354664-mzzvmyea	90	27	of	of	IN
cord-354664-mzzvmyea	90	28	strategy	strategy	NN
cord-354664-mzzvmyea	90	29	-	-	HYPH
cord-354664-mzzvmyea	90	30	adherent	adherent	JJ
cord-354664-mzzvmyea	90	31	and	and	CC
cord-354664-mzzvmyea	90	32	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	90	33	-	-	HYPH
cord-354664-mzzvmyea	90	34	adherent	adherent	JJ
cord-354664-mzzvmyea	90	35	groups	group	NNS
cord-354664-mzzvmyea	90	36	revealed	reveal	VBD
cord-354664-mzzvmyea	90	37	no	no	DT
cord-354664-mzzvmyea	90	38	significant	significant	JJ
cord-354664-mzzvmyea	90	39	difference	difference	NN
cord-354664-mzzvmyea	90	40	in	in	IN
cord-354664-mzzvmyea	90	41	outcomes	outcome	NNS
cord-354664-mzzvmyea	90	42	.	.	.
cord-354664-mzzvmyea	91	1	Van	Van	NNP
cord-354664-mzzvmyea	91	2	Werkhoven	Werkhoven	NNP
cord-354664-mzzvmyea	91	3	et	et	NNP
cord-354664-mzzvmyea	91	4	al	al	NNP
cord-354664-mzzvmyea	91	5	.	.	.
cord-354664-mzzvmyea	92	1	further	further	RB
cord-354664-mzzvmyea	92	2	evaluated	evaluate	VBN
cord-354664-mzzvmyea	92	3	outcomes	outcome	NNS
cord-354664-mzzvmyea	92	4	in	in	IN
cord-354664-mzzvmyea	92	5	a	a	DT
cord-354664-mzzvmyea	92	6	subset	subset	NN
cord-354664-mzzvmyea	92	7	of	of	IN
cord-354664-mzzvmyea	92	8	179	179	CD
cord-354664-mzzvmyea	92	9	patients	patient	NNS
cord-354664-mzzvmyea	92	10	from	from	IN
cord-354664-mzzvmyea	92	11	the	the	DT
cord-354664-mzzvmyea	92	12	CAP	CAP	NNP
cord-354664-mzzvmyea	92	13	-	-	HYPH
cord-354664-mzzvmyea	92	14	START	START	NNP
cord-354664-mzzvmyea	92	15	Trial	Trial	NNP
cord-354664-mzzvmyea	92	16	that	that	WDT
cord-354664-mzzvmyea	92	17	had	have	VBD
cord-354664-mzzvmyea	92	18	previous	previous	JJ
cord-354664-mzzvmyea	92	19	beta	beta	NN
cord-354664-mzzvmyea	92	20	-	-	HYPH
cord-354664-mzzvmyea	92	21	lactam	lactam	NN
cord-354664-mzzvmyea	92	22	exposure	exposure	NN
cord-354664-mzzvmyea	92	23	prior	prior	RB
cord-354664-mzzvmyea	92	24	to	to	IN
cord-354664-mzzvmyea	92	25	hospitalization	hospitalization	NN
cord-354664-mzzvmyea	92	26	[	[	-LRB-
cord-354664-mzzvmyea	92	27	38••	38••	CD
cord-354664-mzzvmyea	92	28	]	]	-RRB-
cord-354664-mzzvmyea	92	29	.	.	.
cord-354664-mzzvmyea	93	1	Thirty	thirty	CD
cord-354664-mzzvmyea	93	2	-	-	HYPH
cord-354664-mzzvmyea	93	3	day	day	NN
cord-354664-mzzvmyea	93	4	mortality	mortality	NN
cord-354664-mzzvmyea	93	5	,	,	,
cord-354664-mzzvmyea	93	6	hospital	hospital	NN
cord-354664-mzzvmyea	93	7	length	length	NN
cord-354664-mzzvmyea	93	8	of	of	IN
cord-354664-mzzvmyea	93	9	stay	stay	NN
cord-354664-mzzvmyea	93	10	,	,	,
cord-354664-mzzvmyea	93	11	and	and	CC
cord-354664-mzzvmyea	93	12	frequency	frequency	NN
cord-354664-mzzvmyea	93	13	of	of	IN
cord-354664-mzzvmyea	93	14	treatment	treatment	NN
cord-354664-mzzvmyea	93	15	escalations	escalation	NNS
cord-354664-mzzvmyea	93	16	were	be	VBD
cord-354664-mzzvmyea	93	17	compared	compare	VBN
cord-354664-mzzvmyea	93	18	between	between	IN
cord-354664-mzzvmyea	93	19	patients	patient	NNS
cord-354664-mzzvmyea	93	20	that	that	WDT
cord-354664-mzzvmyea	93	21	were	be	VBD
cord-354664-mzzvmyea	93	22	continued	continue	VBN
cord-354664-mzzvmyea	93	23	on	on	IN
cord-354664-mzzvmyea	93	24	beta	beta	NN
cord-354664-mzzvmyea	93	25	-	-	HYPH
cord-354664-mzzvmyea	93	26	lactam	lactam	NN
cord-354664-mzzvmyea	93	27	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	93	28	and	and	CC
cord-354664-mzzvmyea	93	29	patients	patient	NNS
cord-354664-mzzvmyea	93	30	that	that	WDT
cord-354664-mzzvmyea	93	31	received	receive	VBD
cord-354664-mzzvmyea	93	32	beta	beta	NN
cord-354664-mzzvmyea	93	33	-	-	HYPH
cord-354664-mzzvmyea	93	34	lactams	lactam	NNS
cord-354664-mzzvmyea	93	35	and	and	CC
cord-354664-mzzvmyea	93	36	atypical	atypical	JJ
cord-354664-mzzvmyea	93	37	coverage	coverage	NN
cord-354664-mzzvmyea	93	38	.	.	.
cord-354664-mzzvmyea	94	1	Despite	despite	IN
cord-354664-mzzvmyea	94	2	the	the	DT
cord-354664-mzzvmyea	94	3	betalactam	betalactam	NNP
cord-354664-mzzvmyea	94	4	monotherapy	monotherapy	IN
cord-354664-mzzvmyea	94	5	group	group	NN
cord-354664-mzzvmyea	94	6	being	be	VBG
cord-354664-mzzvmyea	94	7	older	old	JJR
cord-354664-mzzvmyea	94	8	,	,	,
cord-354664-mzzvmyea	94	9	having	have	VBG
cord-354664-mzzvmyea	94	10	more	more	JJR
cord-354664-mzzvmyea	94	11	medical	medical	JJ
cord-354664-mzzvmyea	94	12	comorbidities	comorbiditie	NNS
cord-354664-mzzvmyea	94	13	,	,	,
cord-354664-mzzvmyea	94	14	and	and	CC
cord-354664-mzzvmyea	94	15	longer	long	JJR
cord-354664-mzzvmyea	94	16	duration	duration	NN
cord-354664-mzzvmyea	94	17	of	of	IN
cord-354664-mzzvmyea	94	18	symptoms	symptom	NNS
cord-354664-mzzvmyea	94	19	prior	prior	RB
cord-354664-mzzvmyea	94	20	to	to	IN
cord-354664-mzzvmyea	94	21	admission	admission	NN
cord-354664-mzzvmyea	94	22	,	,	,
cord-354664-mzzvmyea	94	23	the	the	DT
cord-354664-mzzvmyea	94	24	authors	author	NNS
cord-354664-mzzvmyea	94	25	found	find	VBD
cord-354664-mzzvmyea	94	26	no	no	DT
cord-354664-mzzvmyea	94	27	significant	significant	JJ
cord-354664-mzzvmyea	94	28	differences	difference	NNS
cord-354664-mzzvmyea	94	29	between	between	IN
cord-354664-mzzvmyea	94	30	groups	group	NNS
cord-354664-mzzvmyea	94	31	with	with	IN
cord-354664-mzzvmyea	94	32	respect	respect	NN
cord-354664-mzzvmyea	94	33	to	to	IN
cord-354664-mzzvmyea	94	34	30-day	30-day	CD
cord-354664-mzzvmyea	94	35	mortality	mortality	NN
cord-354664-mzzvmyea	94	36	and	and	CC
cord-354664-mzzvmyea	94	37	hospital	hospital	NN
cord-354664-mzzvmyea	94	38	length	length	NN
cord-354664-mzzvmyea	94	39	of	of	IN
cord-354664-mzzvmyea	94	40	stay	stay	NN
cord-354664-mzzvmyea	94	41	.	.	.
cord-354664-mzzvmyea	95	1	While	while	IN
cord-354664-mzzvmyea	95	2	these	these	DT
cord-354664-mzzvmyea	95	3	recent	recent	JJ
cord-354664-mzzvmyea	95	4	trials	trial	NNS
cord-354664-mzzvmyea	95	5	performed	perform	VBN
cord-354664-mzzvmyea	95	6	by	by	IN
cord-354664-mzzvmyea	95	7	Garin	Garin	NNP
cord-354664-mzzvmyea	95	8	,	,	,
cord-354664-mzzvmyea	95	9	Postma	Postma	NNP
cord-354664-mzzvmyea	95	10	,	,	,
cord-354664-mzzvmyea	95	11	and	and	CC
cord-354664-mzzvmyea	95	12	van	van	NNP
cord-354664-mzzvmyea	95	13	Werkhoven	Werkhoven	NNP
cord-354664-mzzvmyea	95	14	provide	provide	VBP
cord-354664-mzzvmyea	95	15	evidence	evidence	NN
cord-354664-mzzvmyea	95	16	to	to	TO
cord-354664-mzzvmyea	95	17	support	support	VB
cord-354664-mzzvmyea	95	18	a	a	DT
cord-354664-mzzvmyea	95	19	strategy	strategy	NN
cord-354664-mzzvmyea	95	20	of	of	IN
cord-354664-mzzvmyea	95	21	beta	beta	NN
cord-354664-mzzvmyea	95	22	-	-	HYPH
cord-354664-mzzvmyea	95	23	lactam	lactam	NN
cord-354664-mzzvmyea	95	24	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	95	25	for	for	IN
cord-354664-mzzvmyea	95	26	patients	patient	NNS
cord-354664-mzzvmyea	95	27	presenting	present	VBG
cord-354664-mzzvmyea	95	28	with	with	IN
cord-354664-mzzvmyea	95	29	mild	mild	JJ
cord-354664-mzzvmyea	95	30	to	to	IN
cord-354664-mzzvmyea	95	31	moderate	moderate	JJ
cord-354664-mzzvmyea	95	32	CAP	cap	NN
cord-354664-mzzvmyea	95	33	,	,	,
cord-354664-mzzvmyea	95	34	the	the	DT
cord-354664-mzzvmyea	95	35	role	role	NN
cord-354664-mzzvmyea	95	36	of	of	IN
cord-354664-mzzvmyea	95	37	combination	combination	NN
cord-354664-mzzvmyea	95	38	beta	beta	NN
cord-354664-mzzvmyea	95	39	-	-	HYPH
cord-354664-mzzvmyea	95	40	lactam/	lactam/	CD
cord-354664-mzzvmyea	95	41	macrolide	macrolide	NN
cord-354664-mzzvmyea	95	42	therapy	therapy	NN
cord-354664-mzzvmyea	95	43	in	in	IN
cord-354664-mzzvmyea	95	44	critically	critically	RB
cord-354664-mzzvmyea	95	45	ill	ill	JJ
cord-354664-mzzvmyea	95	46	patients	patient	NNS
cord-354664-mzzvmyea	95	47	with	with	IN
cord-354664-mzzvmyea	95	48	severe	severe	JJ
cord-354664-mzzvmyea	95	49	CAP	cap	NN
cord-354664-mzzvmyea	95	50	remains	remain	VBZ
cord-354664-mzzvmyea	95	51	unclear	unclear	JJ
cord-354664-mzzvmyea	95	52	.	.	.
cord-354664-mzzvmyea	96	1	The	the	DT
cord-354664-mzzvmyea	96	2	use	use	NN
cord-354664-mzzvmyea	96	3	of	of	IN
cord-354664-mzzvmyea	96	4	macrolide	macrolide	JJ
cord-354664-mzzvmyea	96	5	combination	combination	NN
cord-354664-mzzvmyea	96	6	therapy	therapy	NN
cord-354664-mzzvmyea	96	7	in	in	IN
cord-354664-mzzvmyea	96	8	severe	severe	JJ
cord-354664-mzzvmyea	96	9	CAP	cap	NN
cord-354664-mzzvmyea	96	10	is	be	VBZ
cord-354664-mzzvmyea	96	11	endorsed	endorse	VBN
cord-354664-mzzvmyea	96	12	in	in	IN
cord-354664-mzzvmyea	96	13	various	various	JJ
cord-354664-mzzvmyea	96	14	clinical	clinical	JJ
cord-354664-mzzvmyea	96	15	guidelines	guideline	NNS
cord-354664-mzzvmyea	96	16	(	(	-LRB-
cord-354664-mzzvmyea	96	17	Table	Table	NNP
cord-354664-mzzvmyea	96	18	1	1	CD
cord-354664-mzzvmyea	96	19	)	)	-RRB-
cord-354664-mzzvmyea	96	20	.	.	.
cord-354664-mzzvmyea	97	1	Again	again	RB
cord-354664-mzzvmyea	97	2	,	,	,
cord-354664-mzzvmyea	97	3	however	however	RB
cord-354664-mzzvmyea	97	4	,	,	,
cord-354664-mzzvmyea	97	5	the	the	DT
cord-354664-mzzvmyea	97	6	data	datum	NNS
cord-354664-mzzvmyea	97	7	to	to	TO
cord-354664-mzzvmyea	97	8	support	support	VB
cord-354664-mzzvmyea	97	9	macrolide	macrolide	NN
cord-354664-mzzvmyea	97	10	use	use	NN
cord-354664-mzzvmyea	97	11	is	be	VBZ
cord-354664-mzzvmyea	97	12	of	of	IN
cord-354664-mzzvmyea	97	13	relatively	relatively	RB
cord-354664-mzzvmyea	97	14	low	low	JJ
cord-354664-mzzvmyea	97	15	quality	quality	NN
cord-354664-mzzvmyea	97	16	and	and	CC
cord-354664-mzzvmyea	97	17	does	do	VBZ
cord-354664-mzzvmyea	97	18	not	not	RB
cord-354664-mzzvmyea	97	19	clearly	clearly	RB
cord-354664-mzzvmyea	97	20	explain	explain	VB
cord-354664-mzzvmyea	97	21	whether	whether	IN
cord-354664-mzzvmyea	97	22	improved	improved	JJ
cord-354664-mzzvmyea	97	23	outcomes	outcome	NNS
cord-354664-mzzvmyea	97	24	in	in	IN
cord-354664-mzzvmyea	97	25	this	this	DT
cord-354664-mzzvmyea	97	26	population	population	NN
cord-354664-mzzvmyea	97	27	are	be	VBP
cord-354664-mzzvmyea	97	28	derived	derive	VBN
cord-354664-mzzvmyea	97	29	from	from	IN
cord-354664-mzzvmyea	97	30	the	the	DT
cord-354664-mzzvmyea	97	31	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	97	32	or	or	CC
cord-354664-mzzvmyea	97	33	immune	immune	JJ
cord-354664-mzzvmyea	97	34	-	-	HYPH
cord-354664-mzzvmyea	97	35	modulatory	modulatory	JJ
cord-354664-mzzvmyea	97	36	properties	property	NNS
cord-354664-mzzvmyea	97	37	of	of	IN
cord-354664-mzzvmyea	97	38	these	these	DT
cord-354664-mzzvmyea	97	39	agents	agent	NNS
cord-354664-mzzvmyea	97	40	.	.	.
cord-354664-mzzvmyea	98	1	Baddour	Baddour	NNP
cord-354664-mzzvmyea	98	2	et	et	FW
cord-354664-mzzvmyea	98	3	al	al	NNP
cord-354664-mzzvmyea	98	4	.	.	.
cord-354664-mzzvmyea	99	1	previously	previously	RB
cord-354664-mzzvmyea	99	2	evaluated	evaluate	VBD
cord-354664-mzzvmyea	99	3	the	the	DT
cord-354664-mzzvmyea	99	4	impact	impact	NN
cord-354664-mzzvmyea	99	5	of	of	IN
cord-354664-mzzvmyea	99	6	combination	combination	NN
cord-354664-mzzvmyea	99	7	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	99	8	therapy	therapy	NN
cord-354664-mzzvmyea	99	9	on	on	IN
cord-354664-mzzvmyea	99	10	844	844	CD
cord-354664-mzzvmyea	99	11	adult	adult	NN
cord-354664-mzzvmyea	99	12	patients	patient	NNS
cord-354664-mzzvmyea	99	13	with	with	IN
cord-354664-mzzvmyea	99	14	severe	severe	JJ
cord-354664-mzzvmyea	99	15	bacteremic	bacteremic	JJ
cord-354664-mzzvmyea	99	16	pneumococcal	pneumococcal	JJ
cord-354664-mzzvmyea	99	17	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	99	18	in	in	IN
cord-354664-mzzvmyea	99	19	a	a	DT
cord-354664-mzzvmyea	99	20	prospective	prospective	JJ
cord-354664-mzzvmyea	99	21	,	,	,
cord-354664-mzzvmyea	99	22	observational	observational	JJ
cord-354664-mzzvmyea	99	23	multicenter	multicenter	JJ
cord-354664-mzzvmyea	99	24	study	study	NN
cord-354664-mzzvmyea	99	25	[	[	-LRB-
cord-354664-mzzvmyea	99	26	39	39	CD
cord-354664-mzzvmyea	99	27	]	]	-RRB-
cord-354664-mzzvmyea	99	28	.	.	.
cord-354664-mzzvmyea	100	1	While	while	IN
cord-354664-mzzvmyea	100	2	overall	overall	RB
cord-354664-mzzvmyea	100	3	14-day	14-day	CD
cord-354664-mzzvmyea	100	4	mortality	mortality	NN
cord-354664-mzzvmyea	100	5	did	do	VBD
cord-354664-mzzvmyea	100	6	not	not	RB
cord-354664-mzzvmyea	100	7	differ	differ	VB
cord-354664-mzzvmyea	100	8	significantly	significantly	RB
cord-354664-mzzvmyea	100	9	in	in	IN
cord-354664-mzzvmyea	100	10	this	this	DT
cord-354664-mzzvmyea	100	11	cohort	cohort	NN
cord-354664-mzzvmyea	100	12	,	,	,
cord-354664-mzzvmyea	100	13	combination	combination	NN
cord-354664-mzzvmyea	100	14	therapy	therapy	NN
cord-354664-mzzvmyea	100	15	was	be	VBD
cord-354664-mzzvmyea	100	16	associated	associate	VBN
cord-354664-mzzvmyea	100	17	with	with	IN
cord-354664-mzzvmyea	100	18	significantly	significantly	RB
cord-354664-mzzvmyea	100	19	reduced	reduce	VBN
cord-354664-mzzvmyea	100	20	mortality	mortality	NN
cord-354664-mzzvmyea	100	21	among	among	IN
cord-354664-mzzvmyea	100	22	a	a	DT
cord-354664-mzzvmyea	100	23	subset	subset	NN
cord-354664-mzzvmyea	100	24	of	of	IN
cord-354664-mzzvmyea	100	25	critically	critically	RB
cord-354664-mzzvmyea	100	26	ill	ill	JJ
cord-354664-mzzvmyea	100	27	patients	patient	NNS
cord-354664-mzzvmyea	100	28	(	(	-LRB-
cord-354664-mzzvmyea	100	29	23.4	23.4	CD
cord-354664-mzzvmyea	100	30	vs	vs	IN
cord-354664-mzzvmyea	100	31	55.3	55.3	CD
cord-354664-mzzvmyea	100	32	%	%	NN
cord-354664-mzzvmyea	100	33	,	,	,
cord-354664-mzzvmyea	100	34	p	p	NN
cord-354664-mzzvmyea	100	35	<	<	XX
cord-354664-mzzvmyea	100	36	0.01	0.01	CD
cord-354664-mzzvmyea	100	37	)	)	-RRB-
cord-354664-mzzvmyea	100	38	regardless	regardless	RB
cord-354664-mzzvmyea	100	39	of	of	IN
cord-354664-mzzvmyea	100	40	nationality	nationality	NN
cord-354664-mzzvmyea	100	41	,	,	,
cord-354664-mzzvmyea	100	42	level	level	NN
cord-354664-mzzvmyea	100	43	of	of	IN
cord-354664-mzzvmyea	100	44	ICU	ICU	NNP
cord-354664-mzzvmyea	100	45	support	support	NN
cord-354664-mzzvmyea	100	46	,	,	,
cord-354664-mzzvmyea	100	47	class	class	NN
cord-354664-mzzvmyea	100	48	of	of	IN
cord-354664-mzzvmyea	100	49	antibiotics	antibiotic	NNS
cord-354664-mzzvmyea	100	50	,	,	,
cord-354664-mzzvmyea	100	51	and	and	CC
cord-354664-mzzvmyea	100	52	in	in	IN
cord-354664-mzzvmyea	100	53	vitro	vitro	FW
cord-354664-mzzvmyea	100	54	activity	activity	NN
cord-354664-mzzvmyea	100	55	of	of	IN
cord-354664-mzzvmyea	100	56	the	the	DT
cord-354664-mzzvmyea	100	57	prescribed	prescribed	JJ
cord-354664-mzzvmyea	100	58	antibiotics	antibiotic	NNS
cord-354664-mzzvmyea	100	59	.	.	.
cord-354664-mzzvmyea	101	1	While	while	IN
cord-354664-mzzvmyea	101	2	this	this	DT
cord-354664-mzzvmyea	101	3	study	study	NN
cord-354664-mzzvmyea	101	4	was	be	VBD
cord-354664-mzzvmyea	101	5	not	not	RB
cord-354664-mzzvmyea	101	6	limited	limit	VBN
cord-354664-mzzvmyea	101	7	to	to	IN
cord-354664-mzzvmyea	101	8	combination	combination	NN
cord-354664-mzzvmyea	101	9	macrolide	macrolide	NN
cord-354664-mzzvmyea	101	10	therapy	therapy	NN
cord-354664-mzzvmyea	101	11	,	,	,
cord-354664-mzzvmyea	102	1	beta	beta	NN
cord-354664-mzzvmyea	102	2	-	-	HYPH
cord-354664-mzzvmyea	102	3	lactam	lactam	NNS
cord-354664-mzzvmyea	102	4	/	/	SYM
cord-354664-mzzvmyea	102	5	macrolide	macrolide	NN
cord-354664-mzzvmyea	102	6	therapy	therapy	NN
cord-354664-mzzvmyea	102	7	remained	remain	VBD
cord-354664-mzzvmyea	102	8	the	the	DT
cord-354664-mzzvmyea	102	9	most	most	RBS
cord-354664-mzzvmyea	102	10	common	common	JJ
cord-354664-mzzvmyea	102	11	regimen	regimen	NN
cord-354664-mzzvmyea	102	12	in	in	IN
cord-354664-mzzvmyea	102	13	the	the	DT
cord-354664-mzzvmyea	102	14	study	study	NN
cord-354664-mzzvmyea	102	15	population	population	NN
cord-354664-mzzvmyea	102	16	.	.	.
cord-354664-mzzvmyea	103	1	Multiple	multiple	JJ
cord-354664-mzzvmyea	103	2	retrospective	retrospective	JJ
cord-354664-mzzvmyea	103	3	cohort	cohort	NN
cord-354664-mzzvmyea	103	4	studies	study	NNS
cord-354664-mzzvmyea	103	5	have	have	VBP
cord-354664-mzzvmyea	103	6	shown	show	VBN
cord-354664-mzzvmyea	103	7	a	a	DT
cord-354664-mzzvmyea	103	8	similar	similar	JJ
cord-354664-mzzvmyea	103	9	effect	effect	NN
cord-354664-mzzvmyea	103	10	in	in	IN
cord-354664-mzzvmyea	103	11	critically	critically	RB
cord-354664-mzzvmyea	103	12	ill	ill	JJ
cord-354664-mzzvmyea	103	13	patients	patient	NNS
cord-354664-mzzvmyea	103	14	with	with	IN
cord-354664-mzzvmyea	103	15	severe	severe	JJ
cord-354664-mzzvmyea	103	16	pneumococcal	pneumococcal	JJ
cord-354664-mzzvmyea	103	17	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	103	18	complicated	complicate	VBN
cord-354664-mzzvmyea	103	19	by	by	IN
cord-354664-mzzvmyea	103	20	bacteremia	bacteremia	NN
cord-354664-mzzvmyea	103	21	[	[	-LRB-
cord-354664-mzzvmyea	103	22	40	40	CD
cord-354664-mzzvmyea	103	23	]	]	-RRB-
cord-354664-mzzvmyea	103	24	.	.	.
cord-354664-mzzvmyea	104	1	In	in	IN
cord-354664-mzzvmyea	104	2	addition	addition	NN
cord-354664-mzzvmyea	104	3	,	,	,
cord-354664-mzzvmyea	104	4	Sligl	Sligl	NNP
cord-354664-mzzvmyea	104	5	et	et	NNP
cord-354664-mzzvmyea	104	6	al	al	NNP
cord-354664-mzzvmyea	104	7	.	.	NNP
cord-354664-mzzvmyea	104	8	explored	explore	VBD
cord-354664-mzzvmyea	104	9	the	the	DT
cord-354664-mzzvmyea	104	10	impact	impact	NN
cord-354664-mzzvmyea	104	11	of	of	IN
cord-354664-mzzvmyea	104	12	beta	beta	NN
cord-354664-mzzvmyea	104	13	-	-	HYPH
cord-354664-mzzvmyea	104	14	lactam	lactam	NNS
cord-354664-mzzvmyea	104	15	/	/	SYM
cord-354664-mzzvmyea	104	16	macrolide	macrolide	NN
cord-354664-mzzvmyea	104	17	combination	combination	NN
cord-354664-mzzvmyea	104	18	therapy	therapy	NN
cord-354664-mzzvmyea	104	19	in	in	IN
cord-354664-mzzvmyea	104	20	critically	critically	RB
cord-354664-mzzvmyea	104	21	ill	ill	JJ
cord-354664-mzzvmyea	104	22	patients	patient	NNS
cord-354664-mzzvmyea	104	23	in	in	IN
cord-354664-mzzvmyea	104	24	a	a	DT
cord-354664-mzzvmyea	104	25	systematic	systematic	JJ
cord-354664-mzzvmyea	104	26	review	review	NN
cord-354664-mzzvmyea	104	27	and	and	CC
cord-354664-mzzvmyea	104	28	meta	meta	NNP
cord-354664-mzzvmyea	104	29	-	-	HYPH
cord-354664-mzzvmyea	104	30	analysis	analysis	NN
cord-354664-mzzvmyea	104	31	involving	involve	VBG
cord-354664-mzzvmyea	104	32	nearly	nearly	RB
cord-354664-mzzvmyea	104	33	10,000	10,000	CD
cord-354664-mzzvmyea	104	34	critically	critically	RB
cord-354664-mzzvmyea	104	35	ill	ill	JJ
cord-354664-mzzvmyea	104	36	patients	patient	NNS
cord-354664-mzzvmyea	104	37	from	from	IN
cord-354664-mzzvmyea	104	38	28	28	CD
cord-354664-mzzvmyea	104	39	observational	observational	JJ
cord-354664-mzzvmyea	104	40	studies	study	NNS
cord-354664-mzzvmyea	104	41	and	and	CC
cord-354664-mzzvmyea	104	42	found	find	VBD
cord-354664-mzzvmyea	104	43	that	that	IN
cord-354664-mzzvmyea	104	44	combination	combination	NN
cord-354664-mzzvmyea	104	45	therapy	therapy	NN
cord-354664-mzzvmyea	104	46	including	include	VBG
cord-354664-mzzvmyea	104	47	macrolides	macrolide	NNS
cord-354664-mzzvmyea	104	48	was	be	VBD
cord-354664-mzzvmyea	104	49	associated	associate	VBN
cord-354664-mzzvmyea	104	50	with	with	IN
cord-354664-mzzvmyea	104	51	a	a	DT
cord-354664-mzzvmyea	104	52	significant	significant	JJ
cord-354664-mzzvmyea	104	53	reduction	reduction	NN
cord-354664-mzzvmyea	104	54	in	in	IN
cord-354664-mzzvmyea	104	55	mortality	mortality	NN
cord-354664-mzzvmyea	104	56	[	[	-LRB-
cord-354664-mzzvmyea	104	57	41	41	CD
cord-354664-mzzvmyea	104	58	]	]	-RRB-
cord-354664-mzzvmyea	104	59	.	.	.
cord-354664-mzzvmyea	105	1	A	a	DT
cord-354664-mzzvmyea	105	2	subgroup	subgroup	NN
cord-354664-mzzvmyea	105	3	analysis	analysis	NN
cord-354664-mzzvmyea	105	4	of	of	IN
cord-354664-mzzvmyea	105	5	the	the	DT
cord-354664-mzzvmyea	105	6	cohort	cohort	NN
cord-354664-mzzvmyea	105	7	evaluated	evaluate	VBN
cord-354664-mzzvmyea	105	8	by	by	IN
cord-354664-mzzvmyea	105	9	Garin	Garin	NNP
cord-354664-mzzvmyea	105	10	et	et	FW
cord-354664-mzzvmyea	105	11	al	al	NNP
cord-354664-mzzvmyea	105	12	.	.	.
cord-354664-mzzvmyea	106	1	also	also	RB
cord-354664-mzzvmyea	106	2	supports	support	VBZ
cord-354664-mzzvmyea	106	3	this	this	DT
cord-354664-mzzvmyea	106	4	literature	literature	NN
cord-354664-mzzvmyea	106	5	-	-	HYPH
cord-354664-mzzvmyea	106	6	demonstrating	demonstrate	VBG
cord-354664-mzzvmyea	106	7	that	that	IN
cord-354664-mzzvmyea	106	8	patients	patient	NNS
cord-354664-mzzvmyea	106	9	with	with	IN
cord-354664-mzzvmyea	106	10	severe	severe	JJ
cord-354664-mzzvmyea	106	11	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	106	12	were	be	VBD
cord-354664-mzzvmyea	106	13	less	less	RBR
cord-354664-mzzvmyea	106	14	likely	likely	JJ
cord-354664-mzzvmyea	106	15	to	to	TO
cord-354664-mzzvmyea	106	16	achieve	achieve	VB
cord-354664-mzzvmyea	106	17	clinical	clinical	JJ
cord-354664-mzzvmyea	106	18	stability	stability	NN
cord-354664-mzzvmyea	106	19	with	with	IN
cord-354664-mzzvmyea	106	20	beta	beta	NN
cord-354664-mzzvmyea	106	21	-	-	HYPH
cord-354664-mzzvmyea	106	22	lactam	lactam	NN
cord-354664-mzzvmyea	106	23	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	106	24	.	.	.
cord-354664-mzzvmyea	107	1	Despite	despite	IN
cord-354664-mzzvmyea	107	2	the	the	DT
cord-354664-mzzvmyea	107	3	lack	lack	NN
cord-354664-mzzvmyea	107	4	of	of	IN
cord-354664-mzzvmyea	107	5	randomized	randomized	JJ
cord-354664-mzzvmyea	107	6	trials	trial	NNS
cord-354664-mzzvmyea	107	7	in	in	IN
cord-354664-mzzvmyea	107	8	severe	severe	JJ
cord-354664-mzzvmyea	107	9	CAP	cap	NN
cord-354664-mzzvmyea	107	10	,	,	,
cord-354664-mzzvmyea	107	11	the	the	DT
cord-354664-mzzvmyea	107	12	available	available	JJ
cord-354664-mzzvmyea	107	13	evidence	evidence	NN
cord-354664-mzzvmyea	107	14	is	be	VBZ
cord-354664-mzzvmyea	107	15	consistent	consistent	JJ
cord-354664-mzzvmyea	107	16	with	with	IN
cord-354664-mzzvmyea	107	17	current	current	JJ
cord-354664-mzzvmyea	107	18	recommendations	recommendation	NNS
cord-354664-mzzvmyea	107	19	published	publish	VBN
cord-354664-mzzvmyea	107	20	in	in	IN
cord-354664-mzzvmyea	107	21	the	the	DT
cord-354664-mzzvmyea	107	22	joint	joint	JJ
cord-354664-mzzvmyea	107	23	IDSA	IDSA	NNP
cord-354664-mzzvmyea	107	24	/	/	SYM
cord-354664-mzzvmyea	107	25	ATS	ATS	NNP
cord-354664-mzzvmyea	107	26	guidelines	guideline	NNS
cord-354664-mzzvmyea	107	27	for	for	IN
cord-354664-mzzvmyea	107	28	management	management	NN
cord-354664-mzzvmyea	107	29	of	of	IN
cord-354664-mzzvmyea	107	30	CAP	CAP	NNP
cord-354664-mzzvmyea	107	31	in	in	IN
cord-354664-mzzvmyea	107	32	patients	patient	NNS
cord-354664-mzzvmyea	107	33	requiring	require	VBG
cord-354664-mzzvmyea	107	34	ICU	ICU	NNP
cord-354664-mzzvmyea	107	35	admission	admission	NN
cord-354664-mzzvmyea	107	36	.	.	.
cord-354664-mzzvmyea	108	1	Further	further	JJ
cord-354664-mzzvmyea	108	2	research	research	NN
cord-354664-mzzvmyea	108	3	to	to	TO
cord-354664-mzzvmyea	108	4	characterize	characterize	VB
cord-354664-mzzvmyea	108	5	the	the	DT
cord-354664-mzzvmyea	108	6	potential	potential	JJ
cord-354664-mzzvmyea	108	7	immune	immune	JJ
cord-354664-mzzvmyea	108	8	-	-	HYPH
cord-354664-mzzvmyea	108	9	modulatory	modulatory	JJ
cord-354664-mzzvmyea	108	10	effects	effect	NNS
cord-354664-mzzvmyea	108	11	of	of	IN
cord-354664-mzzvmyea	108	12	macrolides	macrolide	NNS
cord-354664-mzzvmyea	108	13	in	in	IN
cord-354664-mzzvmyea	108	14	patients	patient	NNS
cord-354664-mzzvmyea	108	15	with	with	IN
cord-354664-mzzvmyea	108	16	severe	severe	JJ
cord-354664-mzzvmyea	108	17	CAP	cap	NN
cord-354664-mzzvmyea	108	18	is	be	VBZ
cord-354664-mzzvmyea	108	19	warranted	warrant	VBN
cord-354664-mzzvmyea	108	20	,	,	,
cord-354664-mzzvmyea	108	21	specifically	specifically	RB
cord-354664-mzzvmyea	108	22	because	because	IN
cord-354664-mzzvmyea	108	23	this	this	DT
cord-354664-mzzvmyea	108	24	population	population	NN
cord-354664-mzzvmyea	108	25	is	be	VBZ
cord-354664-mzzvmyea	108	26	more	more	RBR
cord-354664-mzzvmyea	108	27	likely	likely	JJ
cord-354664-mzzvmyea	108	28	to	to	TO
cord-354664-mzzvmyea	108	29	have	have	VB
cord-354664-mzzvmyea	108	30	concomitant	concomitant	JJ
cord-354664-mzzvmyea	108	31	sepsis	sepsis	NN
cord-354664-mzzvmyea	108	32	and	and	CC
cord-354664-mzzvmyea	108	33	deleterious	deleterious	JJ
cord-354664-mzzvmyea	108	34	systemic	systemic	JJ
cord-354664-mzzvmyea	108	35	inflammation	inflammation	NN
cord-354664-mzzvmyea	108	36	.	.	.
cord-354664-mzzvmyea	109	1	The	the	DT
cord-354664-mzzvmyea	109	2	utility	utility	NN
cord-354664-mzzvmyea	109	3	of	of	IN
cord-354664-mzzvmyea	109	4	macrolide	macrolide	JJ
cord-354664-mzzvmyea	109	5	combination	combination	NN
cord-354664-mzzvmyea	109	6	therapy	therapy	NN
cord-354664-mzzvmyea	109	7	in	in	IN
cord-354664-mzzvmyea	109	8	the	the	DT
cord-354664-mzzvmyea	109	9	management	management	NN
cord-354664-mzzvmyea	109	10	of	of	IN
cord-354664-mzzvmyea	109	11	CAP	CAP	NNP
cord-354664-mzzvmyea	109	12	has	have	VBZ
cord-354664-mzzvmyea	109	13	been	be	VBN
cord-354664-mzzvmyea	109	14	a	a	DT
cord-354664-mzzvmyea	109	15	source	source	NN
cord-354664-mzzvmyea	109	16	of	of	IN
cord-354664-mzzvmyea	109	17	significant	significant	JJ
cord-354664-mzzvmyea	109	18	controversy	controversy	NN
cord-354664-mzzvmyea	109	19	with	with	IN
cord-354664-mzzvmyea	109	20	a	a	DT
cord-354664-mzzvmyea	109	21	large	large	JJ
cord-354664-mzzvmyea	109	22	body	body	NN
cord-354664-mzzvmyea	109	23	of	of	IN
cord-354664-mzzvmyea	109	24	conflicting	conflict	VBG
cord-354664-mzzvmyea	109	25	evidence	evidence	NN
cord-354664-mzzvmyea	109	26	.	.	.
cord-354664-mzzvmyea	110	1	Considering	consider	VBG
cord-354664-mzzvmyea	110	2	the	the	DT
cord-354664-mzzvmyea	110	3	increasing	increase	VBG
cord-354664-mzzvmyea	110	4	resistance	resistance	NN
cord-354664-mzzvmyea	110	5	of	of	IN
cord-354664-mzzvmyea	110	6	typical	typical	JJ
cord-354664-mzzvmyea	110	7	bacterial	bacterial	JJ
cord-354664-mzzvmyea	110	8	isolates	isolate	NNS
cord-354664-mzzvmyea	110	9	(	(	-LRB-
cord-354664-mzzvmyea	110	10	specifically	specifically	RB
cord-354664-mzzvmyea	110	11	S.	S.	NNP
cord-354664-mzzvmyea	110	12	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	110	13	)	)	-RRB-
cord-354664-mzzvmyea	110	14	to	to	IN
cord-354664-mzzvmyea	110	15	macrolides	macrolide	NNS
cord-354664-mzzvmyea	110	16	and	and	CC
cord-354664-mzzvmyea	110	17	the	the	DT
cord-354664-mzzvmyea	110	18	infrequent	infrequent	JJ
cord-354664-mzzvmyea	110	19	identification	identification	NN
cord-354664-mzzvmyea	110	20	of	of	IN
cord-354664-mzzvmyea	110	21	atypical	atypical	JJ
cord-354664-mzzvmyea	110	22	pathogens	pathogen	NNS
cord-354664-mzzvmyea	110	23	as	as	IN
cord-354664-mzzvmyea	110	24	causative	causative	JJ
cord-354664-mzzvmyea	110	25	agents	agent	NNS
cord-354664-mzzvmyea	110	26	of	of	IN
cord-354664-mzzvmyea	110	27	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	110	28	,	,	,
cord-354664-mzzvmyea	110	29	clinicians	clinician	NNS
cord-354664-mzzvmyea	110	30	need	need	VBP
cord-354664-mzzvmyea	110	31	to	to	TO
cord-354664-mzzvmyea	110	32	carefully	carefully	RB
cord-354664-mzzvmyea	110	33	consider	consider	VB
cord-354664-mzzvmyea	110	34	the	the	DT
cord-354664-mzzvmyea	110	35	utility	utility	NN
cord-354664-mzzvmyea	110	36	of	of	IN
cord-354664-mzzvmyea	110	37	macrolides	macrolide	NNS
cord-354664-mzzvmyea	110	38	in	in	IN
cord-354664-mzzvmyea	110	39	the	the	DT
cord-354664-mzzvmyea	110	40	treatment	treatment	NN
cord-354664-mzzvmyea	110	41	of	of	IN
cord-354664-mzzvmyea	110	42	CAP	CAP	NNP
cord-354664-mzzvmyea	110	43	.	.	.
cord-354664-mzzvmyea	111	1	In	in	IN
cord-354664-mzzvmyea	111	2	addition	addition	NN
cord-354664-mzzvmyea	111	3	,	,	,
cord-354664-mzzvmyea	111	4	clinicians	clinician	NNS
cord-354664-mzzvmyea	111	5	need	need	VBP
cord-354664-mzzvmyea	111	6	to	to	TO
cord-354664-mzzvmyea	111	7	balance	balance	VB
cord-354664-mzzvmyea	111	8	any	any	DT
cord-354664-mzzvmyea	111	9	potential	potential	JJ
cord-354664-mzzvmyea	111	10	incremental	incremental	JJ
cord-354664-mzzvmyea	111	11	benefit	benefit	NN
cord-354664-mzzvmyea	111	12	from	from	IN
cord-354664-mzzvmyea	111	13	the	the	DT
cord-354664-mzzvmyea	111	14	anti	anti	JJ
cord-354664-mzzvmyea	111	15	-	-	JJ
cord-354664-mzzvmyea	111	16	inflammatory	inflammatory	JJ
cord-354664-mzzvmyea	111	17	effect	effect	NN
cord-354664-mzzvmyea	111	18	that	that	WDT
cord-354664-mzzvmyea	111	19	macrolides	macrolide	NNS
cord-354664-mzzvmyea	111	20	may	may	MD
cord-354664-mzzvmyea	111	21	possess	possess	VB
cord-354664-mzzvmyea	111	22	against	against	IN
cord-354664-mzzvmyea	111	23	the	the	DT
cord-354664-mzzvmyea	111	24	urgent	urgent	JJ
cord-354664-mzzvmyea	111	25	need	need	NN
cord-354664-mzzvmyea	111	26	for	for	IN
cord-354664-mzzvmyea	111	27	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	111	28	stewardship	stewardship	NN
cord-354664-mzzvmyea	111	29	and	and	CC
cord-354664-mzzvmyea	111	30	responsible	responsible	JJ
cord-354664-mzzvmyea	111	31	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	111	32	use	use	NN
cord-354664-mzzvmyea	111	33	.	.	.
cord-354664-mzzvmyea	112	1	While	while	IN
cord-354664-mzzvmyea	112	2	population	population	NN
cord-354664-mzzvmyea	112	3	-	-	HYPH
cord-354664-mzzvmyea	112	4	based	base	VBN
cord-354664-mzzvmyea	112	5	epidemiologic	epidemiologic	JJ
cord-354664-mzzvmyea	112	6	studies	study	NNS
cord-354664-mzzvmyea	112	7	have	have	VBP
cord-354664-mzzvmyea	112	8	historically	historically	RB
cord-354664-mzzvmyea	112	9	suggested	suggest	VBN
cord-354664-mzzvmyea	112	10	a	a	DT
cord-354664-mzzvmyea	112	11	benefit	benefit	NN
cord-354664-mzzvmyea	112	12	of	of	IN
cord-354664-mzzvmyea	112	13	adjunctive	adjunctive	JJ
cord-354664-mzzvmyea	112	14	macrolides	macrolide	NNS
cord-354664-mzzvmyea	112	15	in	in	IN
cord-354664-mzzvmyea	112	16	the	the	DT
cord-354664-mzzvmyea	112	17	management	management	NN
cord-354664-mzzvmyea	112	18	of	of	IN
cord-354664-mzzvmyea	112	19	CAP	CAP	NNP
cord-354664-mzzvmyea	112	20	,	,	,
cord-354664-mzzvmyea	112	21	most	most	JJS
cord-354664-mzzvmyea	112	22	of	of	IN
cord-354664-mzzvmyea	112	23	these	these	DT
cord-354664-mzzvmyea	112	24	studies	study	NNS
cord-354664-mzzvmyea	112	25	are	be	VBP
cord-354664-mzzvmyea	112	26	of	of	IN
cord-354664-mzzvmyea	112	27	relatively	relatively	RB
cord-354664-mzzvmyea	112	28	low	low	JJ
cord-354664-mzzvmyea	112	29	quality	quality	NN
cord-354664-mzzvmyea	112	30	.	.	.
cord-354664-mzzvmyea	113	1	Emerging	emerge	VBG
cord-354664-mzzvmyea	113	2	evidence	evidence	NN
cord-354664-mzzvmyea	113	3	from	from	IN
cord-354664-mzzvmyea	113	4	several	several	JJ
cord-354664-mzzvmyea	113	5	prospective	prospective	JJ
cord-354664-mzzvmyea	113	6	studies	study	NNS
cord-354664-mzzvmyea	113	7	has	have	VBZ
cord-354664-mzzvmyea	113	8	challenged	challenge	VBN
cord-354664-mzzvmyea	113	9	this	this	DT
cord-354664-mzzvmyea	113	10	practice	practice	NN
cord-354664-mzzvmyea	113	11	by	by	IN
cord-354664-mzzvmyea	113	12	failing	fail	VBG
cord-354664-mzzvmyea	113	13	to	to	TO
cord-354664-mzzvmyea	113	14	show	show	VB
cord-354664-mzzvmyea	113	15	a	a	DT
cord-354664-mzzvmyea	113	16	significant	significant	JJ
cord-354664-mzzvmyea	113	17	improvement	improvement	NN
cord-354664-mzzvmyea	113	18	in	in	IN
cord-354664-mzzvmyea	113	19	relevant	relevant	JJ
cord-354664-mzzvmyea	113	20	clinical	clinical	JJ
cord-354664-mzzvmyea	113	21	outcomes	outcome	NNS
cord-354664-mzzvmyea	113	22	in	in	IN
cord-354664-mzzvmyea	113	23	patients	patient	NNS
cord-354664-mzzvmyea	113	24	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	113	25	with	with	IN
cord-354664-mzzvmyea	113	26	mild	mild	JJ
cord-354664-mzzvmyea	113	27	to	to	IN
cord-354664-mzzvmyea	113	28	moderate	moderate	JJ
cord-354664-mzzvmyea	113	29	CAP	cap	NN
cord-354664-mzzvmyea	113	30	.	.	.
cord-354664-mzzvmyea	114	1	While	while	IN
cord-354664-mzzvmyea	114	2	existing	exist	VBG
cord-354664-mzzvmyea	114	3	evidence	evidence	NN
cord-354664-mzzvmyea	114	4	still	still	RB
cord-354664-mzzvmyea	114	5	supports	support	VBZ
cord-354664-mzzvmyea	114	6	the	the	DT
cord-354664-mzzvmyea	114	7	use	use	NN
cord-354664-mzzvmyea	114	8	of	of	IN
cord-354664-mzzvmyea	114	9	combination	combination	NN
cord-354664-mzzvmyea	114	10	therapy	therapy	NN
cord-354664-mzzvmyea	114	11	in	in	IN
cord-354664-mzzvmyea	114	12	critically	critically	RB
cord-354664-mzzvmyea	114	13	ill	ill	JJ
cord-354664-mzzvmyea	114	14	patients	patient	NNS
cord-354664-mzzvmyea	114	15	with	with	IN
cord-354664-mzzvmyea	114	16	severe	severe	JJ
cord-354664-mzzvmyea	114	17	CAP	cap	NN
cord-354664-mzzvmyea	114	18	,	,	,
cord-354664-mzzvmyea	114	19	further	further	RB
cord-354664-mzzvmyea	114	20	randomized	randomize	VBN
cord-354664-mzzvmyea	114	21	-	-	HYPH
cord-354664-mzzvmyea	114	22	controlled	control	VBN
cord-354664-mzzvmyea	114	23	trials	trial	NNS
cord-354664-mzzvmyea	114	24	are	be	VBP
cord-354664-mzzvmyea	114	25	urgently	urgently	RB
cord-354664-mzzvmyea	114	26	needed	need	VBN
cord-354664-mzzvmyea	114	27	to	to	TO
cord-354664-mzzvmyea	114	28	clarify	clarify	VB
cord-354664-mzzvmyea	114	29	the	the	DT
cord-354664-mzzvmyea	114	30	role	role	NN
cord-354664-mzzvmyea	114	31	of	of	IN
cord-354664-mzzvmyea	114	32	combination	combination	NN
cord-354664-mzzvmyea	114	33	therapy	therapy	NN
cord-354664-mzzvmyea	114	34	in	in	IN
cord-354664-mzzvmyea	114	35	this	this	DT
cord-354664-mzzvmyea	114	36	population	population	NN
cord-354664-mzzvmyea	114	37	.	.	.
cord-354664-mzzvmyea	115	1	In	in	IN
cord-354664-mzzvmyea	115	2	particular	particular	JJ
cord-354664-mzzvmyea	115	3	,	,	,
cord-354664-mzzvmyea	115	4	the	the	DT
cord-354664-mzzvmyea	115	5	potential	potential	JJ
cord-354664-mzzvmyea	115	6	immune	immune	JJ
cord-354664-mzzvmyea	115	7	modulatory	modulatory	JJ
cord-354664-mzzvmyea	115	8	effect	effect	NN
cord-354664-mzzvmyea	115	9	of	of	IN
cord-354664-mzzvmyea	115	10	macrolides	macrolide	NNS
cord-354664-mzzvmyea	115	11	in	in	IN
cord-354664-mzzvmyea	115	12	sepsis	sepsis	NN
cord-354664-mzzvmyea	115	13	remains	remain	VBZ
cord-354664-mzzvmyea	115	14	an	an	DT
cord-354664-mzzvmyea	115	15	area	area	NN
cord-354664-mzzvmyea	115	16	of	of	IN
cord-354664-mzzvmyea	115	17	uncertainty	uncertainty	NN
cord-354664-mzzvmyea	115	18	.	.	.
cord-354664-mzzvmyea	116	1	Based	base	VBN
cord-354664-mzzvmyea	116	2	on	on	IN
cord-354664-mzzvmyea	116	3	the	the	DT
cord-354664-mzzvmyea	116	4	current	current	JJ
cord-354664-mzzvmyea	116	5	literature	literature	NN
cord-354664-mzzvmyea	116	6	,	,	,
cord-354664-mzzvmyea	116	7	we	-PRON-	PRP
cord-354664-mzzvmyea	116	8	suggest	suggest	VBP
cord-354664-mzzvmyea	116	9	a	a	DT
cord-354664-mzzvmyea	116	10	pragmatic	pragmatic	JJ
cord-354664-mzzvmyea	116	11	approach	approach	NN
cord-354664-mzzvmyea	116	12	pending	pende	VBG
cord-354664-mzzvmyea	116	13	further	further	JJ
cord-354664-mzzvmyea	116	14	high	high	JJ
cord-354664-mzzvmyea	116	15	quality	quality	NN
cord-354664-mzzvmyea	116	16	evidence	evidence	NN
cord-354664-mzzvmyea	116	17	to	to	TO
cord-354664-mzzvmyea	116	18	guide	guide	VB
cord-354664-mzzvmyea	116	19	therapy	therapy	NN
cord-354664-mzzvmyea	116	20	.	.	.
cord-354664-mzzvmyea	117	1	For	for	IN
cord-354664-mzzvmyea	117	2	patients	patient	NNS
cord-354664-mzzvmyea	117	3	with	with	IN
cord-354664-mzzvmyea	117	4	mild	mild	JJ
cord-354664-mzzvmyea	117	5	-	-	HYPH
cord-354664-mzzvmyea	117	6	moderate	moderate	JJ
cord-354664-mzzvmyea	117	7	CAP	cap	NN
cord-354664-mzzvmyea	117	8	requiring	require	VBG
cord-354664-mzzvmyea	117	9	hospitalization	hospitalization	NN
cord-354664-mzzvmyea	117	10	,	,	,
cord-354664-mzzvmyea	117	11	we	-PRON-	PRP
cord-354664-mzzvmyea	117	12	suggest	suggest	VBP
cord-354664-mzzvmyea	117	13	treatment	treatment	NN
cord-354664-mzzvmyea	117	14	with	with	IN
cord-354664-mzzvmyea	117	15	beta	beta	NN
cord-354664-mzzvmyea	117	16	-	-	HYPH
cord-354664-mzzvmyea	117	17	lactam	lactam	NN
cord-354664-mzzvmyea	117	18	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	117	19	(	(	-LRB-
cord-354664-mzzvmyea	117	20	e.g.	e.g.	RB
cord-354664-mzzvmyea	117	21	,	,	,
cord-354664-mzzvmyea	117	22	ceftriaxone	ceftriaxone	NN
cord-354664-mzzvmyea	117	23	)	)	-RRB-
cord-354664-mzzvmyea	117	24	or	or	CC
cord-354664-mzzvmyea	117	25	a	a	DT
cord-354664-mzzvmyea	117	26	respiratory	respiratory	JJ
cord-354664-mzzvmyea	117	27	fluoroquinolone	fluoroquinolone	NN
cord-354664-mzzvmyea	117	28	(	(	-LRB-
cord-354664-mzzvmyea	117	29	e.g.	e.g.	RB
cord-354664-mzzvmyea	117	30	,	,	,
cord-354664-mzzvmyea	117	31	moxifloxacin	moxifloxacin	NNS
cord-354664-mzzvmyea	117	32	)	)	-RRB-
cord-354664-mzzvmyea	117	33	.	.	.
cord-354664-mzzvmyea	118	1	For	for	IN
cord-354664-mzzvmyea	118	2	patients	patient	NNS
cord-354664-mzzvmyea	118	3	with	with	IN
cord-354664-mzzvmyea	118	4	severe	severe	JJ
cord-354664-mzzvmyea	118	5	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	118	6	or	or	CC
cord-354664-mzzvmyea	118	7	those	those	DT
cord-354664-mzzvmyea	118	8	requiring	require	VBG
cord-354664-mzzvmyea	118	9	ICU	ICU	NNP
cord-354664-mzzvmyea	118	10	-	-	HYPH
cord-354664-mzzvmyea	118	11	level	level	NN
cord-354664-mzzvmyea	118	12	care	care	NN
cord-354664-mzzvmyea	118	13	,	,	,
cord-354664-mzzvmyea	118	14	we	-PRON-	PRP
cord-354664-mzzvmyea	118	15	suggest	suggest	VBP
cord-354664-mzzvmyea	118	16	beta	beta	NN
cord-354664-mzzvmyea	118	17	-	-	HYPH
cord-354664-mzzvmyea	118	18	lactam	lactam	NN
cord-354664-mzzvmyea	118	19	/	/	SYM
cord-354664-mzzvmyea	118	20	macrolide	macrolide	NN
cord-354664-mzzvmyea	118	21	(	(	-LRB-
cord-354664-mzzvmyea	118	22	e.g.	e.g.	RB
cord-354664-mzzvmyea	118	23	,	,	,
cord-354664-mzzvmyea	118	24	ceftriaxone	ceftriaxone	NN
cord-354664-mzzvmyea	118	25	/	/	SYM
cord-354664-mzzvmyea	118	26	azithromycin	azithromycin	NNP
cord-354664-mzzvmyea	118	27	)	)	-RRB-
cord-354664-mzzvmyea	118	28	combination	combination	NN
cord-354664-mzzvmyea	118	29	therapy	therapy	NN
cord-354664-mzzvmyea	118	30	.	.	.
cord-354664-mzzvmyea	119	1	Empiric	empiric	NN
cord-354664-mzzvmyea	119	2	therapies	therapy	NNS
cord-354664-mzzvmyea	119	3	,	,	,
cord-354664-mzzvmyea	119	4	however	however	RB
cord-354664-mzzvmyea	119	5	,	,	,
cord-354664-mzzvmyea	119	6	may	may	MD
cord-354664-mzzvmyea	119	7	differ	differ	VB
cord-354664-mzzvmyea	119	8	based	base	VBN
cord-354664-mzzvmyea	119	9	on	on	IN
cord-354664-mzzvmyea	119	10	local	local	JJ
cord-354664-mzzvmyea	119	11	epidemiology	epidemiology	NN
cord-354664-mzzvmyea	119	12	and	and	CC
cord-354664-mzzvmyea	119	13	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	119	14	susceptibility	susceptibility	NN
cord-354664-mzzvmyea	119	15	patterns	pattern	NNS
cord-354664-mzzvmyea	119	16	in	in	IN
cord-354664-mzzvmyea	119	17	each	each	DT
cord-354664-mzzvmyea	119	18	individual	individual	JJ
cord-354664-mzzvmyea	119	19	health	health	NN
cord-354664-mzzvmyea	119	20	region	region	NN
cord-354664-mzzvmyea	119	21	or	or	CC
cord-354664-mzzvmyea	119	22	institution	institution	NN
cord-354664-mzzvmyea	119	23	.	.	.
cord-354664-mzzvmyea	120	1	Conflict	conflict	NN
cord-354664-mzzvmyea	120	2	of	of	IN
cord-354664-mzzvmyea	120	3	Interest	Interest	NNP
cord-354664-mzzvmyea	120	4	Geoffrey	Geoffrey	NNP
cord-354664-mzzvmyea	120	5	Shumilak	Shumilak	NNP
cord-354664-mzzvmyea	120	6	and	and	CC
cord-354664-mzzvmyea	120	7	Wendy	Wendy	NNP
cord-354664-mzzvmyea	120	8	Sligl	Sligl	NNP
cord-354664-mzzvmyea	120	9	declare	declare	VBP
cord-354664-mzzvmyea	120	10	that	that	IN
cord-354664-mzzvmyea	120	11	they	-PRON-	PRP
cord-354664-mzzvmyea	120	12	have	have	VBP
cord-354664-mzzvmyea	120	13	no	no	DT
cord-354664-mzzvmyea	120	14	conflicts	conflict	NNS
cord-354664-mzzvmyea	120	15	of	of	IN
cord-354664-mzzvmyea	120	16	interest	interest	NN
cord-354664-mzzvmyea	120	17	.	.	.
cord-354664-mzzvmyea	121	1	Human	human	JJ
cord-354664-mzzvmyea	121	2	and	and	CC
cord-354664-mzzvmyea	121	3	Animal	Animal	NNP
cord-354664-mzzvmyea	121	4	Rights	Rights	NNPS
cord-354664-mzzvmyea	121	5	and	and	CC
cord-354664-mzzvmyea	121	6	Informed	Informed	NNP
cord-354664-mzzvmyea	121	7	Consent	Consent	NNP
cord-354664-mzzvmyea	122	1	This	this	DT
cord-354664-mzzvmyea	122	2	article	article	NN
cord-354664-mzzvmyea	122	3	does	do	VBZ
cord-354664-mzzvmyea	122	4	not	not	RB
cord-354664-mzzvmyea	122	5	contain	contain	VB
cord-354664-mzzvmyea	122	6	any	any	DT
cord-354664-mzzvmyea	122	7	studies	study	NNS
cord-354664-mzzvmyea	122	8	with	with	IN
cord-354664-mzzvmyea	122	9	human	human	JJ
cord-354664-mzzvmyea	122	10	or	or	CC
cord-354664-mzzvmyea	122	11	animal	animal	NN
cord-354664-mzzvmyea	122	12	subjects	subject	NNS
cord-354664-mzzvmyea	122	13	performed	perform	VBN
cord-354664-mzzvmyea	122	14	by	by	IN
cord-354664-mzzvmyea	122	15	any	any	DT
cord-354664-mzzvmyea	122	16	of	of	IN
cord-354664-mzzvmyea	122	17	the	the	DT
cord-354664-mzzvmyea	122	18	authors	author	NNS
cord-354664-mzzvmyea	122	19	.	.	.
cord-354664-mzzvmyea	123	1	Prospective	prospective	JJ
cord-354664-mzzvmyea	123	2	population	population	NN
cord-354664-mzzvmyea	123	3	-	-	HYPH
cord-354664-mzzvmyea	123	4	based	base	VBN
cord-354664-mzzvmyea	123	5	cohort	cohort	NN
cord-354664-mzzvmyea	123	6	study	study	NN
cord-354664-mzzvmyea	123	7	evaluating	evaluate	VBG
cord-354664-mzzvmyea	123	8	incidence	incidence	NN
cord-354664-mzzvmyea	123	9	of	of	IN
cord-354664-mzzvmyea	123	10	CAP	cap	NN
cord-354664-mzzvmyea	123	11	in	in	IN
cord-354664-mzzvmyea	123	12	consecutive	consecutive	JJ
cord-354664-mzzvmyea	123	13	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	123	14	patients	patient	NNS
cord-354664-mzzvmyea	123	15	at	at	IN
cord-354664-mzzvmyea	123	16	all	all	DT
cord-354664-mzzvmyea	123	17	adult	adult	NN
cord-354664-mzzvmyea	123	18	hospitals	hospital	NNS
cord-354664-mzzvmyea	123	19	in	in	IN
cord-354664-mzzvmyea	123	20	Louisville	Louisville	NNP
cord-354664-mzzvmyea	123	21	,	,	,
cord-354664-mzzvmyea	123	22	Kentucky	Kentucky	NNP
cord-354664-mzzvmyea	123	23	.	.	.
cord-354664-mzzvmyea	124	1	Calculation	calculation	NN
cord-354664-mzzvmyea	124	2	of	of	IN
cord-354664-mzzvmyea	124	3	annual	annual	JJ
cord-354664-mzzvmyea	124	4	population	population	NN
cord-354664-mzzvmyea	124	5	-	-	HYPH
cord-354664-mzzvmyea	124	6	based	base	VBN
cord-354664-mzzvmyea	124	7	incidence	incidence	NN
cord-354664-mzzvmyea	124	8	of	of	IN
cord-354664-mzzvmyea	124	9	CAP	cap	NN
cord-354664-mzzvmyea	124	10	,	,	,
cord-354664-mzzvmyea	124	11	mortality	mortality	NN
cord-354664-mzzvmyea	124	12	at	at	IN
cord-354664-mzzvmyea	124	13	1	1	CD
cord-354664-mzzvmyea	124	14	,	,	,
cord-354664-mzzvmyea	124	15	6	6	CD
cord-354664-mzzvmyea	124	16	,	,	,
cord-354664-mzzvmyea	124	17	and	and	CC
cord-354664-mzzvmyea	124	18	12	12	CD
cord-354664-mzzvmyea	124	19	months	month	NNS
cord-354664-mzzvmyea	124	20	following	follow	VBG
cord-354664-mzzvmyea	124	21	hospitalization	hospitalization	NN
cord-354664-mzzvmyea	124	22	National	National	NNP
cord-354664-mzzvmyea	124	23	Hospital	Hospital	NNP
cord-354664-mzzvmyea	124	24	Ambulatory	Ambulatory	NNP
cord-354664-mzzvmyea	124	25	Medical	Medical	NNP
cord-354664-mzzvmyea	124	26	Care	Care	NNP
cord-354664-mzzvmyea	124	27	Survey	Survey	NNP
cord-354664-mzzvmyea	124	28	:	:	:
cord-354664-mzzvmyea	124	29	2014	2014	CD
cord-354664-mzzvmyea	124	30	Emergency	Emergency	NNP
cord-354664-mzzvmyea	124	31	department	department	NN
cord-354664-mzzvmyea	124	32	summary	summary	NN
cord-354664-mzzvmyea	124	33	tables	table	NNS
cord-354664-mzzvmyea	125	1	Deaths	death	NNS
cord-354664-mzzvmyea	125	2	:	:	:
cord-354664-mzzvmyea	125	3	final	final	JJ
cord-354664-mzzvmyea	125	4	for	for	IN
cord-354664-mzzvmyea	125	5	Douglas	Douglas	NNP
cord-354664-mzzvmyea	125	6	and	and	CC
cord-354664-mzzvmyea	125	7	Bennett	Bennett	NNP
cord-354664-mzzvmyea	125	8	's	's	POS
cord-354664-mzzvmyea	125	9	Principles	Principles	NNPS
cord-354664-mzzvmyea	125	10	and	and	CC
cord-354664-mzzvmyea	125	11	Practice	practice	NN
cord-354664-mzzvmyea	125	12	of	of	IN
cord-354664-mzzvmyea	125	13	Infectious	Infectious	NNP
cord-354664-mzzvmyea	125	14	Diseases	Diseases	NNPS
cord-354664-mzzvmyea	125	15	.	.	.
cord-354664-mzzvmyea	126	1	Chapter	chapter	NN
cord-354664-mzzvmyea	126	2	68	68	CD
cord-354664-mzzvmyea	126	3	:	:	:
cord-354664-mzzvmyea	127	1	Acute	acute	JJ
cord-354664-mzzvmyea	127	2	Pneumonia	Pneumonia	NNP
cord-354664-mzzvmyea	128	1	The	the	DT
cord-354664-mzzvmyea	128	2	Canadian	canadian	JJ
cord-354664-mzzvmyea	128	3	CAP	CAP	NNP
cord-354664-mzzvmyea	128	4	Working	Working	NNP
cord-354664-mzzvmyea	128	5	Group	Group	NNP
cord-354664-mzzvmyea	128	6	.	.	.
cord-354664-mzzvmyea	129	1	Summary	summary	NN
cord-354664-mzzvmyea	129	2	of	of	IN
cord-354664-mzzvmyea	129	3	Canadian	Canadian	NNP
cord-354664-mzzvmyea	129	4	Guidelines	Guidelines	NNPS
cord-354664-mzzvmyea	129	5	for	for	IN
cord-354664-mzzvmyea	129	6	the	the	DT
cord-354664-mzzvmyea	129	7	Initial	Initial	NNP
cord-354664-mzzvmyea	129	8	Management	Management	NNP
cord-354664-mzzvmyea	129	9	of	of	IN
cord-354664-mzzvmyea	129	10	Community	Community	NNP
cord-354664-mzzvmyea	129	11	-	-	HYPH
cord-354664-mzzvmyea	129	12	acquired	acquire	VBN
cord-354664-mzzvmyea	129	13	Pneumonia	pneumonia	NN
cord-354664-mzzvmyea	129	14	:	:	:
cord-354664-mzzvmyea	129	15	an	an	DT
cord-354664-mzzvmyea	129	16	evidence	evidence	NN
cord-354664-mzzvmyea	129	17	-	-	HYPH
cord-354664-mzzvmyea	129	18	based	base	VBN
cord-354664-mzzvmyea	129	19	update	update	NN
cord-354664-mzzvmyea	129	20	by	by	IN
cord-354664-mzzvmyea	129	21	the	the	DT
cord-354664-mzzvmyea	129	22	Canadian	Canadian	NNP
cord-354664-mzzvmyea	129	23	Infectious	Infectious	NNP
cord-354664-mzzvmyea	129	24	Disease	Disease	NNP
cord-354664-mzzvmyea	129	25	Society	Society	NNP
cord-354664-mzzvmyea	129	26	and	and	CC
cord-354664-mzzvmyea	129	27	the	the	DT
cord-354664-mzzvmyea	129	28	Canadian	canadian	JJ
cord-354664-mzzvmyea	129	29	Thoracic	Thoracic	NNP
cord-354664-mzzvmyea	129	30	Society	Society	NNP
cord-354664-mzzvmyea	129	31	Active	Active	NNP
cord-354664-mzzvmyea	129	32	population	population	NN
cord-354664-mzzvmyea	129	33	-	-	HYPH
cord-354664-mzzvmyea	129	34	based	base	VBN
cord-354664-mzzvmyea	129	35	surveillance	surveillance	NN
cord-354664-mzzvmyea	129	36	study	study	NN
cord-354664-mzzvmyea	129	37	of	of	IN
cord-354664-mzzvmyea	129	38	immunocompetent	immunocompetent	JJ
cord-354664-mzzvmyea	129	39	adults	adult	NNS
cord-354664-mzzvmyea	129	40	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	129	41	with	with	IN
cord-354664-mzzvmyea	129	42	community	community	NN
cord-354664-mzzvmyea	129	43	-	-	HYPH
cord-354664-mzzvmyea	129	44	acquired	acquire	VBN
cord-354664-mzzvmyea	129	45	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	129	46	.	.	.
cord-354664-mzzvmyea	130	1	In	in	IN
cord-354664-mzzvmyea	130	2	addition	addition	NN
cord-354664-mzzvmyea	130	3	to	to	IN
cord-354664-mzzvmyea	130	4	conventional	conventional	JJ
cord-354664-mzzvmyea	130	5	diagnostic	diagnostic	JJ
cord-354664-mzzvmyea	130	6	testing	testing	NN
cord-354664-mzzvmyea	130	7	,	,	,
cord-354664-mzzvmyea	130	8	extensive	extensive	JJ
cord-354664-mzzvmyea	130	9	molecular	molecular	JJ
cord-354664-mzzvmyea	130	10	and	and	CC
cord-354664-mzzvmyea	130	11	serologic	serologic	NN
cord-354664-mzzvmyea	130	12	testing	testing	NN
cord-354664-mzzvmyea	130	13	was	be	VBD
cord-354664-mzzvmyea	130	14	employed	employ	VBN
cord-354664-mzzvmyea	130	15	to	to	TO
cord-354664-mzzvmyea	130	16	characterize	characterize	VB
cord-354664-mzzvmyea	130	17	causative	causative	JJ
cord-354664-mzzvmyea	130	18	pathogens	pathogen	NNS
cord-354664-mzzvmyea	130	19	and	and	CC
cord-354664-mzzvmyea	130	20	provide	provide	VB
cord-354664-mzzvmyea	130	21	contemporary	contemporary	JJ
cord-354664-mzzvmyea	130	22	data	datum	NNS
cord-354664-mzzvmyea	130	23	on	on	IN
cord-354664-mzzvmyea	130	24	the	the	DT
cord-354664-mzzvmyea	130	25	causative	causative	JJ
cord-354664-mzzvmyea	130	26	agents	agent	NNS
cord-354664-mzzvmyea	130	27	of	of	IN
cord-354664-mzzvmyea	130	28	CAP	CAP	NNP
cord-354664-mzzvmyea	130	29	.	.	.
cord-354664-mzzvmyea	131	1	Despite	despite	IN
cord-354664-mzzvmyea	131	2	extensive	extensive	JJ
cord-354664-mzzvmyea	131	3	testing	testing	NN
cord-354664-mzzvmyea	131	4	The	the	DT
cord-354664-mzzvmyea	131	5	value	value	NN
cord-354664-mzzvmyea	131	6	of	of	IN
cord-354664-mzzvmyea	131	7	macrolide	macrolide	NN
cord-354664-mzzvmyea	131	8	-	-	HYPH
cord-354664-mzzvmyea	131	9	based	base	VBN
cord-354664-mzzvmyea	131	10	regimens	regimen	NNS
cord-354664-mzzvmyea	131	11	for	for	IN
cord-354664-mzzvmyea	131	12	community	community	NN
cord-354664-mzzvmyea	131	13	-	-	HYPH
cord-354664-mzzvmyea	131	14	acquired	acquire	VBN
cord-354664-mzzvmyea	131	15	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	131	16	Structural	structural	JJ
cord-354664-mzzvmyea	131	17	basis	basis	NN
cord-354664-mzzvmyea	131	18	for	for	IN
cord-354664-mzzvmyea	131	19	the	the	DT
cord-354664-mzzvmyea	131	20	interaction	interaction	NN
cord-354664-mzzvmyea	131	21	of	of	IN
cord-354664-mzzvmyea	131	22	antibiotics	antibiotic	NNS
cord-354664-mzzvmyea	131	23	with	with	IN
cord-354664-mzzvmyea	131	24	the	the	DT
cord-354664-mzzvmyea	131	25	peptidyl	peptidyl	JJ
cord-354664-mzzvmyea	131	26	-	-	HYPH
cord-354664-mzzvmyea	131	27	transferase	transferase	NN
cord-354664-mzzvmyea	131	28	centre	centre	NN
cord-354664-mzzvmyea	131	29	in	in	IN
cord-354664-mzzvmyea	131	30	eubacteria	eubacteria	NNP
cord-354664-mzzvmyea	132	1	The	the	DT
cord-354664-mzzvmyea	132	2	mechanism	mechanism	NN
cord-354664-mzzvmyea	132	3	of	of	IN
cord-354664-mzzvmyea	132	4	action	action	NN
cord-354664-mzzvmyea	132	5	of	of	IN
cord-354664-mzzvmyea	132	6	macrolides	macrolide	NNS
cord-354664-mzzvmyea	132	7	,	,	,
cord-354664-mzzvmyea	132	8	lincosamides	lincosamides	NNP
cord-354664-mzzvmyea	132	9	and	and	CC
cord-354664-mzzvmyea	132	10	streptogramin	streptogramin	NNP
cord-354664-mzzvmyea	132	11	B	B	NNP
cord-354664-mzzvmyea	132	12	reveals	reveal	VBZ
cord-354664-mzzvmyea	132	13	the	the	DT
cord-354664-mzzvmyea	132	14	nascent	nascent	JJ
cord-354664-mzzvmyea	132	15	peptide	peptide	JJ
cord-354664-mzzvmyea	132	16	exit	exit	NN
cord-354664-mzzvmyea	132	17	path	path	NN
cord-354664-mzzvmyea	132	18	in	in	IN
cord-354664-mzzvmyea	132	19	the	the	DT
cord-354664-mzzvmyea	132	20	ribosome	ribosome	NN
cord-354664-mzzvmyea	132	21	Antimicrobial	Antimicrobial	NNP
cord-354664-mzzvmyea	132	22	resistance	resistance	NN
cord-354664-mzzvmyea	132	23	among	among	IN
cord-354664-mzzvmyea	132	24	Streptococcus	streptococcus	NN
cord-354664-mzzvmyea	132	25	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	132	26	in	in	IN
cord-354664-mzzvmyea	132	27	the	the	DT
cord-354664-mzzvmyea	132	28	United	United	NNP
cord-354664-mzzvmyea	132	29	States	States	NNP
cord-354664-mzzvmyea	132	30	:	:	:
cord-354664-mzzvmyea	132	31	have	have	VBP
cord-354664-mzzvmyea	132	32	we	-PRON-	PRP
cord-354664-mzzvmyea	132	33	begun	begin	VBN
cord-354664-mzzvmyea	132	34	to	to	TO
cord-354664-mzzvmyea	132	35	turn	turn	VB
cord-354664-mzzvmyea	132	36	the	the	DT
cord-354664-mzzvmyea	132	37	corner	corner	NN
cord-354664-mzzvmyea	132	38	on	on	IN
cord-354664-mzzvmyea	132	39	resistance	resistance	NN
cord-354664-mzzvmyea	132	40	to	to	IN
cord-354664-mzzvmyea	132	41	certain	certain	JJ
cord-354664-mzzvmyea	132	42	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	132	43	classes	class	NNS
cord-354664-mzzvmyea	132	44	?	?	.
cord-354664-mzzvmyea	133	1	Antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	133	2	Resistance	Resistance	NNP
cord-354664-mzzvmyea	133	3	Threats	Threats	NNPS
cord-354664-mzzvmyea	133	4	in	in	IN
cord-354664-mzzvmyea	133	5	the	the	DT
cord-354664-mzzvmyea	133	6	United	United	NNP
cord-354664-mzzvmyea	133	7	States	States	NNP
cord-354664-mzzvmyea	133	8	High	High	NNP
cord-354664-mzzvmyea	133	9	prevalence	prevalence	NN
cord-354664-mzzvmyea	133	10	of	of	IN
cord-354664-mzzvmyea	133	11	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	133	12	resistance	resistance	NN
cord-354664-mzzvmyea	133	13	among	among	IN
cord-354664-mzzvmyea	133	14	clinical	clinical	JJ
cord-354664-mzzvmyea	133	15	Streptococcus	streptococcus	NN
cord-354664-mzzvmyea	133	16	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	133	17	isolates	isolate	VBZ
cord-354664-mzzvmyea	133	18	in	in	IN
cord-354664-mzzvmyea	133	19	Asia	Asia	NNP
cord-354664-mzzvmyea	133	20	(	(	-LRB-
cord-354664-mzzvmyea	133	21	an	an	DT
cord-354664-mzzvmyea	133	22	ANSORP	ANSORP	NNP
cord-354664-mzzvmyea	133	23	study	study	NN
cord-354664-mzzvmyea	133	24	)	)	-RRB-
cord-354664-mzzvmyea	134	1	Macrolide	macrolide	JJ
cord-354664-mzzvmyea	134	2	-	-	HYPH
cord-354664-mzzvmyea	134	3	resistant	resistant	JJ
cord-354664-mzzvmyea	134	4	mycoplasma	mycoplasma	NN
cord-354664-mzzvmyea	134	5	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	134	6	,	,	,
cord-354664-mzzvmyea	134	7	United	United	NNP
cord-354664-mzzvmyea	134	8	States	States	NNP
cord-354664-mzzvmyea	134	9	Nationwide	Nationwide	NNP
cord-354664-mzzvmyea	134	10	surveillance	surveillance	NN
cord-354664-mzzvmyea	134	11	of	of	IN
cord-354664-mzzvmyea	134	12	macrolide	macrolide	JJ
cord-354664-mzzvmyea	134	13	-	-	HYPH
cord-354664-mzzvmyea	134	14	resistant	resistant	JJ
cord-354664-mzzvmyea	134	15	mycoplasma	mycoplasma	NN
cord-354664-mzzvmyea	134	16	pneumoniae	pneumoniae	NN
cord-354664-mzzvmyea	134	17	infection	infection	NN
cord-354664-mzzvmyea	134	18	in	in	IN
cord-354664-mzzvmyea	134	19	pediatric	pediatric	JJ
cord-354664-mzzvmyea	134	20	patients	patient	NNS
cord-354664-mzzvmyea	135	1	Macrolide	macrolide	JJ
cord-354664-mzzvmyea	135	2	antibiotics	antibiotic	NNS
cord-354664-mzzvmyea	135	3	as	as	IN
cord-354664-mzzvmyea	135	4	biological	biological	JJ
cord-354664-mzzvmyea	135	5	response	response	NN
cord-354664-mzzvmyea	136	1	modifiers	modifiers	NNPS
cord-354664-mzzvmyea	136	2	Effect	Effect	NNP
cord-354664-mzzvmyea	136	3	of	of	IN
cord-354664-mzzvmyea	136	4	erythromycin	erythromycin	NN
cord-354664-mzzvmyea	136	5	on	on	IN
cord-354664-mzzvmyea	136	6	Haemophilus	Haemophilus	NNP
cord-354664-mzzvmyea	136	7	influenzae	influenzae	NN
cord-354664-mzzvmyea	136	8	endotoxininduced	endotoxininduced	NN
cord-354664-mzzvmyea	136	9	release	release	NN
cord-354664-mzzvmyea	136	10	of	of	IN
cord-354664-mzzvmyea	136	11	IL-6	IL-6	NNP
cord-354664-mzzvmyea	136	12	,	,	,
cord-354664-mzzvmyea	136	13	IL-8	IL-8	NNP
cord-354664-mzzvmyea	136	14	and	and	CC
cord-354664-mzzvmyea	136	15	sICAM-1	sICAM-1	NNP
cord-354664-mzzvmyea	136	16	by	by	IN
cord-354664-mzzvmyea	136	17	cultured	cultured	JJ
cord-354664-mzzvmyea	136	18	human	human	JJ
cord-354664-mzzvmyea	136	19	bronchial	bronchial	JJ
cord-354664-mzzvmyea	136	20	epithelial	epithelial	JJ
cord-354664-mzzvmyea	136	21	cells	cell	NNS
cord-354664-mzzvmyea	136	22	Membrane	membrane	NN
cord-354664-mzzvmyea	136	23	-	-	HYPH
cord-354664-mzzvmyea	136	24	stabilizing	stabilize	VBG
cord-354664-mzzvmyea	136	25	,	,	,
cord-354664-mzzvmyea	136	26	antiinflammatory	antiinflammatory	JJ
cord-354664-mzzvmyea	136	27	interactions	interaction	NNS
cord-354664-mzzvmyea	136	28	of	of	IN
cord-354664-mzzvmyea	136	29	macrolides	macrolide	NNS
cord-354664-mzzvmyea	136	30	with	with	IN
cord-354664-mzzvmyea	136	31	human	human	JJ
cord-354664-mzzvmyea	136	32	neutrophils	neutrophil	NNS
cord-354664-mzzvmyea	136	33	Molecular	Molecular	NNP
cord-354664-mzzvmyea	136	34	mechanisms	mechanism	NNS
cord-354664-mzzvmyea	136	35	of	of	IN
cord-354664-mzzvmyea	136	36	anti	anti	JJ
cord-354664-mzzvmyea	136	37	-	-	JJ
cord-354664-mzzvmyea	136	38	inflammatory	inflammatory	JJ
cord-354664-mzzvmyea	136	39	action	action	NN
cord-354664-mzzvmyea	136	40	of	of	IN
cord-354664-mzzvmyea	136	41	erythromycin	erythromycin	NN
cord-354664-mzzvmyea	136	42	in	in	IN
cord-354664-mzzvmyea	136	43	human	human	JJ
cord-354664-mzzvmyea	136	44	bronchial	bronchial	JJ
cord-354664-mzzvmyea	136	45	epithelial	epithelial	JJ
cord-354664-mzzvmyea	136	46	cells	cell	NNS
cord-354664-mzzvmyea	136	47	:	:	:
cord-354664-mzzvmyea	136	48	possible	possible	JJ
cord-354664-mzzvmyea	136	49	role	role	NN
cord-354664-mzzvmyea	136	50	in	in	IN
cord-354664-mzzvmyea	136	51	the	the	DT
cord-354664-mzzvmyea	136	52	signaling	signal	VBG
cord-354664-mzzvmyea	136	53	pathway	pathway	NN
cord-354664-mzzvmyea	136	54	that	that	WDT
cord-354664-mzzvmyea	136	55	regulates	regulate	VBZ
cord-354664-mzzvmyea	136	56	nuclear	nuclear	JJ
cord-354664-mzzvmyea	136	57	factor	factor	NN
cord-354664-mzzvmyea	136	58	-	-	HYPH
cord-354664-mzzvmyea	136	59	kappa	kappa	NN
cord-354664-mzzvmyea	136	60	B	B	NNP
cord-354664-mzzvmyea	136	61	activation	activation	NN
cord-354664-mzzvmyea	136	62	Antiinflammatory	antiinflammatory	JJ
cord-354664-mzzvmyea	136	63	effects	effect	NNS
cord-354664-mzzvmyea	136	64	of	of	IN
cord-354664-mzzvmyea	136	65	adjunctive	adjunctive	JJ
cord-354664-mzzvmyea	136	66	macrolide	macrolide	JJ
cord-354664-mzzvmyea	136	67	treatment	treatment	NN
cord-354664-mzzvmyea	136	68	in	in	IN
cord-354664-mzzvmyea	136	69	adults	adult	NNS
cord-354664-mzzvmyea	136	70	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	136	71	with	with	IN
cord-354664-mzzvmyea	136	72	influenza	influenza	NN
cord-354664-mzzvmyea	136	73	:	:	:
cord-354664-mzzvmyea	136	74	a	a	DT
cord-354664-mzzvmyea	136	75	randomized	randomized	JJ
cord-354664-mzzvmyea	136	76	controlled	control	VBN
cord-354664-mzzvmyea	136	77	trial	trial	NN
cord-354664-mzzvmyea	136	78	Immunomodulatory	immunomodulatory	JJ
cord-354664-mzzvmyea	136	79	effects	effect	NNS
cord-354664-mzzvmyea	136	80	of	of	IN
cord-354664-mzzvmyea	136	81	macrolides	macrolide	NNS
cord-354664-mzzvmyea	136	82	during	during	IN
cord-354664-mzzvmyea	136	83	community	community	NN
cord-354664-mzzvmyea	136	84	-	-	HYPH
cord-354664-mzzvmyea	136	85	acquired	acquire	VBN
cord-354664-mzzvmyea	136	86	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	136	87	:	:	:
cord-354664-mzzvmyea	136	88	a	a	DT
cord-354664-mzzvmyea	136	89	literature	literature	NN
cord-354664-mzzvmyea	136	90	review	review	NN
cord-354664-mzzvmyea	136	91	Infectious	Infectious	NNP
cord-354664-mzzvmyea	136	92	Diseases	Diseases	NNPS
cord-354664-mzzvmyea	136	93	Society	Society	NNP
cord-354664-mzzvmyea	136	94	of	of	IN
cord-354664-mzzvmyea	136	95	America/	america/	JJ
cord-354664-mzzvmyea	136	96	American	American	NNP
cord-354664-mzzvmyea	136	97	Thoracic	Thoracic	NNP
cord-354664-mzzvmyea	136	98	Society	Society	NNP
cord-354664-mzzvmyea	136	99	consensus	consensus	NN
cord-354664-mzzvmyea	136	100	guidelines	guideline	NNS
cord-354664-mzzvmyea	136	101	on	on	IN
cord-354664-mzzvmyea	136	102	the	the	DT
cord-354664-mzzvmyea	136	103	management	management	NN
cord-354664-mzzvmyea	136	104	of	of	IN
cord-354664-mzzvmyea	136	105	community	community	NN
cord-354664-mzzvmyea	136	106	-	-	HYPH
cord-354664-mzzvmyea	136	107	acquired	acquire	VBN
cord-354664-mzzvmyea	136	108	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	136	109	in	in	IN
cord-354664-mzzvmyea	136	110	adults	adult	NNS
cord-354664-mzzvmyea	137	1	BTS	BTS	NNP
cord-354664-mzzvmyea	137	2	guidelines	guideline	NNS
cord-354664-mzzvmyea	137	3	for	for	IN
cord-354664-mzzvmyea	137	4	the	the	DT
cord-354664-mzzvmyea	137	5	management	management	NN
cord-354664-mzzvmyea	137	6	of	of	IN
cord-354664-mzzvmyea	137	7	community	community	NN
cord-354664-mzzvmyea	137	8	acquired	acquire	VBD
cord-354664-mzzvmyea	137	9	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	137	10	in	in	IN
cord-354664-mzzvmyea	137	11	adults	adult	NNS
cord-354664-mzzvmyea	137	12	:	:	:
cord-354664-mzzvmyea	137	13	update	update	VB
cord-354664-mzzvmyea	138	1	Diagnosis	diagnosis	NN
cord-354664-mzzvmyea	138	2	and	and	CC
cord-354664-mzzvmyea	138	3	management	management	NN
cord-354664-mzzvmyea	138	4	of	of	IN
cord-354664-mzzvmyea	138	5	community	community	NN
cord-354664-mzzvmyea	138	6	and	and	CC
cord-354664-mzzvmyea	138	7	hospital	hospital	NN
cord-354664-mzzvmyea	138	8	acquired	acquire	VBD
cord-354664-mzzvmyea	138	9	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	138	10	in	in	IN
cord-354664-mzzvmyea	138	11	adults	adult	NNS
cord-354664-mzzvmyea	138	12	:	:	:
cord-354664-mzzvmyea	139	1	summary	summary	NN
cord-354664-mzzvmyea	139	2	of	of	IN
cord-354664-mzzvmyea	139	3	NICE	nice	JJ
cord-354664-mzzvmyea	139	4	guidance	guidance	NN
cord-354664-mzzvmyea	139	5	Associations	association	NNS
cord-354664-mzzvmyea	139	6	between	between	IN
cord-354664-mzzvmyea	139	7	initial	initial	JJ
cord-354664-mzzvmyea	139	8	antimicrobial	antimicrobial	JJ
cord-354664-mzzvmyea	139	9	therapy	therapy	NN
cord-354664-mzzvmyea	139	10	and	and	CC
cord-354664-mzzvmyea	139	11	medical	medical	JJ
cord-354664-mzzvmyea	139	12	outcomes	outcome	NNS
cord-354664-mzzvmyea	139	13	for	for	IN
cord-354664-mzzvmyea	139	14	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	139	15	elderly	elderly	JJ
cord-354664-mzzvmyea	139	16	patients	patient	NNS
cord-354664-mzzvmyea	139	17	with	with	IN
cord-354664-mzzvmyea	139	18	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	139	19	Empiric	Empiric	NNP
cord-354664-mzzvmyea	139	20	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	139	21	therapy	therapy	NN
cord-354664-mzzvmyea	139	22	and	and	CC
cord-354664-mzzvmyea	139	23	mortality	mortality	NN
cord-354664-mzzvmyea	139	24	among	among	IN
cord-354664-mzzvmyea	139	25	Medicare	Medicare	NNP
cord-354664-mzzvmyea	139	26	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	139	27	inpatients	inpatient	NNS
cord-354664-mzzvmyea	139	28	in	in	IN
cord-354664-mzzvmyea	139	29	10	10	CD
cord-354664-mzzvmyea	139	30	western	western	JJ
cord-354664-mzzvmyea	139	31	states	state	NNS
cord-354664-mzzvmyea	139	32	Antimicrobial	Antimicrobial	NNP
cord-354664-mzzvmyea	139	33	selection	selection	NN
cord-354664-mzzvmyea	139	34	for	for	IN
cord-354664-mzzvmyea	139	35	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	139	36	patients	patient	NNS
cord-354664-mzzvmyea	139	37	with	with	IN
cord-354664-mzzvmyea	139	38	presumed	presumed	JJ
cord-354664-mzzvmyea	139	39	community	community	NN
cord-354664-mzzvmyea	139	40	-	-	HYPH
cord-354664-mzzvmyea	139	41	acquired	acquire	VBN
cord-354664-mzzvmyea	139	42	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	139	43	:	:	:
cord-354664-mzzvmyea	139	44	a	a	DT
cord-354664-mzzvmyea	139	45	survey	survey	NN
cord-354664-mzzvmyea	139	46	of	of	IN
cord-354664-mzzvmyea	139	47	nonteaching	nonteache	VBG
cord-354664-mzzvmyea	139	48	US	US	NNP
cord-354664-mzzvmyea	139	49	community	community	NN
cord-354664-mzzvmyea	139	50	hospitals	hospital	NNS
cord-354664-mzzvmyea	139	51	Impact	Impact	NNP
cord-354664-mzzvmyea	139	52	of	of	IN
cord-354664-mzzvmyea	139	53	initial	initial	JJ
cord-354664-mzzvmyea	139	54	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	139	55	choice	choice	NN
cord-354664-mzzvmyea	139	56	on	on	IN
cord-354664-mzzvmyea	139	57	clinical	clinical	JJ
cord-354664-mzzvmyea	139	58	outcomes	outcome	NNS
cord-354664-mzzvmyea	139	59	in	in	IN
cord-354664-mzzvmyea	139	60	community	community	NN
cord-354664-mzzvmyea	139	61	-	-	HYPH
cord-354664-mzzvmyea	139	62	acquired	acquire	VBN
cord-354664-mzzvmyea	139	63	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	139	64	:	:	:
cord-354664-mzzvmyea	139	65	analysis	analysis	NN
cord-354664-mzzvmyea	139	66	of	of	IN
cord-354664-mzzvmyea	139	67	a	a	DT
cord-354664-mzzvmyea	139	68	hospital	hospital	NN
cord-354664-mzzvmyea	139	69	claims	claim	NNS
cord-354664-mzzvmyea	139	70	-	-	HYPH
cord-354664-mzzvmyea	139	71	made	make	VBN
cord-354664-mzzvmyea	139	72	database	database	NN
cord-354664-mzzvmyea	139	73	Antibiotics	antibiotic	NNS
cord-354664-mzzvmyea	139	74	for	for	IN
cord-354664-mzzvmyea	139	75	communityacquired	communityacquired	JJ
cord-354664-mzzvmyea	139	76	lower	low	JJR
cord-354664-mzzvmyea	139	77	respiratory	respiratory	JJ
cord-354664-mzzvmyea	139	78	tract	tract	NN
cord-354664-mzzvmyea	139	79	infections	infection	NNS
cord-354664-mzzvmyea	139	80	secondary	secondary	JJ
cord-354664-mzzvmyea	139	81	to	to	TO
cord-354664-mzzvmyea	139	82	in	in	IN
cord-354664-mzzvmyea	139	83	children	child	NNS
cord-354664-mzzvmyea	139	84	Antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	139	85	treatment	treatment	NN
cord-354664-mzzvmyea	139	86	of	of	IN
cord-354664-mzzvmyea	139	87	moderate	moderate	JJ
cord-354664-mzzvmyea	139	88	-	-	HYPH
cord-354664-mzzvmyea	139	89	severe	severe	JJ
cord-354664-mzzvmyea	139	90	community	community	NN
cord-354664-mzzvmyea	139	91	-	-	HYPH
cord-354664-mzzvmyea	139	92	acquired	acquire	VBN
cord-354664-mzzvmyea	139	93	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	139	94	:	:	:
cord-354664-mzzvmyea	140	1	design	design	NN
cord-354664-mzzvmyea	140	2	and	and	CC
cord-354664-mzzvmyea	140	3	rationale	rationale	NN
cord-354664-mzzvmyea	140	4	of	of	IN
cord-354664-mzzvmyea	140	5	a	a	DT
cord-354664-mzzvmyea	140	6	multicenter	multicenter	JJ
cord-354664-mzzvmyea	140	7	cluster	cluster	NN
cord-354664-mzzvmyea	140	8	-	-	HYPH
cord-354664-mzzvmyea	140	9	randomized	randomized	JJ
cord-354664-mzzvmyea	140	10	cross	cross	NN
cord-354664-mzzvmyea	140	11	-	-	HYPH
cord-354664-mzzvmyea	140	12	over	over	RP
cord-354664-mzzvmyea	140	13	trial	trial	NN
cord-354664-mzzvmyea	141	1	The	the	DT
cord-354664-mzzvmyea	141	2	controversy	controversy	NN
cord-354664-mzzvmyea	141	3	of	of	IN
cord-354664-mzzvmyea	141	4	combination	combination	NN
cord-354664-mzzvmyea	141	5	vs	vs	IN
cord-354664-mzzvmyea	141	6	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	141	7	in	in	IN
cord-354664-mzzvmyea	141	8	the	the	DT
cord-354664-mzzvmyea	141	9	treatment	treatment	NN
cord-354664-mzzvmyea	141	10	of	of	IN
cord-354664-mzzvmyea	141	11	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	141	12	community	community	NN
cord-354664-mzzvmyea	141	13	-	-	HYPH
cord-354664-mzzvmyea	141	14	acquired	acquire	VBN
cord-354664-mzzvmyea	141	15	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	141	16	Does	do	VBZ
cord-354664-mzzvmyea	141	17	empiric	empiric	JJ
cord-354664-mzzvmyea	141	18	therapy	therapy	NN
cord-354664-mzzvmyea	141	19	for	for	IN
cord-354664-mzzvmyea	141	20	atypical	atypical	JJ
cord-354664-mzzvmyea	141	21	pathogens	pathogen	NNS
cord-354664-mzzvmyea	141	22	improve	improve	VBP
cord-354664-mzzvmyea	141	23	outcomes	outcome	NNS
cord-354664-mzzvmyea	141	24	for	for	IN
cord-354664-mzzvmyea	141	25	patients	patient	NNS
cord-354664-mzzvmyea	141	26	with	with	IN
cord-354664-mzzvmyea	141	27	CAP	cap	NN
cord-354664-mzzvmyea	141	28	?	?	.
cord-354664-mzzvmyea	142	1	Azithromycin	Azithromycin	NNP
cord-354664-mzzvmyea	142	2	and	and	CC
cord-354664-mzzvmyea	142	3	the	the	DT
cord-354664-mzzvmyea	142	4	risk	risk	NN
cord-354664-mzzvmyea	142	5	of	of	IN
cord-354664-mzzvmyea	142	6	cardiovascular	cardiovascular	JJ
cord-354664-mzzvmyea	142	7	death	death	NN
cord-354664-mzzvmyea	142	8	Fluoroquinolone	Fluoroquinolone	NNP
cord-354664-mzzvmyea	142	9	and	and	CC
cord-354664-mzzvmyea	142	10	macrolide	macrolide	NN
cord-354664-mzzvmyea	142	11	exposure	exposure	NN
cord-354664-mzzvmyea	142	12	predict	predict	VBP
cord-354664-mzzvmyea	142	13	Clostridium	clostridium	NN
cord-354664-mzzvmyea	142	14	difficile	difficile	NN
cord-354664-mzzvmyea	142	15	infection	infection	NN
cord-354664-mzzvmyea	142	16	with	with	IN
cord-354664-mzzvmyea	142	17	the	the	DT
cord-354664-mzzvmyea	142	18	highly	highly	RB
cord-354664-mzzvmyea	142	19	fluorquinolone	fluorquinolone	NN
cord-354664-mzzvmyea	142	20	and	and	CC
cord-354664-mzzvmyea	142	21	macrolide	macrolide	NN
cord-354664-mzzvmyea	142	22	-	-	HYPH
cord-354664-mzzvmyea	142	23	resistant	resistant	JJ
cord-354664-mzzvmyea	142	24	epidemic	epidemic	NN
cord-354664-mzzvmyea	143	1	C.	C.	NNP
cord-354664-mzzvmyea	143	2	difficile	difficile	NN
cord-354664-mzzvmyea	143	3	strain	strain	NN
cord-354664-mzzvmyea	143	4	BI	BI	NNP
cord-354664-mzzvmyea	143	5	/	/	SYM
cord-354664-mzzvmyea	143	6	NAP1/027	NAP1/027	NNP
cord-354664-mzzvmyea	143	7	Empiric	Empiric	NNP
cord-354664-mzzvmyea	143	8	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	143	9	coverage	coverage	NN
cord-354664-mzzvmyea	143	10	of	of	IN
cord-354664-mzzvmyea	143	11	atypical	atypical	JJ
cord-354664-mzzvmyea	143	12	pathogens	pathogen	NNS
cord-354664-mzzvmyea	143	13	for	for	IN
cord-354664-mzzvmyea	143	14	community	community	NN
cord-354664-mzzvmyea	143	15	-	-	HYPH
cord-354664-mzzvmyea	143	16	acquired	acquire	VBN
cord-354664-mzzvmyea	143	17	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	143	18	in	in	IN
cord-354664-mzzvmyea	143	19	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	143	20	adults	adult	NNS
cord-354664-mzzvmyea	143	21	Macrolide	Macrolide	NNP
cord-354664-mzzvmyea	143	22	-	-	HYPH
cord-354664-mzzvmyea	143	23	based	base	VBN
cord-354664-mzzvmyea	143	24	regimens	regimen	NNS
cord-354664-mzzvmyea	143	25	and	and	CC
cord-354664-mzzvmyea	143	26	mortality	mortality	NN
cord-354664-mzzvmyea	143	27	in	in	IN
cord-354664-mzzvmyea	143	28	hospitalized	hospitalize	VBN
cord-354664-mzzvmyea	143	29	patients	patient	NNS
cord-354664-mzzvmyea	143	30	with	with	IN
cord-354664-mzzvmyea	143	31	community	community	NN
cord-354664-mzzvmyea	143	32	-	-	HYPH
cord-354664-mzzvmyea	143	33	acquired	acquire	VBN
cord-354664-mzzvmyea	143	34	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	143	35	:	:	:
cord-354664-mzzvmyea	144	1	a	a	DT
cord-354664-mzzvmyea	144	2	systematic	systematic	JJ
cord-354664-mzzvmyea	144	3	review	review	NN
cord-354664-mzzvmyea	144	4	and	and	CC
cord-354664-mzzvmyea	144	5	meta	meta	NNP
cord-354664-mzzvmyea	144	6	-	-	HYPH
cord-354664-mzzvmyea	144	7	analysis	analysis	NN
cord-354664-mzzvmyea	144	8	Evaluated	evaluate	VBD
cord-354664-mzzvmyea	144	9	the	the	DT
cord-354664-mzzvmyea	144	10	non	non	JJ
cord-354664-mzzvmyea	144	11	-	-	JJ
cord-354664-mzzvmyea	144	12	inferiority	inferiority	NN
cord-354664-mzzvmyea	144	13	of	of	IN
cord-354664-mzzvmyea	144	14	beta	beta	NN
cord-354664-mzzvmyea	144	15	-	-	HYPH
cord-354664-mzzvmyea	144	16	lactam	lactam	NN
cord-354664-mzzvmyea	144	17	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	144	18	compared	compare	VBN
cord-354664-mzzvmyea	144	19	with	with	IN
cord-354664-mzzvmyea	144	20	beta	beta	NN
cord-354664-mzzvmyea	144	21	-	-	HYPH
cord-354664-mzzvmyea	144	22	lactam	lactam	NNS
cord-354664-mzzvmyea	144	23	/	/	SYM
cord-354664-mzzvmyea	144	24	macrolide	macrolide	NN
cord-354664-mzzvmyea	144	25	combination	combination	NN
cord-354664-mzzvmyea	144	26	therapy	therapy	NN
cord-354664-mzzvmyea	144	27	in	in	IN
cord-354664-mzzvmyea	144	28	moderately	moderately	RB
cord-354664-mzzvmyea	144	29	severe	severe	JJ
cord-354664-mzzvmyea	144	30	CAP	cap	NN
cord-354664-mzzvmyea	144	31	in	in	IN
cord-354664-mzzvmyea	144	32	an	an	DT
cord-354664-mzzvmyea	144	33	open	open	JJ
cord-354664-mzzvmyea	144	34	-	-	HYPH
cord-354664-mzzvmyea	144	35	label	label	NN
cord-354664-mzzvmyea	144	36	,	,	,
cord-354664-mzzvmyea	144	37	multicenter	multicenter	JJ
cord-354664-mzzvmyea	144	38	,	,	,
cord-354664-mzzvmyea	144	39	noninferiority	noninferiority	NNP
cord-354664-mzzvmyea	144	40	randomized	randomized	JJ
cord-354664-mzzvmyea	144	41	control	control	NN
cord-354664-mzzvmyea	144	42	trial	trial	NN
cord-354664-mzzvmyea	144	43	.	.	.
cord-354664-mzzvmyea	145	1	Failed	fail	VBD
cord-354664-mzzvmyea	145	2	to	to	TO
cord-354664-mzzvmyea	145	3	meet	meet	VB
cord-354664-mzzvmyea	145	4	primary	primary	JJ
cord-354664-mzzvmyea	145	5	outcome	outcome	NN
cord-354664-mzzvmyea	145	6	and	and	CC
cord-354664-mzzvmyea	145	7	demonstrate	demonstrate	VB
cord-354664-mzzvmyea	145	8	non	non	JJ
cord-354664-mzzvmyea	145	9	-	-	JJ
cord-354664-mzzvmyea	145	10	inferiority	inferiority	NN
cord-354664-mzzvmyea	145	11	of	of	IN
cord-354664-mzzvmyea	145	12	beta	beta	NN
cord-354664-mzzvmyea	145	13	-	-	HYPH
cord-354664-mzzvmyea	145	14	lactam	lactam	NN
cord-354664-mzzvmyea	145	15	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	145	16	in	in	IN
cord-354664-mzzvmyea	145	17	moderately	moderately	RB
cord-354664-mzzvmyea	145	18	severe	severe	JJ
cord-354664-mzzvmyea	145	19	community	community	NN
cord-354664-mzzvmyea	145	20	-	-	HYPH
cord-354664-mzzvmyea	145	21	acquired	acquire	VBN
cord-354664-mzzvmyea	145	22	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	145	23	.	.	.
cord-354664-mzzvmyea	146	1	Subgroup	subgroup	NN
cord-354664-mzzvmyea	146	2	analyses	analysis	NNS
cord-354664-mzzvmyea	146	3	revealed	reveal	VBD
cord-354664-mzzvmyea	146	4	equivalent	equivalent	JJ
cord-354664-mzzvmyea	146	5	outcomes	outcome	NNS
cord-354664-mzzvmyea	146	6	in	in	IN
cord-354664-mzzvmyea	146	7	patients	patient	NNS
cord-354664-mzzvmyea	146	8	with	with	IN
cord-354664-mzzvmyea	146	9	mild	mild	JJ
cord-354664-mzzvmyea	146	10	to	to	IN
cord-354664-mzzvmyea	146	11	moderate	moderate	JJ
cord-354664-mzzvmyea	146	12	CAP	cap	NN
cord-354664-mzzvmyea	146	13	(	(	-LRB-
cord-354664-mzzvmyea	146	14	PSI	PSI	NNP
cord-354664-mzzvmyea	146	15	1	1	CD
cord-354664-mzzvmyea	146	16	-	-	SYM
cord-354664-mzzvmyea	146	17	3	3	CD
cord-354664-mzzvmyea	146	18	)	)	-RRB-
cord-354664-mzzvmyea	146	19	but	but	CC
cord-354664-mzzvmyea	146	20	worse	bad	JJR
cord-354664-mzzvmyea	146	21	outcomes	outcome	NNS
cord-354664-mzzvmyea	146	22	in	in	IN
cord-354664-mzzvmyea	146	23	patients	patient	NNS
cord-354664-mzzvmyea	146	24	managed	manage	VBN
cord-354664-mzzvmyea	146	25	with	with	IN
cord-354664-mzzvmyea	146	26	beta	beta	NN
cord-354664-mzzvmyea	146	27	-	-	HYPH
cord-354664-mzzvmyea	146	28	lactam	lactam	NN
cord-354664-mzzvmyea	146	29	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	146	30	and	and	CC
cord-354664-mzzvmyea	146	31	severe	severe	JJ
cord-354664-mzzvmyea	146	32	CAP	CAP	NNP
cord-354664-mzzvmyea	146	33	Multi	multi	JJ
cord-354664-mzzvmyea	146	34	-	-	JJ
cord-354664-mzzvmyea	146	35	center	center	JJ
cord-354664-mzzvmyea	146	36	cluster	cluster	NN
cord-354664-mzzvmyea	146	37	-	-	HYPH
cord-354664-mzzvmyea	146	38	randomized	randomized	JJ
cord-354664-mzzvmyea	146	39	,	,	,
cord-354664-mzzvmyea	146	40	crossover	crossover	NN
cord-354664-mzzvmyea	146	41	,	,	,
cord-354664-mzzvmyea	146	42	non	non	JJ
cord-354664-mzzvmyea	146	43	-	-	JJ
cord-354664-mzzvmyea	146	44	inferiority	inferiority	JJ
cord-354664-mzzvmyea	146	45	trial	trial	NN
cord-354664-mzzvmyea	146	46	conducted	conduct	VBN
cord-354664-mzzvmyea	146	47	at	at	IN
cord-354664-mzzvmyea	146	48	7	7	CD
cord-354664-mzzvmyea	146	49	hospitals	hospital	NNS
cord-354664-mzzvmyea	146	50	in	in	IN
cord-354664-mzzvmyea	146	51	the	the	DT
cord-354664-mzzvmyea	146	52	Netherlands	Netherlands	NNP
cord-354664-mzzvmyea	146	53	to	to	TO
cord-354664-mzzvmyea	146	54	determine	determine	VB
cord-354664-mzzvmyea	146	55	if	if	IN
cord-354664-mzzvmyea	146	56	empiric	empiric	JJ
cord-354664-mzzvmyea	146	57	therapy	therapy	NN
cord-354664-mzzvmyea	146	58	for	for	IN
cord-354664-mzzvmyea	146	59	CAP	cap	NN
cord-354664-mzzvmyea	146	60	with	with	IN
cord-354664-mzzvmyea	146	61	beta	beta	NN
cord-354664-mzzvmyea	146	62	-	-	HYPH
cord-354664-mzzvmyea	146	63	lactam	lactam	NN
cord-354664-mzzvmyea	146	64	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	146	65	was	be	VBD
cord-354664-mzzvmyea	146	66	non	non	JJ
cord-354664-mzzvmyea	146	67	-	-	JJ
cord-354664-mzzvmyea	146	68	inferior	inferior	JJ
cord-354664-mzzvmyea	146	69	to	to	IN
cord-354664-mzzvmyea	146	70	combination	combination	NN
cord-354664-mzzvmyea	146	71	beta	beta	NN
cord-354664-mzzvmyea	146	72	-	-	HYPH
cord-354664-mzzvmyea	146	73	lactam	lactam	NN
cord-354664-mzzvmyea	146	74	/	/	SYM
cord-354664-mzzvmyea	146	75	macrolide	macrolide	NN
cord-354664-mzzvmyea	146	76	therapy	therapy	NN
cord-354664-mzzvmyea	146	77	or	or	CC
cord-354664-mzzvmyea	146	78	a	a	DT
cord-354664-mzzvmyea	146	79	respiratory	respiratory	JJ
cord-354664-mzzvmyea	146	80	fluoroquinolone	fluoroquinolone	NN
cord-354664-mzzvmyea	146	81	.	.	.
cord-354664-mzzvmyea	147	1	90-day	90-day	CD
cord-354664-mzzvmyea	148	1	all	all	DT
cord-354664-mzzvmyea	148	2	-	-	HYPH
cord-354664-mzzvmyea	148	3	cause	cause	NN
cord-354664-mzzvmyea	148	4	mortality	mortality	NN
cord-354664-mzzvmyea	148	5	was	be	VBD
cord-354664-mzzvmyea	148	6	lowest	low	JJS
cord-354664-mzzvmyea	148	7	in	in	IN
cord-354664-mzzvmyea	148	8	the	the	DT
cord-354664-mzzvmyea	148	9	betalactam	betalactam	NNP
cord-354664-mzzvmyea	148	10	monotherapy	monotherapy	IN
cord-354664-mzzvmyea	148	11	arm	arm	VBP
cord-354664-mzzvmyea	148	12	.	.	.
cord-354664-mzzvmyea	149	1	Adjusted	adjusted	JJ
cord-354664-mzzvmyea	149	2	comparisons	comparison	NNS
cord-354664-mzzvmyea	149	3	for	for	IN
cord-354664-mzzvmyea	149	4	90-day	90-day	CD
cord-354664-mzzvmyea	149	5	all	all	DT
cord-354664-mzzvmyea	149	6	-	-	HYPH
cord-354664-mzzvmyea	149	7	cause	cause	NN
cord-354664-mzzvmyea	149	8	mortality	mortality	NN
cord-354664-mzzvmyea	149	9	favored	favor	VBN
cord-354664-mzzvmyea	149	10	beta	beta	NN
cord-354664-mzzvmyea	149	11	-	-	HYPH
cord-354664-mzzvmyea	149	12	lactam	lactam	NN
cord-354664-mzzvmyea	149	13	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	149	14	with	with	IN
cord-354664-mzzvmyea	149	15	a	a	DT
cord-354664-mzzvmyea	149	16	1.9	1.9	CD
cord-354664-mzzvmyea	149	17	%	%	NN
cord-354664-mzzvmyea	149	18	lower	low	JJR
cord-354664-mzzvmyea	149	19	risk	risk	NN
cord-354664-mzzvmyea	149	20	of	of	IN
cord-354664-mzzvmyea	149	21	death	death	NN
cord-354664-mzzvmyea	149	22	when	when	WRB
cord-354664-mzzvmyea	149	23	compared	compare	VBN
cord-354664-mzzvmyea	149	24	to	to	IN
cord-354664-mzzvmyea	149	25	macrolide	macrolide	JJ
cord-354664-mzzvmyea	149	26	combination	combination	NN
cord-354664-mzzvmyea	149	27	therapy	therapy	NN
cord-354664-mzzvmyea	149	28	.	.	.
cord-354664-mzzvmyea	150	1	Time	time	NN
cord-354664-mzzvmyea	150	2	to	to	IN
cord-354664-mzzvmyea	150	3	oral	oral	JJ
cord-354664-mzzvmyea	150	4	antibiotic	antibiotic	NN
cord-354664-mzzvmyea	150	5	de	de	NN
cord-354664-mzzvmyea	150	6	-	-	NN
cord-354664-mzzvmyea	150	7	escalation	escalation	NN
cord-354664-mzzvmyea	150	8	Evaluation	Evaluation	NNP
cord-354664-mzzvmyea	150	9	of	of	IN
cord-354664-mzzvmyea	150	10	outcomes	outcome	NNS
cord-354664-mzzvmyea	150	11	in	in	IN
cord-354664-mzzvmyea	150	12	a	a	DT
cord-354664-mzzvmyea	150	13	subset	subset	NN
cord-354664-mzzvmyea	150	14	of	of	IN
cord-354664-mzzvmyea	150	15	179	179	CD
cord-354664-mzzvmyea	150	16	patients	patient	NNS
cord-354664-mzzvmyea	150	17	from	from	IN
cord-354664-mzzvmyea	150	18	the	the	DT
cord-354664-mzzvmyea	150	19	CAP	CAP	NNP
cord-354664-mzzvmyea	150	20	-	-	HYPH
cord-354664-mzzvmyea	150	21	START	START	NNP
cord-354664-mzzvmyea	150	22	Trial	Trial	NNP
cord-354664-mzzvmyea	150	23	that	that	WDT
cord-354664-mzzvmyea	150	24	had	have	VBD
cord-354664-mzzvmyea	150	25	previous	previous	JJ
cord-354664-mzzvmyea	150	26	beta	beta	NN
cord-354664-mzzvmyea	150	27	-	-	HYPH
cord-354664-mzzvmyea	150	28	lactam	lactam	NN
cord-354664-mzzvmyea	150	29	exposure	exposure	NN
cord-354664-mzzvmyea	150	30	prior	prior	RB
cord-354664-mzzvmyea	150	31	to	to	IN
cord-354664-mzzvmyea	150	32	hospitalization	hospitalization	NN
cord-354664-mzzvmyea	150	33	.	.	.
cord-354664-mzzvmyea	151	1	Compared	compare	VBN
cord-354664-mzzvmyea	151	2	thirty	thirty	CD
cord-354664-mzzvmyea	151	3	-	-	HYPH
cord-354664-mzzvmyea	151	4	day	day	NN
cord-354664-mzzvmyea	151	5	mortality	mortality	NN
cord-354664-mzzvmyea	151	6	,	,	,
cord-354664-mzzvmyea	151	7	hospital	hospital	NN
cord-354664-mzzvmyea	151	8	length	length	NN
cord-354664-mzzvmyea	151	9	of	of	IN
cord-354664-mzzvmyea	151	10	stay	stay	NN
cord-354664-mzzvmyea	151	11	,	,	,
cord-354664-mzzvmyea	151	12	and	and	CC
cord-354664-mzzvmyea	151	13	frequency	frequency	NN
cord-354664-mzzvmyea	151	14	of	of	IN
cord-354664-mzzvmyea	151	15	treatment	treatment	NN
cord-354664-mzzvmyea	151	16	escalations	escalation	NNS
cord-354664-mzzvmyea	151	17	between	between	IN
cord-354664-mzzvmyea	151	18	patients	patient	NNS
cord-354664-mzzvmyea	151	19	that	that	WDT
cord-354664-mzzvmyea	151	20	were	be	VBD
cord-354664-mzzvmyea	151	21	continued	continue	VBN
cord-354664-mzzvmyea	151	22	on	on	IN
cord-354664-mzzvmyea	151	23	beta	beta	NN
cord-354664-mzzvmyea	151	24	-	-	HYPH
cord-354664-mzzvmyea	151	25	lactam	lactam	NN
cord-354664-mzzvmyea	151	26	monotherapy	monotherapy	NN
cord-354664-mzzvmyea	151	27	and	and	CC
cord-354664-mzzvmyea	151	28	patients	patient	NNS
cord-354664-mzzvmyea	151	29	that	that	WDT
cord-354664-mzzvmyea	151	30	received	receive	VBD
cord-354664-mzzvmyea	151	31	beta	beta	NN
cord-354664-mzzvmyea	151	32	-	-	HYPH
cord-354664-mzzvmyea	151	33	lactams	lactam	NNS
cord-354664-mzzvmyea	151	34	and	and	CC
cord-354664-mzzvmyea	151	35	atypical	atypical	JJ
cord-354664-mzzvmyea	151	36	coverage	coverage	NN
cord-354664-mzzvmyea	151	37	Combination	combination	NN
cord-354664-mzzvmyea	151	38	antibiotic	antibiotic	JJ
cord-354664-mzzvmyea	151	39	therapy	therapy	NN
cord-354664-mzzvmyea	151	40	lowers	lower	VBZ
cord-354664-mzzvmyea	151	41	mortality	mortality	NN
cord-354664-mzzvmyea	151	42	among	among	IN
cord-354664-mzzvmyea	151	43	severely	severely	RB
cord-354664-mzzvmyea	151	44	ill	ill	JJ
cord-354664-mzzvmyea	151	45	patients	patient	NNS
cord-354664-mzzvmyea	151	46	with	with	IN
cord-354664-mzzvmyea	151	47	pneumococcal	pneumococcal	JJ
cord-354664-mzzvmyea	151	48	bacteremia	bacteremia	NN
cord-354664-mzzvmyea	151	49	Macrolide	Macrolide	NNP
cord-354664-mzzvmyea	151	50	therapy	therapy	NN
cord-354664-mzzvmyea	151	51	is	be	VBZ
cord-354664-mzzvmyea	151	52	associated	associate	VBN
cord-354664-mzzvmyea	151	53	with	with	IN
cord-354664-mzzvmyea	151	54	lower	low	JJR
cord-354664-mzzvmyea	151	55	mortality	mortality	NN
cord-354664-mzzvmyea	151	56	in	in	IN
cord-354664-mzzvmyea	151	57	community	community	NN
cord-354664-mzzvmyea	151	58	-	-	HYPH
cord-354664-mzzvmyea	151	59	acquired	acquire	VBN
cord-354664-mzzvmyea	151	60	bacteremic	bacteremic	JJ
cord-354664-mzzvmyea	151	61	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	151	62	Macrolides	macrolide	NNS
cord-354664-mzzvmyea	151	63	and	and	CC
cord-354664-mzzvmyea	151	64	mortality	mortality	NN
cord-354664-mzzvmyea	151	65	in	in	IN
cord-354664-mzzvmyea	151	66	critically	critically	RB
cord-354664-mzzvmyea	151	67	ill	ill	JJ
cord-354664-mzzvmyea	151	68	patients	patient	NNS
cord-354664-mzzvmyea	151	69	with	with	IN
cord-354664-mzzvmyea	151	70	community	community	NN
cord-354664-mzzvmyea	151	71	-	-	HYPH
cord-354664-mzzvmyea	151	72	acquired	acquire	VBN
cord-354664-mzzvmyea	151	73	pneumonia	pneumonia	NN
cord-354664-mzzvmyea	151	74	:	:	:
cord-354664-mzzvmyea	151	75	a	a	DT
cord-354664-mzzvmyea	151	76	systematic	systematic	JJ
cord-354664-mzzvmyea	151	77	review	review	NN
cord-354664-mzzvmyea	151	78	and	and	CC
cord-354664-mzzvmyea	151	79	metaanalysis	metaanalysis	NN